STATE OF TENNESSEE
MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES

REQUEST FOR QUALIFICATIONS # 33901-15113 AMENDMENT # 3 FOR GOODS OR AUTOMATED MEDICATION DISPENSING CABINETS

DATE: 1/21/2016

RFQ # 33901-15113 IS AMENDED AS FOLLOWS:

1. **This RFQ Schedule of Events updates and confirms scheduled RFQ dates.** Any event, time, or date containing revised or new text is highlighted.

EVENT		TIME (Central Time Zone)	DATE (all dates are State business days)
1.	RFQ Issued		11/20/2015
2.	Disability Accommodation Request Deadline	2:00 p.m.	11/25/2015
3.	Pre-Response Conference	10:30 a.m.	12/01/2015
4.	Notice of Intent to Respond Deadline	2:00 p.m.	12/02/2015
5.	Written "Questions & Comments" Deadline	2:00 p.m.	12/08/2015
6.	State response to written "Questions & Comments"		12/15/2015
7.	RFQ Technical Response Deadline	2:00 p.m.	01/06/2016
8.	State Schedules Respondent Oral Presentations (ONLY Respondents who pass Mandatory Requirements)		01/14/2016
9.	Respondent Oral Presentations	8:00 a.m. – 4:30 p.m.	01/21/2016 – 01/29/2016
10.	State Notice of Qualified Respondents Released		02/01/2016
11.	RFQ Cost Proposal Deadline (ONLY for Qualified Respondents)	2:00 p.m.	02/08/2016
12.	State Evaluation Notice Released		02/09/2016
13.	Solicitation Files Opened for Public Inspections		02/10/2016
14.	Respondent Contract Signature Deadline	2:00 p.m.	02/19/2016
15.	Anticipated Contract Start Date (anticipated date for contract to be fully executed and vendor to begin work)		03/08/2016

2. **RFQ Amendment Effective Date.** The revisions set forth herein shall be effective upon release. All other terms and conditions of this RFQ not expressly amended herein shall remain in full force and effect.

STATE OF TENNESSEE
MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES

REQUEST FOR QUALIFICATIONS # 33901-15113 AMENDMENT # 2 FOR GOODS OR AUTOMATED MEDICATION DISPENSING CABINETS

DATE: 12/15/2015

RFQ # 33901-15113 IS AMENDED AS FOLLOWS:

1. **This RFP Schedule of Events updates and confirms scheduled RFP dates.** Any event, time, or date containing revised or new text is highlighted.

EVENT		TIME (Central Time Zone)	DATE (all dates are State business days)
1.	RFQ Issued		11/20/2015
2.	Disability Accommodation Request Deadline	2:00 p.m.	11/25/2015
3.	Pre-Response Conference	10:30 a.m.	12/01/2015
4.	Notice of Intent to Respond Deadline	2:00 p.m.	12/02/2015
5.	Written "Questions & Comments" Deadline	2:00 p.m.	12/08/2015
6.	State response to written "Questions & Comments"		12/15/2015
7.	RFQ Technical Response Deadline	2:00 p.m.	01/06/2016
8.	State Schedules Respondent Oral Presentations (ONLY Respondents who pass Mandatory Requirements)		01/14/2016
9.	Respondent Oral Presentations	8:00 a.m. – 4:30 p.m.	01/21/2016 – 01/22/2016
10.	State Notice of Qualified Respondents Released		01/25/2016
11.	RFQ Cost Proposal Deadline (ONLY for Qualified Respondents)	2:00 p.m.	02/01/2016
12.	State Evaluation Notice Released		02/03/2016
13.	Solicitation Files Opened for Public Inspections		02/04/2016
14.	Respondent Contract Signature Deadline	2:00 p.m.	02/12/2016
15.	Anticipated Contract Start Date (anticipated date for contract to be fully executed and vendor to begin work)		03/01/2016

2. State responses to questions and comments in the table below amend and clarify this RFQ.

Any restatement of RFQ text in the Question/Comment column shall NOT be construed as a change in the actual wording of the RFQ document.

	QUESTION / COMMENT	STATE RESPONSE
1	Do you know exactly what the customer is looking for? Are they looking for more of an Omnicell/Pyxis unit? At first I thought that maybe they wanted cabinets, but it sounds like more of a Pyxis unit. We have a First Dose unit which will hold around 300 drugs, but after looking at the list, it looks like a lot more drugs than that. Do you know how many of these units they are wanting?	See RFQ Section 1.1 for the Purpose of Procurement. See System Requirements located in RFQ Attachment H Pro Forma attachment 1. See RFQ Attachment K for drug usage information.
2	Clarify the following statement from section 1.1: "Each of the four TDMHSAS hospitals will also receive an extra AMDC for customized applications." What is meant by "customized applications"?	The extra AMDC at each RMHI is intended to contain overflow or emergency medications or items typically stored in night closets. The exact configurations of the extra AMDCs will be customized and determined by each RMHI.
3	Prior to any submission of a pricing proposal or quotation, will there be an opportunity to walkthrough each RMHI where the equipment will be located? If yes, will there be access to facility subject matter experts who will work with our teams to answer questions such as verification of data connectivity, power supply capabilities, space capabilities, space capacity, medications to be stored and any other questions that allow us to quote no more nor no less than is required for storage of each facilities' medications?	No. Vendor should reference RFQ Attachment J. RMHI Floor Plans for measurements of each room the cabinets will be located in. The RMHIs will provide data connectivity and power in each area as needed. See RFQ Attachment K. RMHI Drug Usage Information for details of what is currently being dispensed from each facility.
4	Would TDMHSAS be amenable to sharing further detailed information on the scoring requirements pertaining to cost?	Please refer to RFQ section 5.3 and RFQ Attachment E which details how the cost will be scored. Cost is valued at 30 out of 100 total points for the RFQ evaluation.
5	Would TDMHSAS be amenable to allowing our reference partners to electronically submit (email) their reference documents instead of ground mail?	No. The State requires the physical copy of the reference materials to be included with the submitted proposals.
6	If asked to demonstrate our solutions, will any of the following information be shared prior to the demonstration? a. Names of other companies invited to demonstrate b. List of attendees c. Technical requirements for demonstration	a. No, Respondent names cannot be disclosed until the notice of intent to award is released and the files are open for public inspection. b. State employees that participate in the event can be shared; however, Respondent names cannot be disclosed until the notice of intent to award is released and the files are open for public inspection.

QUESTION / COMMENT	STATE RESPONSE
	c. Yes. These are required to be disclosed

3. **RFQ Amendment Effective Date.** The revisions set forth herein shall be effective upon release. All other terms and conditions of this RFQ not expressly amended herein shall remain in full force and effect.

STATE OF TENNESSEE
MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES

REQUEST FOR QUALIFICATIONS # 33901-15113 AMENDMENT # 1 FOR GOODS OR AUTOMATED MEDICATION DISPENSING CABINETS

DATE: 11/30/2015

RFP # 33901-15113 IS AMENDED AS FOLLOWS:

1. **Delete RFQ section 1.2 in its entirety and insert the following in its place** (any sentence or paragraph containing revised or new text is highlighted)**:**

   1.2. Pre-Response Conference

   A Pre-Response Conference will be held at the time and date detailed in the RFQ Schedule of Events, RFQ § 2. Pre-Response Conference attendance is not mandatory, and potential Respondents may be limited to a maximum number of attendees depending upon overall attendance and space limitations. Please contact the Solicitation Coordinator to RSVP for the Pre-Response Conference. The Conference will be held at:

   Tennessee Tower, 3rd Floor, Conference Room G
   312 Rosa L. Parks Ave., Nashville, TN 37243

2. **RFQ Amendment Effective Date.** The revisions set forth herein shall be effective upon release. All other terms and conditions of this RFQ not expressly amended herein shall remain in full force and effect.

STATE OF TENNESSEE
DEPARTMENT OF MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES

REQUEST FOR QUALIFICATIONS FOR AUTOMATED MEDICATION DISPENSING CABINETS

RFQ # 33901-15113

TABLE OF CONTENTS

SECTIONS:

1. **Introduction**
2. **RFQ Schedule of Events**
3. **Response Requirements**
4. **General Information & Requirements**
5. **Procurement Process & Contract Award**

ATTACHMENTS:

A. **Technical Response & Evaluation Guide – Mandatory Requirement Items**
B. **Technical Response & Evaluation Guide – General Qualifications & Experience Items**
C. **Technical Response & Evaluation Guide – Technical Qualifications, Experience & Approach Items**
D. **Technical Response & Evaluation Guide – Oral Presentation and Demonstration Items**
E. **Cost Proposal & Evaluation Guide**
F. **Statement of Certifications & Assurances**
G. **Reference Questionnaire**
H. ***Pro Forma* Contract**
   Attachment 1 - System Requirements
   Attachment 2 – Attestation Re: Personnel Used in Contract Performance
   Attachment 3 – Letter of Diversity Commitment
   Attachment 4 – Tennessee Enterprise Architecture
I. **Request for Confidential Documents**
J. **RMHI Floor Plans**
K. **RMHI Drug Usage Information**
L. **Pharmacy Interface Requirements**

1. INTRODUCTION

The State of Tennessee, Department of Mental Health and Substance Abuse Services, hereinafter referred to as "the State," has issued this Request for Qualifications ("RFQ") to define mandatory goods or services requirements; solicit responses; detail response requirements; and, outline the State's process for evaluating responses and selecting a Respondent for contract award to provide the needed goods or services.

Through this RFQ or any subsequent solicitation, the State seeks to buy the requested goods or services at the most favorable, competitive prices and to give ALL qualified businesses, including those that are owned by minorities, women, Tennessee service-disabled veterans, and small business enterprises, the opportunity to do business with the state as contractors or subcontractors.

1.1. Statement of Procurement Purpose

The Tennessee Department of Mental Health and Substance Abuse Services(TDMHSAS) operates four Joint Commission Accredited Regional Mental Health Institutes (RMHIs) across the State of Tennessee. Currently medications are dispensed from the hospital pharmacy per patient from hand-written Medication Orders. Once filled, the orders are either picked up by nursing staff at the pharmacy door or delivered by pharmacy technicians to the units and stored in medication rooms. Medications are administered to the patients on the units by the unit's assigned medication nurse. Medication administration is currently a manual process that is time consuming and susceptible to errors.

It is the desire of TDMHSAS to increase the productivity of the pharmacy and nursing staff and to improve patient safety related to medication administration. This project will procure and implement one Automated Medication Dispensing Cabinets (AMDC) for each unit in each of the four TDMHSAS hospitals. Each of the four TDMHSAS hospitals will also receive an extra AMDC for customized applications. Once implemented, the AMDCs will streamline the dispensing of medication from the pharmacy to the cabinets and automate the administration of medications to the patients thus reducing medication errors and medication dispensing times, ultimately satisfying our Department's goal of improved clinical efficiency.

Once the contract has been awarded, we expect it will take approximately three months to complete the implementation at the pilot site and six additional months to complete the implementation at the remaining three sites.

Since this is the first time a purchase for goods/services of this nature has been done in the State, the estimated maximum liability is unknown.

1.2. Pre-Response Conference

A Pre-Response Conference will be held at the time and date detailed in the RFQ Schedule of Events, RFQ § 2. Pre-Response Conference attendance is not mandatory, and potential Respondents may be limited to a maximum number of attendees depending upon overall attendance and space limitations. Please contact the Solicitation Coordinator to RSVP for the Pre-Response Conference. The Conference will be held at:

Middle Tennessee Mental Health Institute
221 Stewarts Ferry Pike
Nashville, TN 37214

1.3. Notice of Intent to Respond

Before the Notice of Intent to Respond Deadline detailed in RFQ § 2, Schedule of Events, potential Respondents should submit to the Solicitation Coordinator a Notice of Intent to Respond in the form of a simple e-mail or other written communication. Such notice should include the following information: the business or individual's name (as appropriate), a contact person's name and title, the contact person's mailing address, telephone number, facsimile, number, and e-mail address.

Filing a Notice of Intent to Respond is not a prerequisite for submitting a response; however, it is necessary to ensure receipt of notices and communications relating to this RFQ.

1.3.1. System Overview

It is important for the State to understand, as completely as possible, the hardware and software that will be required to develop, implement and operate (collectively, "support") the system. Because these considerations can have a direct and significant impact on the overall cost of the system, they must be factored into the RFQ evaluation process and the vendor compensation structure. To this end, the State must evaluate the following aspects of the system:

1. Potential or actual deviations from State-standard hardware and software. This might include Contractor-owned or third-party software, such as reporting or development tools;

2. Any additional State-standard hardware/software the State must purchase to implement/operate the system;

3. The impact on the State's Total Cost of Ownership (TCO) of core components such as servers, databases, storage, and other infrastructure or staffing requirements that will be needed to support the system.

1.3.2. Tennessee Enterprise Technology Architecture Standards

The State maintains a document entitled *State of Tennessee Enterprise Technology Architecture Standards*. This document provides a list of State-standard hardware and software and will be the basis for determining which proposed products are standard, and which are deviations from State standards.

The vendor may request a copy of the Technology Architecture by submitting a written request (an email will suffice) to the Solicitation Coordinator listed in 3.2. <u>The content of this document may prompt vendor questions and/or significantly impact the vendor's proposal; therefore the State encourages interested vendors to request this document and review it carefully prior to the Written "Questions and Comments Deadline given in the Schedule of Events</u>.

In order to obtain a copy of the *State of Tennessee Enterprise Technology Architecture Standards*, Potential bidders must send in their "Intent to Respond" and the signed *Confidentiality Agreement* attached to the RFQ as Attachment I.

Once the signed *Confidentiality Agreement* is received by the State, the State will send a copy of *Tennessee Enterprise Technology Architecture* Standards. Prospective respondents must propose any exceptions to standards during the written "Questions and Comments" phase of the solicitation.

When a contract is executed pursuant to this RFQ, the *State of Tennessee Enterprise Architecture* will be included as Contract Attachment 4.

1.3.3. Exceptions to the Tennessee Enterprise Technology Architecture Standards

The State recognizes there may be cases where use of a non-standard technology product is justifiable. Potential bidders may request a waiver or an exception to a policy or standard via the State's Waiver / Exception Request Process in order to implement proposed new functionality and/or technologies.

Non-State standard products are defined as:

Any software that is not listed and designated as "Current" in, or is not compatible with the standards listed in the Enterprise Technology Architecture; or any hardware that is not listed and designated as "Current" in, or is not compatible with standards listed in the Enterprise Technology Architecture.

The use of non-State standard technology products in the proposed solution requires an approved exception to State standards. Respondents must submit exception request(s) to the State well before the response submission deadline so that they may adjust their responses depending on State approval or rejection of the requests. Respondents must submit exception requests in writing (email is acceptable) to the Solicitation Coordinator so that the State receives them by no later than the Written "Questions and Comments" Deadline in the Schedule of Events.

For each non-State standard product, the Respondent must include the following information in the exception request:

a. List the Standard product to be replaced (if applicable)

b. List the exception product being requested

c. Describe why the State standard product will not support the solution, the functionality provided by the exception product, and how the exception product will be used in the proposed solution.

d. If there is no Domain, Discipline, Technology, or Product Component listed in the Enterprise Technology Architecture that the respondent intends to propose (i.e., there is no current State standard for the product), the vendor should request an exception to use the product in question.

Proposing non-State standard product(s) that are not pre-approved will delay response evaluation and risk disqualification of the response.

Waiver / Exception requests will be forwarded to the Office of Information Resources and approved or disapproved by the State Response to written "Questions and Comments" deadline in the Schedule of Events.

Submitted responses will be reviewed for non-State standard products and handled as follows:

Responses that include non-State standard product(s), which were submitted to the State as a Written Comment and approved, will not be disqualified for proposing the approved non-State standard product(s).

Responses that include non-State standard product(s), which were submitted to the State as a Written Comment and disapproved, will be disqualified for proposing the disapproved non-State standard product(s); unless the Respondent will agree, through a written clarification response, to replace the disapproved product(s) with product(s) approved by OIR, at no additional cost to the State.

For Responses that include non-State standard product(s), which were not submitted to the State as a Written Question and approved as an exception, OIR will evaluate the proposed product(s) on a case by case basis. The decision to allow or disallow such products shall be at OIR's sole discretion and shall be documented through a written clarification. If product(s) are disallowed, the Response will be disqualified, unless the Respondent will agree, through a written clarification response, to replace the disapproved product(s) with product(s) approved by OIR, at no additional cost to the State.

The State will publish a list of the approved and disapproved exceptions as an amendment to the solicitation. Approval of an exception for any given respondent grants permission for any Respondent to use that product in their solution, i.e., use of an approved non-State standard product is not limited to the respondent that submitted the written request for approval.

1.4. Definitions and Abbreviations

TERM	DEFINITION
TDMHSAS	Tennessee Department of Mental Health and Substance

	Abuse Services
RMHI	Regional Mental Health Institutes
AMDC	Automated Medication Dispensing Cabinets
HL7	Health Level 7 Interface engine
NIST	National Institute of Standards and Technology
FIPS 201	Federal Information Processing Standard Publication 201

2. RFQ SCHEDULE OF EVENTS

The following schedule represents the State's best estimates for this RFQ; however, the State reserves the right, at its sole discretion, to adjust the schedule at any time, or cancel and reissue a similar solicitation. Nothing in this RFQ is intended by the State to create any property rights or expectations of a property right in any Respondent.

EVENT		TIME (Central Time Zone)	DATE (all dates are State business days)
1.	RFQ Issued		11/20/2015
2.	Disability Accommodation Request Deadline	2:00 p.m.	11/25/2015
3.	Pre-Response Conference	10:30 a.m.	12/01/2015
4.	Notice of Intent to Respond Deadline	2:00 p.m.	12/02/2015
5.	Written "Questions & Comments" Deadline	2:00 p.m.	12/08/2015
6.	State response to written "Questions & Comments"		12/15/2015
7.	RFQ Technical Response Deadline	2:00 p.m.	01/06/2016
8.	State Schedules Respondent Oral Presentations (ONLY Respondents who pass Mandatory Requirements)		01/14/2016
9.	Respondent Oral Presentations	8:00 a.m. – 4:30 p.m.	01/21/2016 – 01/22/2016
10.	State Notice of Qualified Respondents Released		01/25/2016
11.	RFQ Cost Proposal Deadline (ONLY for Qualified Respondents)	2:00 p.m.	02/01/2016
12.	State Evaluation Notice Released		02/03/2016
13.	Solicitation Files Opened for Public Inspections		02/04/2016
14.	Respondent Contract Signature Deadline	2:00 p.m.	02/12/2016
15.	Anticipated Contract Start Date (anticipated date for contract to be fully executed and vendor to begin work)		03/01/2016

3. RESPONSE REQUIREMENTS

3.1. **Response Contents**: A response to this RFQ should address the following:

3.1.1. Mandatory Requirements: This section details the mandatory technical, functional, and experience requirements that must be demonstrated in the response to this RFQ in order to be passed on to Phase II of the Technical Response evaluation. A Respondent must duplicate and use RFQ Attachment A as a guide to organize responses for the Mandatory Requirements of the RFQ response. The Respondent should reference the page location of the information within the response in the indicated column of the table. This section is included in the State's evaluation as to whether or not a Respondent meets mandatory qualifications (Phase I).

3.1.2. General Qualifications & Experience: This section is included in the State's evaluation of Phase II of the Technical Response Evaluation and details general information and qualifications that must be demonstrated in the response to this RFQ. A Respondent must duplicate and use RFQ Attachment B as a guide to organize responses for this portion of the RFQ response. The Respondent should reference the page location in the information within the response in the indicated column of the table.

3.1.3. Technical Qualifications, Experience & Approach: This section is also included in the State's evaluation of Phase II of the Technical Response Evaluation and details technical qualifications, experience, and approach items that must be demonstrated in the response to this RFQ. A Respondent must duplicate and use RFQ Attachment C as a guide to organize responses for this portion of the RFQ response. The Respondent should reference the page location in the information within the response in the indicated column of the table.

3.1.4. Cost Proposal: ***For Qualified Respondents only***

3.1.4.1. This section only applies to those respondents identified as being Qualified. See RFQ § 2, Schedule of Events, "State Notice of Qualified Respondents Released."

3.1.4.2. If included as part of this solicitation, then the Cost Proposal must be recorded on an exact duplicate of RFQ Attachment E, Cost Proposal & Evaluation Guide. Any response that does not follow the instructions included in RFQ Attachment E may be deemed nonresponsive.

3.1.4.3. A Respondent must only record the proposed cost exactly as required by the RFQ Attachment E, Cost Proposal & Evaluation Guide and must NOT record any other rates, amounts, or information.

3.1.4.4. The proposed cost shall incorporate ALL costs for services under the contract for the total contract period.

3.1.4.5. A Respondent must sign and date the Cost Proposal.

3.1.4.6. A Respondent must submit the Cost Proposal to the State in a sealed package separate from the Technical Response.

3.2. Response Delivery Location

A Respondent must ensure that the State receives a Response to this RFQ no later than the Response Deadline time and dates detailed in the RFQ § 2, Schedule of Events. All responses must be delivered to:

Christopher Romaine
Central Procurement Office
312 Rosa L. Parks Ave., Nashville, TN 37243
615-253-5613
Christopher.Romaine@tn.gov

3.3. Response Format

3.3.1. A Respondent must ensure that the original response meets all form and content requirements detailed within this RFQ.

3.3.2 A Respondent must submit original response documents and copies as specified below.

3.3.2.1. Technical Response
One (1) original Technical Response paper document clearly labeled:

"RFQ #33901-15113 TECHNICAL RESPONSE ORIGINAL"

and five (5) copies of the Technical Response each in the form of one (1) digital document in "PDF" format properly recorded on its own otherwise blank, standard CD-R recordable disc or USB flash drive labeled:

"RFQ #33901-15113 TECHNICAL RESPONSE COPY"

The digital copies should not include copies of sealed customer references or cost information in the general and technical evaluation phase. However, any other discrepancy between the paper response document and digital copies may result in the State rejecting the response as nonresponsive.

3.3.2.2. Cost Proposal: ***For Qualified Respondents only***
One (1) original Cost Proposal paper document labeled:

"RFQ #33901-15113 COST PROPOSAL ORIGINAL"

and one (1) copy in the form of a digital document in "XLS" format properly recorded on a separate, blank, standard CD-R recordable disc or USB flash-drive labeled:

"RFQ #33901-15113 COST PROPOSAL COPY"

In the event of a discrepancy between the original Cost Proposal document and the digital copy, the original, signed document will take precedence.

3.4. Response Prohibitions: A response to this RFQ shall not:

3.4.1. Restrict the rights of the State or otherwise qualify the response to this RFQ;

3.4.2. Include, for consideration in this procurement process or subsequent contract negotiations, incorrect information that the Respondent knew or should have known was materially incorrect;

3.4.3. Include more than one response, per Respondent, to this RFQ;

3.4.4. Include any information concerning costs (in specific dollars or numbers) associated with the Technical Response;

3.4.5. Include the respondent's own contract terms and conditions (unless specifically requested by the RFQ); or

3.4.6. Include the respondent as a prime contractor while also permitting one or more other respondents to offer the respondent as a subcontractor in their own responses;

3.4.7. Include any end-user license agreement, manufacturer's terms and conditions, service guide, clickwrap agreement, shrinkwrap agreement, online terms and conditions, or other terms and conditions that will supplement, modify, or contradict the terms set forth in the *pro forma* contract;

3.4.8. Provide an oral presentation to exceed 3 hours in length including time for questions. A topic outline will be provided with the oral presentation invitation.

3.5. Response Errors & Revisions

A Respondent is responsible for any and all errors or omissions in its response to this RFQ. A Respondent will not be allowed to alter or revise its response after the Response Deadline time and dates as detailed in RFQ § 2, Schedule of Events, unless such is formally requested in writing by the State (e.g., through a request for clarification, etc.).

3.6. Response Withdrawal

A Respondent may withdraw a response at any time before the Response Deadline time and date as detailed in RFQ § 2, Schedule of Events, by submitting a written signed request by an authorized representative of the Respondent. After withdrawing a response, a Respondent may submit another Response at any time before the Response Deadline time and date as detailed in RFQ § 2, Schedule of Events.

3.7. Response Preparation Costs

The State will not pay any costs associated with the preparation, submittal, or presentation of any response. Each Respondent is solely responsible for the costs it incurs in responding to this RFQ.

4. GENERAL INFORMATION & REQUIREMENTS

4.1. Communications

4.1.1 Respondents shall reference RFQ #33901-15113 in all communications relating to this solicitation, and direct any such communications to the following person designated as the Solicitation Coordinator:

Christopher Romaine, Sourcing Analyst
Central Procurement Office
312 Rosa L. Parks Avenue
Nashville, TN 37243
615-253-5613
Email: Christopher.Romaine@tn.gov

The State will convey all official responses and communications related to this RFQ to the potential respondents from whom the State has received a Notice of Intent to Respond (refer to RFQ Section 1.3.).

4.1.2. Potential respondents with a handicap or disability may receive accommodation relating to the communication of this RFQ and participating in the RFQ process. Potential respondents may contact the RFQ Coordinator to request such reasonable accommodation no later than the Disability Accommodation Request Deadline detailed in RFQ § 2, Schedule of Events.

4.1.3. **Unauthorized contact about this RFQ with other employees or officials of the State of Tennessee may result in disqualification from contract award consideration.**

4.1.4. Notwithstanding the foregoing, potential Respondents may also contact the following as appropriate:4.1.4.1. Staff of the Governor's Office of Diversity Business Enterprise may be contacted for assistance with respect to available minority-owned, woman-owned, Tennessee service-disabled veteran-owned, and small business enterprises as well as general public information relating to this request; or

4.1.4.2. The following individual designated by the State to coordinate compliance with the nondiscrimination requirements of the State of Tennessee, Title VI of the Civil Rights Act of 1964, the Americans with Disabilities Act of 1990, and associated federal regulations:

Gwen Hamer
Tennessee Department of Mental Health and Substance Abuse Services
500 Deaderick Street
Nashville, TN 37243

4.2. Nondiscrimination

No person shall be excluded from participation in, be denied benefits of, or be otherwise subjected to discrimination in the performance of a contract pursuant to this solicitation or in the employment practices of the Vendor on the grounds of handicap or disability, age, race, color, religion (subject to *Tennessee Code Annotated,* Sections 4-21-401 and 405), sex, national origin, or any other classification protected by federal, Tennessee state constitutional, or statutory law. The Vendor pursuant to this solicitation shall post in conspicuous places, available to all employees and applicants, notices of nondiscrimination.

4.3. Conflict of Interest

4.3.1. The State may not consider a proposal from an individual who is, or within the past six (6) months has been, a State employee. For these purposes,

4.3.1.1 An individual shall be deemed a State employee until such time as all compensation for salary, termination pay, and annual leave has been paid;

4.3.1.2. A contract with or a proposal from a company, corporation, or any other contracting entity in which a controlling interest is held by any State employee shall be considered to be a contract with or proposal from the employee; and

4.3.1.3. A contract with or a proposal from a company, corporation, or any other contracting entity that employs an individual who is, or within the past six months has been, a State employee shall not be considered a contract with or a proposal from the employee and shall not constitute a prohibited conflict of interest.

4.3.2. This RFQ is also subject to *Tennessee Code Annotated*, Section 12-4-101.

4.4. **Respondent Required Review & Waiver of Objections**

4.4.1. Each potential respondent must carefully review this RFQ, including but not limited to, attachments, the RFQ Attachment H, *pro forma* Contract, and any amendments for questions, comments, defects, objections, or any other matter requiring clarification or correction (collectively called "questions and comments").

4.4.2. Any potential respondent having questions and comments concerning this RFQ must provide such in writing to the State no later than the written "Questions & Comments Deadline" detailed in RFQ § 2, Schedule of Events.

4.4.3. Protests based on any objection shall be considered waived and invalid if the objection has not been brought to the attention of the State, in writing, by the written "Questions & Comments Deadline."

4.5 **Disclosure of Response Contents**

4.5.1. All materials submitted to the State in response to this solicitation become property of the State of Tennessee. Selection for award does not affect this right. By submitting a response, a Respondent acknowledges and accepts that the full contents and associated documents submitted in response to this request will become open to public inspection. Refer to RFQ § 2, Schedule of Events.

4.5.2. The RFQ responses will be available for public inspection only after the completion of evaluation of the RFQ or any resulting solicitation which this RFQ becomes a part of, whichever is later.

4.6 **Notice of Professional Licensure, Insurance, and Department of Revenue Registration Requirements**

4.6.1. All persons, agencies, firms or other entities that provide legal or financial opinions, which a Respondent provides for consideration and evaluation by the State as part of a response to this RFQ, shall be properly licensed to render such opinions.

4.6.2. Before the Contract resulting from this RFQ is signed, the apparent successful Respondent (and Respondent employees and subcontractors, as applicable) must hold all necessary, appropriate business and professional licenses to provide service as required. The State may require any Respondent to submit evidence of proper licensure.

4.6.3. Before the Contract resulting from this RFQ is signed, the apparent successful Respondent must provide a valid, Certificate of Insurance indicating current insurance coverage meeting minimum requirements as may be specified by the RFQ.

4.6.4. Before the Contract resulting from this RFP is signed, the apparent successful Respondent must be registered with the Department of Revenue for the collection of Tennessee sales and use tax. The State shall not approve a contract unless the Respondent provides proof of such registration. The foregoing is a mandatory requirement of an award of a contract pursuant to this solicitation.

4.7. **RFQ Amendments & Cancellation**

4.7.1. The State reserves the right to amend this RFQ at any time, provided that it is amended in writing. However, prior to any such amendment, the State will consider whether it would negatively impact the ability of potential respondents to meet the deadlines and revise the

RFQ Schedule of Events if deemed appropriate. If a RFQ amendment is issued, the State will convey it to potential respondents who submitted a Notice of Intent to Respond (refer to RFQ § 1.3). A response must respond, as required, to the final RFQ (including its attachments) as may be amended.

4.7.2. The State reserves the right, at its sole discretion, to cancel or to cancel and reissue this RFQ in accordance with applicable laws and regulations.

4.8. **State Right of Rejection**

4.8.1. Subject to applicable laws and regulations, the State reserves the right to reject, at its sole discretion, any and all proposals.

4.8.2. The State may deem as nonresponsive and reject any proposal that does not comply with all terms, conditions, and performance requirements of this RFQ. Notwithstanding the foregoing, the State reserves the right to seek clarifications or to waive, at its sole discretion, a response's minor variances from full compliance with this RFQ. If the State waives variances in a response, such waiver shall not modify the RFQ requirements or excuse the Respondent from full compliance with such, and the State may hold any resulting vendor to strict compliance with this RFQ.

4.8.3. The State will review the response evaluation record and any other available information pertinent to whether or not each respondent is responsive and responsible. If the evaluation team identifies any respondent that appears <u>not</u> to meet the responsive and responsible thresholds such that the team would not recommend the respondent for potential contract award, this determination will be fully documented for the record. ("Responsive" is defined as submitting a response that conforms in all material respects to the RFQ. "Responsible" is defined as having the capacity in all respects to perform fully the contract requirements, and the integrity and reliability which will assure good faith performance.)

4.9. **Assignment & Subcontracting**

4.9.1. The vendor may not subcontract, transfer, or assign any portion of the Contract awarded as a result of this RFQ without prior approval of the State. The State reserves the right to refuse approval, at its sole discretion, of any subcontract, transfer, or assignment.

4.9.2. If a Respondent intends to use subcontractors, the response to this RFQ must specifically identify the scope and portions of the work each subcontractor will perform (refer to RFQ Attachment B, Item B.14.).

4.9.3. Subcontractors identified within a response to this RFQ will be deemed as approved by the State unless the State expressly disapproves one or more of the proposed subcontractors prior to signing the Contract.

4.9.4. The Contractor resulting from this RFQ may only substitute another subcontractor for a proposed subcontractor at the discretion of the State and with the State's prior, written approval.

4.9.5. Notwithstanding any State approval relating to subcontracts, the Contractor resulting from this RFQ will be the prime contractor and will be responsible for all work under the Contract.

4.10. **Next Ranked Respondent**

The State reserves the right to initiate negotiations with the next ranked respondent should the State cease doing business with any respondent selected via this RFQ process.

5. PROCUREMENT PROCESS & CONTRACT AWARD

5.1. The complete vendor selection will be a two-part process: (1) Qualification of Technical Responses; and (2) Evaluation of Cost Proposals. Any contract award is subject to successful contract negotiation.

5.2. Qualification of Technical Responses: Technical Responses will be short-listed for further evaluation, analysis or negotiation if they are apparently responsive, responsible, and within the competitive range. A Technical Response will be deemed within the competitive range based on the following criterion:

The Technical Response must be ranked in the top 3 after the Technical Response score is totaled and put in ordinal ranking (1 being the best evaluated ranking).

Phase I: The State will evaluate the Mandatory Requirements set forth in RFQ Attachment A on a pass/fail basis.

Phase II: Following the Phase I evaluation, the State will apply a standard equitable evaluation model, which will represent a qualitative assessment of each response. Each response will be scored by Evaluation Team members according to the Technical Response & Evaluation Guides (See RFQ Attachments B & C).

The Solicitation Coordinator will total the average score from the evaluation team for each responsive and responsible Respondent's Technical Response Points for RFQ Attachments B & C to determine which of the Respondents are considered Qualified and within the competitive range.

The State may invite those who passed the Phase I evaluation to give oral presentations to the State. The qualitative assessment of each Respondent will include the information derived from the oral presentations (See RFQ Attachment D).

5.3. Cost Proposals: If included as part of this solicitation then only Qualified Respondents, that are responsive and responsible and in the competitive range, will continue onto Part Two, Cost Proposal evaluation. The Cost Proposal containing the lowest cost will receive the maximum number of points per each section. See RFQ Attachment E, Cost Proposal & Evaluation Guide.

5.4. Clarifications and Negotiations: The State reserves the right to award a contract on the basis of initial responses received; therefore, each response should contain the respondent's best terms from a technical and cost standpoint. However, the State reserves the right to conduct clarifications or negotiations with respondents. All communications, clarifications, and negotiations shall be conducted in a manner that supports fairness in response improvement.

5.4.1. Clarifications: The State may identify areas of a response that may require further clarification or areas in which it is apparent that there may have been miscommunications or misunderstandings as to the State's specifications or requirements. The State may seek to clarify those issues identified during one or multiple clarification round(s). Each clarification sought by the State may be unique to an individual respondent.

5.4.2. Negotiations: The State may elect to negotiate with Qualified Respondents, within the competitive range, by requesting revised responses, negotiating costs, or finalizing contract terms and conditions. The State reserves the right to conduct multiple negotiation rounds

5.4.2.1. Cost Negotiations: All responsive respondents within the competitive range will be given equivalent information with respect to cost negotiations. All cost negotiations will be documented for the procurement file. Additionally, the State may conduct target pricing and other goods or services level negotiations. Target pricing may be based on considerations such as current pricing, market considerations, benchmarks, budget availability, or other methods that do not reveal individual

respondent pricing. During target price negotiations, respondents are not obligated to meet or beat target prices, but will not be allowed to increase prices.

5.4.2.2. If the State determines costs and contract finalization discussions and negotiations are not productive, the State reserves the right to bypass the apparent best evaluated Respondent and enter into contract negotiations with the next apparent best evaluated Respondent.

5.5. Evaluation Guide

The State will consider qualifications, experience, technical approach, and cost (if applicable) in the evaluation of responses and award points in each of the categories detailed below. The maximum evaluation points possible for each category are detailed below.

Evaluation Category	Maximum Points Possible
Mandatory Requirements (refer to RFQ Attachment A)	Pass/Fail
General Qualifications, Experience, Technical Qualifications, Experience & Approach (refer to RFQ Attachment B)	15
Technical Qualifications, Experience & Approach (refer to RFQ Attachment C)	35
Oral Presentation (refer to RFQ Attachment D)	20
Cost Proposal (refer to RFQ Attachment E)	30

5.6. Contract Award

5.6.1. The Solicitation Coordinator will submit the Evaluation Team determinations and response scores to the head of the contracting agency, or the agency head's designee, for consideration along with any other relevant information that might be available and pertinent to contract award.

5.6.2. The contracting agency head, or the agency head's designee, will determine the apparent best-evaluated response. (To effect a contract award to a Respondent other than the one receiving the highest evaluation score, the head of the contracting agency must provide written justification and obtain written approval of the Chief Procurement Officer and the Comptroller of the Treasury.)

5.6.3. The State reserves the right to make an award without further discussion of any response.

5.6.4. The State will issue an Evaluation Notice and make the RFQ files available for public inspection at the time and date specified in the RFQ §2, Schedule of Events.

NOTICE: The Evaluation Notice shall not create rights, interests, or claims of entitlement in either the Respondent identified as the apparent best evaluated or any other Respondent.

5.6.5. The Respondent identified as offering the apparent best-evaluated must sign a contract drawn by the State pursuant to this RFQ. The contract shall be substantially the same as the RFQ Attachment H, pro forma contract. The Respondent must sign said contract no later than the Respondent Contract Signature Deadline detailed in RFQ § 2, Schedule of Events. If the Respondent fails to provide the signed contract by the deadline, the State may determine the Respondent is non-responsive to this RFQ and reject the response.

5.6.6. Notwithstanding the foregoing, the State may, at its sole discretion, entertain limited

negotiation prior to contract signing and, as a result, revise the pro forma contract terms and conditions or performance requirements in the State's best interests, PROVIED THAT such revision of terms and conditions or performance requirements shall NOT materially affect the basis of response evaluation or negatively impact the competitive nature of the RFQ and vendor selection process.

5.6.7. If the State determines that a response is nonresponsive and rejects it after opening Cost Proposals, the Solicitation Coordinator will re-calculate scores for each remaining responsive Cost Proposal to determine (or re-determine) the apparent best-evaluated response.

ATTACHMENT A

TECHNICAL RESPONSE & EVALUATION GUIDE

SECTION A: MANDATORY REQUIREMENTS. All Respondents must address all items detailed below and provide, in sequence, the information and documentation as required (referenced with the associated item references). All Respondents must also detail the response page number for each item in the appropriate space below.

The Solicitation Coordinator will review all responses to determine if the Mandatory Requirement Items are addressed as required and mark each with pass or fail. For each item that is not addressed as required, the Evaluation Team must review the responses and attach a written determination. In addition to the Mandatory Requirement Items, the Solicitation Coordinator will review each response for compliance with all RFQ requirements.

RESPONDENT LEGAL ENTITY NAME:			
Response Page # (Respondent completes)	**Item Ref.**	**Section A— Mandatory Requirement Items**	**Pass/Fail**
		The Technical Response must be delivered to the State no later than the Technical Response Deadline specified in the RFQ § 2, Schedule of Events.	
		The Technical Response must not contain cost or pricing information of any type.	
		The Technical Response must not contain any restrictions of the rights of the State or other qualification of the response.	
		A Respondent must not submit alternate responses.	
		A Respondent must not submit multiple responses in different forms (as a prime and a subcontractor).	
	A.1.	Provide the Statement of Certifications and Assurances (RFQ Attachment F) completed and signed by an individual empowered to bind the Respondent to the provisions of this RFQ and any resulting contract. The document must be signed without exception or qualification.	
	A.2.	Provide a statement, based upon reasonable inquiry, of whether the Respondent or any individual who shall perform work under the contract has a possible conflict of interest (*e.g.*, employment by the State of Tennessee) and, if so, the nature of that conflict. NOTE: Any questions of conflict of interest shall be solely within the discretion of the State, and the State reserves the right to cancel any award.	
	A.3.	Provide a current bank reference indicating that the Respondent's business relationship with the financial institution is in positive standing. Such reference must be written in the form of a standard business letter, signed, and dated within the past three (3) months.	
	A.4.	Provide two current positive credit references from vendors with which the Respondent has done business written in the form of standard business letters, signed, and dated within the past three (3) months.	
	A.5.	Provide an official document or letter from an accredited credit bureau, verified and dated within the last three (3) months and indicating a positive credit rating for the Respondent (NOTE: A credit bureau report number without the full report is insufficient and will not be considered responsive.)	
	A.6.	Provide a narrative describing procedures to be used and challenges to be faced in installing the proposed AMDC solution on the State's VMWare	

RESPONDENT LEGAL ENTITY NAME:			
Response Page # (Respondent completes)	**Item Ref.**	**Section A— Mandatory Requirement Items**	**Pass/Fail**
		environment. Currently the State supports VMWare ESXi 5.1 Update 3.	
	A.7.	Provide a detailed description that validates the ability of the proposed solution to configure settings and manage devices, users, and formulary items at enterprise-wide, individual RMHI, and AMDC levels.	
	A.8.	Provide documentation that verifies the proposed solution's abilities to provide both biometric and conventional (typed user id and password) access to the AMDC in compliance with NIST and FIPS 201.	
	A.9.	Provide documentation that verifies the proposed solution's abilities and constraints in communicating with the QS1 PrimeCare Pharmacy System utilizing HL7 standards.	
State Use – RFQ Coordinator Signature, Printed Name & Date:			

ATTACHMENT B

TECHNICAL RESPONSE & EVALUATION GUIDE

SECTION B: GENERAL QUALIFICATIONS & EXPERIENCE. The Respondent must address all items detailed below and provide, in sequence, the information and documentation as required (referenced with the associated item references). The Respondent must also detail the response page number for each item in the appropriate space below. Evaluation Team members will independently evaluate and assign one score for all responses to Section B— General Qualifications & Experience Items.

RESPONDENT LEGAL ENTITY NAME:		
Response Page # (Respondent completes)	**Item Ref.**	**Section B— General Qualifications & Experience Items**
	B.1.	Detail the name, e-mail address, mailing address, telephone number, and facsimile number of the person the State should contact regarding the response.
	B.2.	Describe the Respondent's form of business (*i.e.*, individual, sole proprietor, corporation, non-profit corporation, partnership, limited liability company) and business location (physical location or domicile).
	B.3.	Detail the number of years the Respondent has been in business.
	B.4.	Briefly describe how long the Respondent has been performing the goods or services required by this RFQ.
	B.5.	Describe the Respondent's number of employees, client base, and location of offices.
	B.6.	Provide a statement of whether there have been any mergers, acquisitions, or sales of the Respondent within the last ten (10) years. If so, include an explanation providing relevant details.
	B.7.	Provide a statement of whether the Respondent or, to the Respondent's knowledge, any of the Respondent's employees, agents, independent contractors, or subcontractors, proposed to provide work on a contract pursuant to this RFQ, have been convicted of, pled guilty to, or pled *nolo contendere* to any felony. If so, include an explanation providing relevant details.
	B.8.	Provide a statement of whether, in the last ten (10) years, the Respondent has filed (or had filed against it) any bankruptcy or insolvency proceeding, whether voluntary or involuntary, or undergone the appointment of a receiver, trustee, or assignee for the benefit of creditors. If so, include an explanation providing relevant details.
	B.9.	Provide a statement of whether there is any material, pending litigation against the Respondent that the Respondent should reasonably believe could adversely affect its ability to meet contract requirements pursuant to this RFQ or is likely to have a material adverse effect on the Respondent's financial condition. If such exists, list each separately, explain the relevant details, and attach the opinion of counsel addressing whether and to what extent it would impair the Respondent's performance in a contract pursuant to this RFQ. NOTE: All persons, agencies, firms, or other entities that provide legal opinions regarding the Respondent must be properly licensed to render such opinions. The State may require the Respondent to submit proof of such licensure detailing the state of licensure and licensure number for each person or entity that renders such opinions.
	B.10.	Provide a statement of whether there is any pending or in progress Securities Exchange Commission investigations involving the Respondent. If such exists, list each separately, explain the relevant details, and attach the opinion of counsel addressing whether and to what extent it will impair the Respondent's performance in a contract pursuant to this RFQ. NOTE: All persons, agencies, firms, or other entities that provide legal opinions regarding the Respondent must be properly licensed to render such opinions. The State may require the

RESPONDENT LEGAL ENTITY NAME:		
Response Page # (Respondent completes)	**Item Ref.**	**Section B— General Qualifications & Experience Items**
		Respondent to submit proof of such licensure detailing the state of licensure and licensure number for each person or entity that renders such opinions.
	B.11.	Provide a brief, descriptive statement detailing evidence of the Respondent's ability to deliver the goods or services sought under this RFQ (*e.g.*, prior experience, training, certifications, resources, program and quality management systems, *etc*.).
	B.12.	Provide a narrative description of the proposed contract team, its members, and organizational structure along with an organizational chart identifying the key people who will be assigned to provide the goods or services required by this RFQ, illustrating the lines of authority, and designating the individual responsible for the completion of each task and deliverable of the RFQ.
	B.13.	Provide a personnel roster listing the names of key people who the Respondent will assign to perform tasks required by this RFQ along with the estimated number of hours that each individual will devote to the required tasks. Follow the personnel roster with a resume for each of the people listed. The resumes must detail the individual's title, education, current position with the Respondent, and employment history.
	B.14.	Provide a statement of whether the Respondent intends to use subcontractors to accomplish the work required by this RFQ, and if so, detail: a. the names of the subcontractors along with the contact person, mailing address, telephone number, and e-mail address for each; b. a description of the scope and portions of the work each subcontractor will perform; <u>and</u> c. (c) a statement specifying that each proposed subcontractor has expressly assented to being proposed as a subcontractor in the Respondent's response to this RFQ.
	B.15.	Provide documentation of the Respondent's commitment to diversity as represented by the following: a. <u>Business Strategy</u>. Provide a description of the Respondent's existing programs and procedures designed to encourage and foster commerce with business enterprises owned by minorities, women, Tennessee service-disabled veterans, and small business enterprises. Please also include a list of the Respondent's certifications as a diversity business, if applicable. b. <u>Business Relationships</u>. Provide a listing of the Respondent's current contracts with business enterprises owned by minorities, women, Tennessee service-disabled veterans and small business enterprises. Please include the following information: (i) contract description; (ii) contractor name and ownership characteristics (*i.e.*, ethnicity, gender, Tennessee service-disabled); and (iii) contractor contact name and telephone number. c. <u>Estimated Participation</u>. Provide an estimated level of participation by business enterprises owned by minorities, women, Tennessee service-disabled veterans, and small business enterprises if a contract is awarded to the Respondent pursuant to this RFP. Please include the following information: (i) a percentage (%) indicating the participation estimate. (Express the estimated participation number as a percentage of the total estimated contract value that will be dedicated to business with subcontractors and supply contractors having such ownership characteristics only and **DO <u>NOT</u> INCLUDE DOLLAR AMOUNTS**); (ii) anticipated goods or services contract descriptions; (iii) names and ownership characteristics (i.e., ethnicity, gender, Tennessee service-disabled veterans) of anticipated subcontractors and supply contractors.

RESPONDENT LEGAL ENTITY NAME:		
Response Page # (Respondent completes)	**Item Ref.**	**Section B— General Qualifications & Experience Items**
		NOTE: In order to claim status as a Diversity Business Enterprise under this contract, businesses must be certified by the Governor's Office of Diversity Business Enterprise (Go-DBE). Please visit the Go-DBE website at https://tn.diversitysoftware.com/FrontEnd/StartCertification.asp?TN=tn&XID=9265 for more information. d. Workforce. Provide the percentage of the Respondent's total current employees by ethnicity and gender. NOTE: Respondents that demonstrate a commitment to diversity will advance State efforts to expand opportunity to do business with the State as contractors and subcontractors. Response evaluations will recognize the positive qualifications and experience of a Respondent that does business with enterprises owned by minorities, women, Tennessee service-disabled veterans and small business enterprises and who offer a diverse workforce.
	B.16.	Provide a statement of whether or not the Respondent has any current contracts with the State of Tennessee or has completed any contracts with the State of Tennessee within the previous five-year period. If so, provide the following information for all current and completed contracts: a. the name, title, telephone number and e-mail address of the State contact responsible for the contract at issue; b. the name of the procuring State agency; c. a brief description of the contract's specification for goods or scope of services; d. the contract term; and e. the contract number. NOTES: Current or prior contracts with the State are not a prerequisite and are not required for the maximum evaluation score, and the existence of such contracts with the State will not automatically result in the addition or deduction of evaluation points. Each evaluator will generally consider the results of inquiries by the State regarding all contracts responsive to Section B.16 of this RFQ.
	B.17.	Provide customer references from individuals who are not current or former State employees for projects similar to the goods or services sought under this RFQ and which represent: two (2) accounts Respondent currently services that are similar in size to the State; and three (3) completed projects. References from at least three (3) different individuals are required to satisfy the requirements above, e.g., an individual may provide a reference about a completed project and another reference about a currently serviced account. The standard reference questionnaire, which must be used and completed is provided at RFQ Attachment F. References that are not completed as required may be deemed nonresponsive and may not be considered. The Respondent will be solely responsible for obtaining fully completed reference questionnaires and including them in the sealed Technical Response. In order to obtain and submit the completed reference questionnaires, follow the process below: a. Add the Respondent's name to the standard reference questionnaire at Attachment F, and make a copy for each reference. b. Send a reference questionnaire and a new, standard #10 envelope to each reference. c. Instruct the reference to: d. complete the reference questionnaire; a. (ii) sign and date the completed reference questionnaire; b. (iii) seal the completed, signed, and dated reference questionnaire within the envelope provided; c. (iv) sign his or her name in ink across the sealed portion of the envelope; and d. (v) return the sealed envelope directly to the Respondent (the Respondent may wish to give each reference a deadline, such that the Respondent will be able to collect all required references in time to include them within the sealed Technical Response).

RESPONDENT LEGAL ENTITY NAME:		
Response Page # (Respondent completes)	**Item Ref.**	**Section B— General Qualifications & Experience Items**
		e. Do NOT open the sealed references upon receipt. f. Enclose all sealed reference envelopes within a larger, labeled envelope for inclusion in the Technical Response as required. NOTES: The State will not accept late references or references submitted by any means other than that which is described above, and each reference questionnaire submitted must be completed as required. The State will not review more than the number of required references indicated above. While the State will base its reference check on the contents of the sealed reference envelopes included in the Technical Response package, the State reserves the right to confirm and clarify information detailed in the completed reference questionnaires, and may consider clarification responses in the evaluation of references. The State is under no obligation to clarify any reference information.
	B.18.	Provide a statement and any relevant details addressing whether the Respondent is any of the following: is presently debarred, suspended, proposed for debarment, or voluntarily excluded from covered transactions by any federal or state department or agency; has within the past three (3) years, been convicted of, or had a civil judgment rendered against the contracting party from commission of fraud, or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (federal, state, or local) transaction or grant under a public transaction; violation of federal or state antitrust statutes or commission of embezzlement, theft, forgery, bribery, falsification or destruction of records, making false statements, or receiving stolen property; is presently indicted or otherwise criminally or civilly charged by a government entity (federal, state, or local) with commission of any of the offenses detailed above; and has within a three (3) year period preceding the contract had one or more public transactions (federal, state, or local) terminated for cause or default.
	B.19.	The State is amenable to making changes to RFQ Attachment H, *pro forma* contract. The State will take all reasonable suggested alternative or supplemental contract language changes by Respondents under advisement during the evaluation and post award processes, subject to any mandates or restrictions imposed on the State by applicable state or federal law. The State, however, recommends that Respondents include with their response any alternative or supplemental suggested contract language that a Respondent would propose. Clearly indicate, by providing a "red-line" of RFQ Attachment H, *pro forma* contract, all suggested alternative or supplemental contract language. Do **not** include any exceptions or changes that (1) contradict a Federal requirement or a Mandatory Requirement, or (2) push back any deadlines.
	B.20	Provide a description of your company's experience and policies regarding direct leasing to your customers. Include copies of your leased agreements you have signed in the past. Do not include any cost or rate information in this response.
SCORE *(for all Section B— Qualifications & Experience Items above)*: *(maximum possible score = 15)*		

RESPONDENT LEGAL ENTITY NAME:		
Response Page # (Respondent completes)	**Item Ref.**	**Section B— General Qualifications & Experience Items**
State Use – Evaluator Identification:		

ATTACHMENT C

TECHNICAL RESPONSE & EVALUATION GUIDE

SECTION C: TECHNICAL QUALIFICATIONS, EXPERIENCE & APPROACH. The Respondent should explain its approach to providing goods or services to the State. The items listed below represent specific questions the State would request you answer in your response. For ease of review, please annotate your explanation so that it contains references to the items listed below where they are addressed. Respondent should not feel constrained to answer only the specific questions listed below in its explanation and should feel free to provide attachments if necessary in an effort to provide a more thorough response.

The Evaluation Team, made up of three (3) or more State employees, will independently evaluate and score the response to each item. Each evaluator will use the following whole number, raw point scale for scoring each item:

0 = little value 1 = poor 2 = fair 3 = satisfactory 4 = good 5 = excellent

The Solicitation Coordinator will multiply the Item Score by the associated Evaluation Factor (indicating the relative emphasis of the item in the overall evaluation). The resulting product will be the item's raw, weighted score for purposes of calculating the section scores as indicated.

RESPONDENT LEGAL ENTITY NAME:					
Response Page # (Respondent completes)	**Item Ref.**	**Section C— Technical Qualifications, Experience & Approach Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
	C.1.	Provide a narrative that illustrates the Respondent's understanding of the State's requirements and project schedule.		10	
	C.2.	Provide a narrative that illustrates how the Respondent will complete the delivery of goods or scope of services, accomplish required objectives, and meet the State's project schedule.		**5**	
	C.3.	Provide a narrative that describes the Respondent's experience in implementing product for a new customer of similar size and scope as the State is envisioning. Include staffing and skill requirements for the Respondent's and State's staff for this implementation.		**5**	
	C.4.	Provide a narrative that illustrates how the Respondent will manage the project, ensure delivery of specified goods or completion of the scope of services, and accomplish required objectives. Include in this narrative the methodology used to build, test and implement the final product. Deliverables identified should include but are not limited to the following: a. Master Project Management Plan b. Requirements Verification Plan c. Interface Solution Plan d. Implementation Plan e. Security Plan f. Data Recovery Plan g. Training Plan h. Support and Maintenance Plan		**7**	
	C.5.	Provide a narrative that describes the successful training processes the Respondent has used in projects of similar scope, size and complexity. Include at least one Training Plan that meets the requirements described in Attachment H Pro Forma Contract Section A.4.i.		**5**	

RESPONDENT LEGAL ENTITY NAME:					
Response Page # (Respondent completes)	**Item Ref.**	**Section C— Technical Qualifications, Experience & Approach Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
	C.6.	Provide a narrative that defines the physical configuration options for the proposed AMDC including any constraints that require consideration with each option.		**8**	
	C.7.	Provide a detailed recommendation for the configuration(s) of the cabinets including a justification for each recommended option based on the requirements listed in the Attachment J RMHI Floor Plans and Attachment K RMHI Drug Usage Information.		**10**	
	C.8.	Submit written evidence of the sturdiness and life expectancy of the physical cabinet components.		**10**	
	C.9.	Provide a written description of the Respondent's customer support process including service level metrics. Reference Pro Forma Scope of Work Section A.12. Include the following topics in your response: a. Issue submission process b. Onsite technical support c. Remote technical support availability d. Emergency maintenance procedures for critical issues or disasters affecting the AMDC system		**10**	
	C.10.	Provide instructions and work flow diagrams to describe the Respondent's recommended processes for the following: a. Configuring cabinet drawers and bins to meet changing medication needs b. Accessing, wasting, returning and inventorying controlled substances, including security measures c. Removing partial quantities of a whole unit (i.e. multi-dose vials or bulk liquids)		**10**	
	C.11.	Provide a narrative that describes the process and procedures by which reports are generated, formatted and stored. Include examples of dashboards and frequently used reports. Address the following topics in your response: a. Analytical tools available to support drill down and dashboard functions for the following: tracking, delivering, and dispensing medications b. Process for generating system-level reports from a workstation not directly connected to an AMDC c. Tracking reports for attempted access of non-authorized medication compartments. d. System's ability to automatically generate scheduled reports e. Data retention policies for reportable data for live system and archives f. Amount of data storage and its effect on system performance g. Method used by pharmacy staff to build custom reports h. The file formats supported for exported report data		**8**	
	C.12.	Provide a narrative to describe how your AMDC server solution supports RMHIs located in multiple time zones.		**10**	

RESPONDENT LEGAL ENTITY NAME:	

Response Page # (Respondent completes)	**Item Ref.**	**Section C— Technical Qualifications, Experience & Approach Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
	C.13.	Provide a narrative that describes security measures contained in the AMDC system solution. Address the following areas: a. Security authentication and access management of the AMDC b. Security authentication and access for remote workstations c. User role management and configuration access d. System security configuration options and constraints		**10**	
	C.14.	Provide a narrative describing how the Respondent's system will satisfy the following security compliance requirements found in the following sections of Attachment H: a. A.18. Federal and Tennessee Data Security and Privacy Compliance b. A.19. Compliance with Enterprise Information Security Policies c. A.21. Encryption d. A.23. Removable Media e. A.24. Protection of Information		**10**	
	C.15.	Provide a description of the processes in which the AMDC solution will interface with the State's QS1 PrimeCare pharmacy system using HL7. Include the following topics in your response: a. Frequency in which usage transaction data is sent to the pharmacy software system, explain all available options and the benefits of each b. The trigger event that initiates a usage transaction to the pharmacy software system c. Any limitations to receiving patient or medication order information pushed from pharmacy software system (refer to Attachment L Pharmacy Interface Requirements)		**10**	

The Solicitation Coordinator will use this sum and the formula below to calculate the section score. All calculations will use and result in numbers rounded to two (2) places to the right of the decimal point.	**Total Raw Weighted Score:** *(sum of Raw Weighted Scores above)*	
Total Raw Weighted Score / **Maximum Possible Raw Weighted Score** *(i.e., 5 x the sum of item weights above)*	**X 35** *(maximum possible score)*	**= SCORE:**

State Use – Evaluator Identification:

State Use – Solicitation Coordinator Signature, Printed Name & Date:

ATTACHMENT D

TECHNICAL RESPONSE & EVALUATION GUIDE

SECTION D: ORAL PRESENTATION AND DEMONSTRATION. If selected as a Qualified Respondent, the Respondent must address ALL Oral Presentation and Demonstration Items (below). The Oral Presentation and Demonstration period shall not exceed three (3) hours. The Respondent is required to include key personnel that will be assigned to this project in their presentation, as appropriate, and be available to answer questions. Respondent should not include company marketing materials in any Oral Presentation and Demonstration handouts.

Respondent must not include any cost information in the oral presentation and demonstration, including in any accompanying materials.

A Proposal Evaluation Team, made up of three or more State employees, will independently evaluate and score the presentation response to each item. Each evaluator will use the following whole-number, raw point scale for scoring each item:

0 = little value 1 = poor 2 = fair 3 = satisfactory 4 = good 5 = excellent

The Solicitation Coordinator will multiply the Item Score by the associated Evaluation Factor (indicating the relative emphasis of the item in the overall evaluation). The resulting product will be the item's raw, weighted score for purposes of calculating the section scores as indicated.

RESPONDENT LEGAL ENTITY NAME:				
Ref #	**Oral Presentation and Demonstration Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
	Demonstrate the following features and functionality in the Respondent's proposed AMDC solution:			
D.1.	Provide an overview that illustrates how the Respondent has completed the delivery of the scope of services, and accomplished the required objectives on projects with similar requirements.		2	
D.2.	Provide a presentation of the physical configuration options for the recommended AMDC solution and include justifications for each recommended option.		2	

RESPONDENT LEGAL ENTITY NAME:				
Ref #	**Oral Presentation and Demonstration Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
D.3.	Demonstrate the processes, functional capabilities and available settings of the Respondent's proposed AMDC solution that are typically used by nursing and administrative staff based on requirements detailed in Attachment H Pro Forma Contract Attachment 1 – System Requirements. Address the following topics: a. Viewing patient-specific medication orders, administration times, and listed allergies at the AMDC b. System's ability to sort and filter patient lists or queues c. Process for how users obtain medications not yet verified by pharmacy, with specifics on how nursing is prompted at the cabinet to enter a reason for override d. System alerts for the following scenarios: nursing attempting to remove medications outside of administration time range, or if an attempt is made to remove a medication that is more or less than the ordered quantity e. Interconnectivity of the medication order information contained in the system, specifically addressing whether a patient's medication order is searchable from any AMDC within the hospital f. Method used to search for drugs on the AMDC system. Specifically address if the system can search both generic and brand names and if the drug names can be customized. g. How the system flags or identifies patients with identical last names found on a searched list or within the same unit h. Availability and means of accessing Help information from the AMDC i. Describe how patient allergies are displayed and which interactions are required if a medication administering override is entered j. System alert to notify user if patient allergy information is unknown k. System's ability to provide drug information to user at the AMDC		10	
D.4.	Demonstrate or describe the processes, functional capabilities and available options of the client software available to pharmacy staff. Include the following topics in your response. a. Managing settings for devices, users, and formularies b. Managing multiple National Drug Codes or multiple manufacturers of same drug product c. Tracking and reporting on medication lot numbers and expiration dates d. Assigning par levels and critical low levels e. Defining medication override messages for nursing to select from if removing medication for a patient prior to order entry by pharmacy f. Developing customized messages that can be viewed by the nurse at the cabinet		10	

RESPONDENT LEGAL ENTITY NAME:					
Ref #	**Item Ref.**	**Oral Presentation and Demonstration Items**	**Item Score**	**Evaluation Factor**	**Raw Weighted Score**
The Solicitation Coordinator will use this sum and the formula below to calculate the section score. All calculations will use and result in numbers rounded to two (2) places to the right of the decimal point.			**Total Raw Weighted Score:** *(sum of Raw Weighted Scores above)*		
Total Raw Weighted Score / **Maximum Possible Raw Weighted Score** *(i.e., 5 x the sum of item weights above)*			**X 20** *(maximum possible score)*	**= SCORE:**	
State Use – Evaluator Identification:					
State Use – Solicitation Coordinator Signature, Printed Name & Date:					

Cost Proposal & Evaluation Guide

For Qualified Respondents Only

NOTICE: THIS COST PROPOSAL MUST BE COMPLETED EXACTLY AS REQUIRED

COST PROPOSAL SCHEDULE— The Cost Proposal, detailed below, shall indicate the proposed price for the delivery of specified goods for the entire scope of services including all services defined in the Scope of Services of the RFQ Attachment H, *Pro Forma* Contract and for the entire contract period. The Cost Proposal shall remain valid for at least 120 days subsequent to the date of the Cost Proposal opening and thereafter in accordance with any contract resulting from this RFQ. All monetary amounts shall be in U.S. currency and limited to two (2) places to the right of the decimal point.

The Cost Proposal shall be broken out into two (2) parts (refer to Attachment H Pro Forma Section C.3.):

Part #1 Total implementation costs which includes:

- Delivery of all plans detailed in Deliverables table (Pro Forma Section A.13.)
- Delivery of System Implementation at Pilot Site, Pilot Site Training and Implementation Assessment Report
- Delivery of System Implementation at remaining RMHI sites

Part #2 includes:

- Monthly rental fee per AMDC to include support and maintenance

Information to assist in estimating costs can also be found in Attachment J RMHI Floor Plans and Attachment K RMHI Medication Dispensing Information

NOTICE: The Evaluation Factor associated with each line item of cost is for evaluation purposes only. The evaluation factors do NOT and should NOT be construed as any type of volume guarantee or minimum purchase quantity. The evaluation factors shall NOT create rights, interests, or claims of entitlement in the Respondent.

Notwithstanding the line item of costs herein, pursuant to the second paragraph of the *pro forma* contract section C.1. (refer to RFQ Attachment H), "The State is under no obligation to request work from the Contractor in any specific dollar amounts or to request any work at all from the Contractor during any period of this Contract."

This Cost Proposal must be signed, in the space below, by an individual empowered to bind the entity responding to the provisions of this RFQ and any contract awarded pursuant thereto. If said individual is not responding in an individual capacity or is the *President* or *Chief Executive Officer*, this document must attach evidence showing the individual's authority to legally bind the entity responding to this RFQ.

RESPONDENT SIGNATURE:	
PRINTED NAME & TITLE:	
DATE:	
RESPONDENT LEGAL ENTITY NAME:	

Line item of cost Description	Proposed Cost	State Use Only	
		Evaluation Factor	**Evaluation Cost** (cost x factor)
Part #1	**$**	1	
Part #2	**$** **/ AMDC per month**	1620*	
Change Order Work (See Contract Section A.14)	**$** **/ per hour**	1440**	
EVALUATION COST AMOUNT (sum of evaluation costs above)**:** The RFQ Coordinator will use this sum and the formula below to calculate the Cost Proposal Score. Numbers rounded to two (2) places to the right of the decimal point will be standard for calculations.			
lowest evaluation cost amount from all responses / **evaluation cost amount being evaluated**	**x 30** **(maximum section score)**	**= SCORE:**	
***27 cabinets times 60 months **40 hours per month times 36 months			
State Use – RFQ Coordinator Signature, Printed Name & Date:			

ATTACHMENT F

STATEMENT OF CERTIFICATIONS AND ASSURANCES

An individual responding in his or her individual capacity or legally empowered to contractually bind the Respondent must complete and sign the Statement of Certifications and Assurances below as required, and this signed statement must be included with the response as required by the Request for Qualifications.

The Respondent does, hereby, expressly affirm, declare, confirm, certify, and assure ALL of the following:

1. The Respondent will comply with all of the provisions and requirements of the RFQ.
2. The Respondent will provide all specified goods or services as required by the contract awarded pursuant to this RFQ.
3. The Respondent accepts and agrees to all terms and conditions set out in the contract awarded pursuant to this RFQ.
4. The Respondent acknowledges and agrees that a contract resulting from the RFQ shall incorporate, by reference, all Response responses as a part of the contract.
5. The Respondent will comply, as applicable, with:
   (a) the laws of the State of Tennessee;
   (b) Title VI of the federal Civil Rights Act of 1964;
   (c) Title IX of the federal Education Amendments Act of 1972;
   (d) the Equal Employment Opportunity Act and the regulations issued there under by the federal government; and,
   (e) the Americans with Disabilities Act of 1990 and the regulations issued there under by the federal government.
6. To the best of the undersigned's knowledge, information or belief, the information detailed within the Response to the RFQ is accurate.
7. The Response submitted to the RFQ was independently prepared, without collusion, and under penalty of perjury.
8. No amount shall be paid directly or indirectly to an employee or official of the State of Tennessee as wages, compensation, or gifts in exchange for acting as an officer, agent, employee, subcontractor, or consultant to the Respondent in connection with the request or any potential resulting contract.
9. The Response submitted in response to the RFQ shall remain valid for at least 120 days subsequent to the date of the Response opening and thereafter in accordance with any contract pursuant to the RFQ.

By signature below, the signatory certifies legal authority to bind the responding entity to the provisions of this request and any contract awarded pursuant to it. The State may, at its sole discretion and at any time, require evidence documenting the signatory's authority to be personally bound or to legally bind the responding entity.

DO NOT SIGN THIS DOCUMENT IF YOU ARE NOT LEGALLY AUTHORIZED TO DO SO BY THE ENTITY RESPONDING TO THIS RFQ.

SIGNATURE & DATE: _____

PRINTED NAME & TITLE: _____

LEGAL ENTITY NAME: _____

FEIN or SSN: _____

REFERENCE QUESTIONNAIRE

The standard reference questionnaire provided on the following pages of this attachment MUST be completed by all individuals offering a reference for the Respondent.

The Respondent will be solely responsible for obtaining completed reference questionnaires as required (refer to RFQ Attachment B., Technical Response & Evaluation Guide, Section B, Item B.17.), and for enclosing the sealed reference envelopes within the Respondent's Technical Response.

RFQ # 33901-15113 QUESTIONNAIRE

REFERENCE SUBJECT: RESPONDENT NAME (completed by Respondent before reference is requested)

The "reference subject" specified above, intends to submit a response to the State of Tennessee in response to the Request for Qualifications (RFQ) indicated. As a part of such response, the reference subject must include a number of completed and sealed reference questionnaires (using this form).

Each individual responding to this reference questionnaire is asked to follow these instructions:

- complete this questionnaire (either using the form provided or an exact duplicate of this document);
- sign and date the completed questionnaire;
- seal the completed, signed, and dated questionnaire in a new standard #10 envelope;
- sign in ink across the sealed portion of the envelope; and
- return the sealed envelope containing the completed questionnaire directly to the reference subject.

(1) What is the name of the individual, company, organization, or entity responding to this reference questionnaire?

(2) Please provide the following information about the individual completing this reference questionnaire on behalf of the above-named individual, company, organization, or entity.

NAME:	
TITLE:	
TELEPHONE #	
E-MAIL ADDRESS:	

(3) What goods or services does/did the reference subject provide to your company or organization?

(4) What is the level of your overall satisfaction with the reference subject as a vendor of the goods or services described above?

Please respond by circling the appropriate number on the scale below.

	1	2	3	4	5	
least satisfied						**most satisfied**

If you circled 3 or less above, what could the reference subject have done to improve that rating?

(5) If the goods or services that the reference subject provided to your company or organization are completed, were the goods or services provided in compliance with the terms of the contract, on time, and within budget? If not, please explain.

(6) If the reference subject is still providing goods or services to your company or organization, are these goods or services being provided in compliance with the terms of the contract, on time, and within budget? If not, please explain.

(7) How satisfied are you with the reference subject's ability to perform based on your expectations and according to the contractual arrangements?

(8) In what areas of goods or service delivery does/did the reference subject excel?

(9) In what areas of goods or service delivery does/did the reference subject fall short?

(10) What is the level of your satisfaction with the reference subject's project management structures, processes, and personnel?

Please respond by circling the appropriate number on the scale below.

	1	2	3	4	5	
least satisfied						**most satisfied**

What, if any, comments do you have regarding the score selected above?

(11) Considering the staff assigned by the reference subject to deliver the goods or services described in response to question 3 above, how satisfied are you with the technical abilities, professionalism, and interpersonal skills of the individuals assigned?

Please respond by circling the appropriate number on the scale below.

	1	2	3	4	5	
least satisfied						**most satisfied**

What, if any, comments do you have regarding the score selected above?

(12) Would you contract again with the reference subject for the same or similar goods or services?

Please respond by circling the appropriate number on the scale below.

	1	2	3	4	5	
least satisfied						**most satisfied**

What, if any, comments do you have regarding the score selected above?

REFERENCE SIGNATURE:
(by the individual completing this request for reference information)

_____

(must be the same as the signature across the envelope seal)

DATE: _____

RFQ # 33901-15113 PRO FORMA CONTRACT

CONTRACT
BETWEEN THE STATE OF TENNESSEE,
DEPARTMENT OF MENTAL HEALTH AND
SUBSTANCE ABUSE SERVICES
AND
CONTRACTOR NAME

This contract, by and between the State of Tennessee, Department of Mental Health and Substance Abuse Services, hereinafter referred to as the 'State," and Contractor Legal Entity Name, hereinafter referred to as the "Contractor," is for the installation, support and maintenance of Automatic Medication Dispensing Cabinets for each of the Regional Mental Health Institutes.

The Contractor is a/an Individual, For-Profit Corporation, Non-Profit Corporation, Special Purpose Corporation Or Association, Partnership, Joint Venture, Or Limited Liability Company.
Contractor Place of Incorporation or Organization: Location
Contractor Edison Registration ID # Number

A. SCOPE OF SERVICES:

A.1. The Contractor shall provide all goods or services and deliverables as required, described, and detailed below and shall meet all service and delivery timelines as specified by this Contract.

A.2. Definitions. Following are key definitions related to specific services requested in this Contract.

AMDC - Automated Medication Dispensing Cabinet

RMHI – Regional Mental Health Institute

HL7 - Health Level-7 is the accepted standard for health data interoperability

Hours - sequential hours unless otherwise stated in the Contract section.

Days - calendar days unless otherwise stated in the Contract section.

Defect - a condition in the product which does not meet requirements or end-user expectations, which may not be specified, but are reasonable.

Deliverables - a set of products to be delivered to the State by the Contractor to fulfill the terms of this Contract.

Third Party Software - software not owned by the State or the Contractor.

Contractor-Owned Software - commercially available software the rights to which are owned by Contractor, including but not limited to commercial "off-the-shelf" software which is not developed using State's money or resources.

Work Product - all deliverables exclusive of hardware, such as software, software source code, documentation, planning, etc., that are created, designed, developed, or documented by the Contractor exclusively for the State during the course of the project using State's money or resources, including Custom-Developed Application Software. If the deliverables under this Contract include Rights Transfer Application Software, the definition of Work Product shall also include such software. Work Product shall not include Contractor-Owned Software or Third-Party Software.

Sanitized – the process of deliberately, permanently, and irreversibly removing or destroying data stored on a memory device.

MAR – Medication Administration Record.

A.3. Service Goal. The goal is to obtain a system solution that supports the installation of AMDCs on each care unit located in each of the four RMHIs. The solution shall include a single State-hosted server and shall interface with the current Pharmacy Information System using Health Level-Seven (HL7). The solution will also include one additional customized cabinet for each RMHI. Efficiency, reduced cost and improved patient safety are the key objectives of this project.

A.4. Project Management and Reporting. Contractor shall designate a single Project Manager to serve as the Contractor's primary point of contact for all activities and issues. The Contractor shall ensure that all project activities are performed efficiently, accurately and on schedule. The Contractor Project Manager shall coordinate all project activities with the State Project Manager to ensure the Contractor activities are managed consistently with overall Contract requirements. The Contract Project Manager shall ensure timely and accurate submission of project management deliverables to the State Project Manager as listed below.

a. Kickoff Meeting and Presentation. Contractor shall participate in a State-led Kickoff Meeting. The purpose of the Kickoff Meeting shall be to introduce the Contractor to State project stakeholders, and ensure agreement regarding project objectives, roles and responsibilities, strategy, and known risks. The Contractor shall prepare and deliver a presentation for the kickoff meeting that synthesizes their approach to the overall project, provides high-level milestones, and introduces the Contractor team.

b. Master Project Management Plan. The Contractor's Project Manager shall collaborate with the State Project Manager to develop a Master Project Management Plan that describes the approach, activities, stages, duration and risks for all Project work. The State shall provide written acceptance of the Master Project Management Plan. The State shall be responsible for the Master Project Management Plan. The Contractor shall collaborate with the State Project Manager to prepare and provide the following for inclusion in the Master Project Management Plan:

(1) Work Breakdown Structure and Project Schedule: lists the work packages to be performed for the project and a schedule baseline that will be used as a reference point for managing project progress as it pertains to schedule and timeline.

(2) Change Management Plan: a proposed plan for managing project changes including, but not limited to: processes, scope, resources and implementation.

(3) Risk Management Plan: potential project risks, mitigation strategies and risk management processes.

(4) Issue Management Plan: a plan for documenting, tracking and reporting of issues, including the process for escalating issues for joint management decisions by the Contractor and State.

c. Requirements Verification and Gap Analysis. Contractor shall work with State project team members, as identified by the State, to verify requirements (See Attachment 1 System Requirements) and to document the extent that the Contractor's solution meets each requirement. The Contractor and the State shall reach, and the Contractor shall document, a common understanding of Requirements and Gaps (changes required in the Contractor's solution to meet Requirements). The Contractor shall prepare and deliver to the State for review and approval a Requirements Verification and Gap Analysis document that includes a finalized list of Requirements Specifications, which detail the specific features and functions of each requirement. This document shall include identified Gaps (requirements that are not met or not met fully by the Contractor's solution prior to modification) and a high-level statement of how each Gap will be filled. The State shall provide written acceptance of the Requirements Verification and Gap Analysis document.

d. Interface Solution Plan. Contractor shall create an Interface Solution Plan that addresses

the HL7 interface with the current Pharmacy System. Plan should include:

(1) Interface design

(2) Description of data transactions between the systems

(3) Description of data fields exchanged

The State shall provide written acceptance of the Interface Solution Plan and reserves the right to request periodic updates to the document.

e. Implementation Plan. Contractor shall, in collaboration with the project team, create an Implementation Plan. The Implementation Plan shall describe the following:

(1) Implementation schedule detailing installation milestones

(2) Pilot Site Installation Plan including:

i. Installation of System software onto a State-hosted VMWare server

ii. Installation of AMDCs on each unit of the Pilot Site

iii. Installation of the Interface Solution at the Pilot Site

(3) Installation of AMDCs at remaining RMHI sites.

(4) Electrical and environmental recommendations for each cabinet type

(5) Initial AMDC configurations for each care unit at the RMHI

(6) Authentication and access configurations for the system

(7) Implementation of the interface solution

The State shall provide written acceptance of the Implementation Plan and reserves the right to request periodic updates to the document.

f. Operations Guide. Contractor shall provide an Operations Guide which gives system users and technical staff the knowledge to operate and update cabinet configurations independent of Contractor assistance. The Guide shall address a view of the system explaining levels of configuration and relationships between settings. It should also address security levels contained in the system and describe access granted by each level.

g. Security Plan. The Contractor shall prepare and deliver a comprehensive written Security Plan describing how the System's application security features shall satisfy the security requirements found in this contract. The Plan shall include all recommended levels of security, limitations of capabilities, and any required rules, and shall incorporate any reasonable and lawful requests or requirements of the State. The format and content of security tables shall be included, as well as the recommended starting phase for establishing security profiles.

h. Data Recovery Plan. In a State-hosted solution, data stored on the server is addressed in the State of Tennessee's Disaster Recovery Plan. The Contractor shall create a Data Recovery Plan that addresses data stored on the AMDCs. In order to prevent loss of data, the Contractor shall develop recovery procedures, including the process for restoring data within 24 hours of cabinet equipment failure. The data recovery point should be within 24 hours of the cabinet equipment failure. The Data Recovery Plan shall be reviewed annually. The State shall provide written acceptance of the Data Recovery Plan and reserves the right to request periodic updates to the document.

i. Training Plan. Contractor shall provide a Training Plan that addresses the following areas:

(1) Customized Training. The Contractor shall develop a Training Plan detailing customized training for each role type that will interact with the AMDC solution. The Contractor and the State shall collaborate and develop the specific role types, permissions and training for each category of users.

(2) Training Material. The Contractor shall develop and deliver to the State Train-the-Trainer material for the final AMDC functionality as approved by the State. Training material shall be prepared using State-standard Microsoft Office products. The Contractor shall provide training materials for the State's designated trainers, including unlimited right to copy.

(3) Train-the-Trainer Training. The Contractor shall offer a train-the-trainer program to train State-designated AMDC Trainers using the Training Material and the State-approved Training Plan. A variety of training approaches may be proposed, such as:

i. On-site training
ii. Virtual classroom
iii. Training Video
iv. Help Content. The Contractor shall develop and deliver content for the Help functions of AMDC.

The State reserves the right to make final determination of the training approaches to be used as part of the Train-the-Trainer Training and any other Training formats. The State shall provide written acceptance of the Training Plan, Training Material and Help Content.

j. Support and Maintenance Plan. The Contractor shall deliver to the State for review and approval a Support and Maintenance Plan that describes how the Contractor will provide the support and maintenance services outlined in this Contract. The Support and Maintenance Plan shall include a description of the Contractor's support organizational structure.

A.5. Pilot Site Implementation Services. Contractor shall provide implementation services for the Pilot Site according to the Implementation Plan to include:

(1) Server Installation. Contractor will work with the Department of Finance and Administration, Office of Information Resources (OIR) to install AMDC solution software on a State-hosted VMWare server.

(2) AMDC Installation at the Pilot Site location. Contractor shall install and configure each AMDC in its agreed upon location according to the Implementation Plan. The RMHI will be responsible for ensuring the proper electrical resources and network connections for the cabinets are available before the installation date.

(3) Interface with Pharmacy System Installation. Contractor will configure and install the interface to the Pharmacy system according to the Interface Solution Plan.

A.6. Pilot Site Training Services. Contractor shall provide training services according to the Training Plan developed for the Pilot Site pursuant to Section A.4.i.

A.7. Pilot Site Post Implementation Assessment Report. The Contractor shall prepare and deliver to the State, a Pilot Site Post Implementation Assessment Report that shall describe any issues encountered during implementation, actions taken to remediate the issues, and lessons learned from the implementation. The State shall review the Assessment and, if acceptable, provide written approval. Written approval must be received before continuing with further implementations.

A.8. RMHI Site Implementation Services(3). After completion of the Pilot Site Installation and State approval of the Pilot Site Post Implementation Assessment, Contractor will continue to install AMDCs in the 3 remaining RMHIs according to the Implementation Schedule.

A.9. RMHI Site Training Services(3). Contractor shall provide training services according to the Training

Plan for each of the 3 remaining RMHIs.

A.10. RMHI Site Post Implementation Assessment Report(3). The Contractor shall prepare and deliver to the State, an RMHI Site Post Implementation Assessment Report that shall describe any issues encountered during implementation, actions taken to remediate the issues, and lessons learned from the implementation. The State shall review the Assessment and, if acceptable, provide written approval. Written approval must be received before continuing with the next implementation.

A.11. Final Project Report. The Contractor shall create a Final Project Report using the State's Project Closure Report, summarizing project activities, lessons learned and recommended next steps. The Project Closure Report shall be submitted to the State Project Manager no later than fifteen (15) business days prior to the final signoff of the final project implementation. The State will provide written acceptance of the Project Closure Report.

A.12. Support and Maintenance Services. Contractor shall provide support and maintenance for the AMDC solution. The Contractor shall provide direct, second-tier technical support and shall maintain the operational readiness, interoperability, and conformance to specifications and requirements of the server and AMDCs.

(1) The Contractor shall be responsible for establishing a Support Center as required by this Contract.

(i) The Contractor shall establish a support center and dedicated point(s) of contact to provide communication and technical assistance to the State.

(ii) The Contractor shall provide 24/7 support.

(iii) The Contractor shall establish an email address dedicated to this initiative to facilitate communication and provide access to technical support.

(iv) The Contractor shall provide a toll-free phone number to facilitate communication and provide access to technical support.

(v) The Contractor may establish additional points or modes of contact (e.g., chat or messaging through secure website) to expand or enhance access to service or support.

(vi) The Contractor shall respond to any calls or messages within **30 minutes** of the State notifying the Contractor.

(2) Support. The Contractor shall, at a minimum:

(i) Make appropriate Contractor support resources available to the State on a 24/7 basis, to provide the services described and detailed in this section.

(ii) Diagnose and resolve problems reported by the State that have not been diagnosed and resolved at lower levels of support within the State. The State will determine the severity level of each reported problem. The levels and the corresponding Service Level Goals are indicated below:

Severity Level	**Description**	**Service Level Goal**

Severity Level	Description	Service Level Goal
Level 1	System-wide or facility-wide problem impacting critical functions of the system which prevents medication dispensing.	Within 30 minutes from the time a Severity Level 1 problem is reported to the Contractor, the Contractor shall assign dedicated resources as required to solve the problem. The Contractor shall provide a status update to the State's Technical Contact or their designee every one (1) hour until the problem is resolved. The goal for Level 1 issues is to have the problem resolved within two (2) hours; otherwise, the issue shall be escalated to the Contractor's Chief Product Officer or the Contractor's equivalent senior management.
Level 2	System-wide or facility-wide problem impacting less critical functions of the system. System is still operable but has become unstable or less critical functions have failed to operate properly.	Within two (2) hours from the time a Severity Level 2 problem is reported to the Contractor, the Contractor shall assign dedicated resources as required to solve the problem. The Contractor shall provide a status update to the State's Technical Contact or their designee every four (4) hours for the first 24 hours of the incident; then every 24 hours thereafter until the problem is resolved. The goal for Level 2 issues is to have the problem resolved within eight (8) hours; otherwise, the issue shall be escalated to the Contractor's senior management.
Level 3	Isolated problem has a moderate impact on less critical functions such as reporting. These circumstances create conditions that inconvenience users of the system.	The Contractor shall work with the State's Technical Contact or their designee to determine resources that the Contractor shall assign and the frequency of updates on the status of the problem or fix.

(3) Maintenance. The Contractor shall maintain fully-supported, current versions of all software components. The Contractor shall perform AMDC hardware and software maintenance and support services as necessary to ensure proper operation and maintenance of systems.

(i) The Contractor shall repair or replace AMDC hardware or software, or any portion thereof, so the system operates in accordance with the specifications, terms, and requirements of the Contract.

(ii) All upgrades and/or enhancements to the Solution will be made available to the State as soon as they are released to any of the Contractor's customers.

(iii) All maintenance shall be scheduled and the State shall be notified seventy-two (72) hours in advance of any downtime. The Contractor shall maintain a record of maintenance activities.

(4) Change Management. The Contractor must propose change control processes and procedures for State review and approval. The Contractor is responsible for release management and shall implement changes and releases, as appropriate, according to approved change control processes.

(5) Business Continuity Procedures. AMDC cabinets shall be configured with levels of redundancy so that typical component failures shall not disrupt service. The Contractor shall define, implement and exercise adequate business continuity procedures.

A.13. Deliverables.

#	Deliverable	Contract Section	Delivery Date
1.	Kickoff Meeting Presentation	A.4.a	Within 30 days of the Contract Effective Date
2.	Master Project Management Plan	A.4.b.(1)	Within 30 days of the Contract Effective Date
3.	Requirements Verification and Gap Analysis	A.4.c.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
4.	Interface Solution Plan	A.4.d.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
5.	Implementation Plan	A.4.e.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
6.	Operations Guide	A.4.f.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
7.	Security Plan	A.4.g	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
8.	Data Recovery Plan	A.4.h.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
9.	Training Plan	A.4.i.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
10.	Support and Maintenance Plan	A.4.j.	Within sixty (60) calendar days of the Contract Effective Date

#	Deliverable	Contract Section	Delivery Date
11.	Pilot Site Implementation Services	A.5.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
12.	Pilot Site Training Services	A.6.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
13.	Pilot Site Implementation Assessment Report	A.7.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
14.	Implementation Services at the Remaining RMHIs	A.8.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
15.	Training Services for the Remaining RMHIs	A.9.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
16.	Implementation Assessment Reports for Remaining RMHIs	A.10.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
17.	Final Project Report	A.11.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule
18.	Support and Maintenance Services	A.12.	As mutually agreed upon by the State and Contractor in accordance with the Project Schedule

A.14. Change Orders. The State may, at its sole discretion and within written notice to the Contractor, request changes in the Scope that are necessary but were inadvertently unspecified in this contract.

a. Change Order Creation. After receipt of a written request for additional services from the State, the Contractor shall respond to the State, within a maximum of ten (10) business days, with a written proposal for completing the service. Contractor's proposal must specify:

(1) The effect, if any, of implementing the requested change(s) on all other services required under this Contract;

(2) The specific effort involved in completing the change(s);

(3) The specific schedule for completing the change(s);

(4) The maximum number of person hours required for the change(s)

(5) The maximum cost for the change(s) – this maximum cost shall in no instance exceed the product of the person hours required multiplied by the appropriate payment rate proposed for such work.

The Contractor shall not perform any additional service until the State has approved the proposal. If approved, the State will sign the proposal, and it shall constitute a Change Order between the Contract Parties pertaining to the specified change(s) and shall be incorporated, hereby, as a part of this Contract.

b. Change Order Performance. Subsequent to creation of a Change Order, the Contractor shall complete the required services. The State will be the sole judge of the acceptable completion of work and, upon such determination, shall provide the Contractor written approval.

c. Change Order Remuneration. The State will remunerate the Contractor only for acceptable work.

All acceptable work performed pursuant to an approved Change Order, without a formal amendment of this Contract, shall be remunerated in accordance with and further limited by Contract Section C.3.c. The State shall be liable to the Contractor only for the cost of the actual goods or services provided to complete the necessary work, not to exceed the maximum cost for the change detailed in the Change Order. In no instance shall the State be liable to the Contractor for any amount exceeding the maximum cost specified by the change Order authorizing the goods or services. Upon State approval of the work, the Contractor shall invoice the State in accordance with the relevant provisions of this Contract.

A.15. System Availability.

a. Following implementation, the System shall be available continuously, as measured over the course of each calendar month, an average of 99% of the time. "Available" means the System shall be available for access and use by the State to conduct normal business associated with this system.

b. For purposes of calculating the availability percentage, the following are "Exceptions" to the service level requirement:
   (1) regularly scheduled downtime (which shall occur only upon advance written notice during non-core business hours); or
   (2) loss of the State's Internet connectivity

A.16. System Performance.

a. Consistent and responsive system performance is important to provide uninterrupted availability of means to dispense and administer medication to patients, even during peak workload times. System performance will be measured in terms of response time. The average System response time shall be no more than one (1) to three (3) seconds. Ninety five percent (95%) of all response time should be less than two (2) seconds.

b. Contractor must ensure the AMDC Solution will support at least fifty (50) concurrent users.

c. Contractor must notify the State as soon as possible if system performance or availability is outside of the specified requirements. Notification must happen through telephone and/or email to contacts provided by the State. Acknowledgment of the notification must be logged. The notification should be specific and detailed. The Contractor will provide frequent and regular updates until system performance or availability has returned to normal as per the specified requirements.

A.17. Compliance with Enterprise Information Security Policies. The Contractor is required to meet all the security controls stated in the Tennessee *Enterprise Information Security Policies* (http://tn.gov/finance/topic/oir-security-policies), and conform to all applicable State and Federal laws regarding information security. As additional State and Federal Security and Regulatory requirements are imposed, the Contractor shall ensure that the environment content and applications are kept up to date with the emerging requirements.

A.18. Compliance with State's Technology Standards.

a. In the event that the Contractor wishes to introduce non-State standard software or hardware components ("products") into the State's technology environment, in support of, or related to, the services the Contractor is providing under this Contract, the Contractor must make a formal written request to the State prior to introducing the non-State Standard Products. Such a request is referred to as a "Non-State Standard Product Request."

b. Non-State Standard Products are defined as:

Any software that is not listed and designated as “Current” in, or is not compatible with the standards listed in the *Enterprise Technology Architecture*; or
Any hardware that is not listed and designated as “Current” in, or is not compatible with standards listed in the *Enterprise Technology Architecture*.

c. The State’s Department of Finance and Administration, Office for Information Resources (OIR), shall consider the Non-State Standard Product Request and shall render a written determination, in the State’s best interest, to approve or disapprove the request. If OIR disapproves the request, the Contractor agrees to withdraw the request and substitute State Standard Products in place of the Non-State Standard Products, at no additional cost to the State.

A.19. Encryption. All data shall be encrypted at rest and in transit with controlled access. Unless otherwise stipulated, the Contractor is responsible for encryption of the data. The Contractor shall ensure drive encryption consistent with validated cryptography standards as referenced in FIPS 140-2, Security Requirements for Cryptographic Modules for all personal data. The solution should support 256 bit encryption or latest State standard. This provision also applies to the data-at-rest and data-in-transit protections provided by the solution, even if protection of data-at-rest and/or data-in-transit is implemented by external modules (rather than the solution itself). The State will hold all encryption keys.

A.20. Separation of Duties. To reduce the risk of accidental change or unauthorized access to operational software and business data, there should be a separation of duties based on development, test, and operational facilities.

Confidential data should not be copied into test and development systems. Development and test environments should not be directly connected to production environments. Data and operational software test systems should emulate production systems as closely as possible. The Contractor shall limit staff knowledge of State data to that which is absolutely necessary to perform job duties.

A.21. Removable Media. Removable media should be sanitized prior to removing it from the facilities for maintenance or repair. Removable media should be disposed of securely when no longer required, using approved State procedures. Removable media containing confidential information, confidential data, or sensitive data must be protected against unauthorized access, misuse or corruption during transport.

A.22. Protection of Information. The Contractor shall be responsible for properly protecting all information used, gathered, or developed as a result of work under this contract. It is anticipated that this information will be gathered, created, and stored within the primary work location. If contractor personnel must remove any information from the primary work area they should protect it to the same extent they would their own proprietary data and/or company trade secrets. The use of any information that is subject to the Privacy Act will be utilized in full accordance with all rules of conduct as applicable to Privacy Act Information. The State will retain unrestricted rights to State data. The State also maintains the right to request full copies of the data at any time.

The data that is processed and stored by the various applications within the network infrastructure contains financial data as well as Personally Identifiable Information (PII). This data shall be protected against unauthorized access, disclosure or modification, theft, or destruction. The Contractor shall ensure that the facilities that house the network infrastructure are physically secure. The data must be available to the State upon request within one business day or within the timeframe specified otherwise, and shall not be used for any other purpose other than that specified herein. The contractor shall provide requested data at no additional cost to the State..

A.23. Confidentiality and Non-Disclosure. The State has unlimited data rights to all deliverables and associated working papers and materials.

All documents produced for this project are the property of the State and cannot be reproduced, or retained by the contractor. All appropriate project documentation will be given to the State during and at the end of this contract. The contractor shall not release any information without the written consent of

the State. Personnel working on any of the described tasks may, at State request, be required to sign formal non-disclosure and/or conflict of interest agreements to guarantee the protection and integrity of State information and documents. Data will only be disclosed to authorized personnel on a "Need-To-Know" basis. The contractor shall ensure that appropriate administrative, technical, and physical safeguards are established to ensure the security and confidentiality of this information, data, and/or equipment is properly protected. Any information made available to the Contractor by the State shall be used only for the purpose of carrying out the provisions of this contract and shall not be divulged or made known in any manner to any persons except as may be necessary in the performance of the contract. In performance of this contract, the Contractor assumes responsibility for protection of the confidentiality of State records. Each officer or employee of the Contractor to whom any State record may be made available or disclosed shall be notified in writing by the Contractor that information disclosed to such officer or employee can be used only for that purpose and to the extent authorized herein. Further disclosure of any such information, by any means, for a purpose or to an extent unauthorized herein, may subject the offender to criminal sanctions.

A.24. Data Ownership. Data created and managed by the State remain the sole property of the State. The Contractor will not review, share, distribute, print, or reference any Client's data except as expressly defined by the terms of a Contract between the Contractor and the State. The Contractor may at times view or access individual records and State configuration details for the purpose of preventive maintenance or diagnosis and resolution of system problems or user support issues.

A.25. Transfer of Data. Upon termination of this Contract all data created and managed by the State on Contractor's equipment shall be removed and returned to the State in a usable format acceptable to the State, unless the parties enter into a similar, successive Contract. Contractor must perform a sanitization of confidential digital data and destruction of hard copy confidential data when the contract ends.

A.26. Source Code in Escrow.

a. The Contractor represents that it maintains, in a secure environment, a current copy of the software source code in escrow with its escrow agent. The Contractor acknowledges that throughout the term of the Contract, the source code in escrow shall be kept current with the most current version of the Source Code periodically escrowed by the Contractor.
b. The Contractor shall ensure that a copy of the up-to-date Source code shall be deposited with the Escrow Company at the time of the execution of this Contract. The State may demand confirmation at any time during the course of the Contract from the Contractor or Escrow Company that the Source Code in escrow is up to date and the Contractor or Escrow Company will provide confirmation of such within thirty (30) calendar days of such request
c. If the Contractor goes out of business, the State shall be able to obtain the Source Code from the Escrow Company.

A.27. Warranty. Contractor represents and warrants that the term of the warranty ("Warranty Period") shall be the greater of the Term of this Contract or any other warranty general offered by Contractor, its suppliers, or manufacturers to customers of its goods or services. The goods or services provided under this Contract shall conform to the terms and conditions of this Contract throughout the Warranty Period. Any nonconformance of the goods or services to the terms and conditions of this Contract shall constitute a "Defect" and shall be considered "Defective." If Contractor receives notice of a Defect during the Warranty Period, then Contractor shall correct the Defect, at no additional charge.

Contractor represents and warrants that the State is authorized to possess and use all equipment, materials, software, and deliverables provided under this Contract.

Contractor represents and warrants that all goods or services provided under this Contract shall be provided in a timely and professional manner, by qualified and skilled individuals, and in conformity with standards generally accepted in Contractor's industry.

If Contractor fails to provide the goods or services as warranted, then Contractor will re-provide the goods or services at no additional charge. If Contractor is unable or unwilling to re-provide the goods or

services as warranted, then the State shall be entitled to recover the fees paid to Contractor for the Defective goods or services. Any exercise of the State's rights under this Section shall not prejudice the State's rights to seek any other remedies available under this Contract or applicable law.

A.28. Inspection and Acceptance. The State shall have the right to inspect all goods or services provided by Contractor under this Contract. If, upon inspection, the State determines that the goods or services are Defective, the State shall notify Contractor, and Contractor shall deliver the goods or provide the services at no additional cost to the State. If after a period of thirty (30) days following delivery of goods or performance of services the State does not provide a notice of any Defects, the goods or services shall be deemed to have been accepted by the State.

B. TERM OF CONTRACT

This Contract shall be effective on DATE ("Effective Date") and extend for a period of 60 months after the Effective Date ("Term"). The State shall have no obligation for goods or services provided by the Contractor prior to the Effective Date.

C. PAYMENT TERMS AND CONDITIONS

C.1. Maximum Liability. In no event shall the maximum liability of the State under this Contract exceed Written Dollar Amount ($Number) ("Maximum Liability"). This Contract does not grant the Contractor any exclusive rights. The State does not guarantee that it will buy any minimum quantity of goods or services under this Contract. Subject to the terms and conditions of this Contract, the Contractor will only be paid for goods or services provided under this Contract after a purchase order is issued to Contractor by the State or as otherwise specified by this Contract.

C.2. Compensation Firm. The payment methodology in Section C.3. of this Contract shall constitute the entire compensation due the Contractor for all goods or services provided under this Contract regardless of the difficulty, materials or equipment required. The payment methodology includes all applicable taxes, fees, overhead, and all other direct and indirect costs incurred or to be incurred by the Contractor.

C.3. Payment Methodology. The Contractor shall be compensated based on the payment methodology for goods or services authorized by the State in a total amount as set forth in Section C.1.

a. The Contractor's compensation shall be contingent upon the satisfactory provision of goods or services as set forth in Section A.

b. The Contractor shall be compensated based upon the following payment methodology.

Goods or Services Description	**Amount** (per compensable increment)
Milestone 1 - Completion and State approval of the following Deliverables (See Contract Section A.13): Deliverable #1: Kickoff Meeting Presentation Deliverable #2: Master Project Management Plan Deliverable #3: Requirements Verification and Gap Analysis Deliverable #4: Interface Solution Plan Deliverable #5: Implementation Plan Deliverable #6: Operations Guide Deliverable #7: Security Plan Deliverable #8: Data Recovery Plan Deliverable #9: Training Plan Deliverable #10: Support and Maintenance Plan	$ Number (*25% of the Total Implementation Cost*)
Milestone 2 - Completion and State approval of the following Deliverables	$ Number

(See Contract Section A.13): Deliverable #11 Pilot Site Implementation Deliverable #12 Pilot Site Training Services Deliverable #13 Pilot Site Implementation Assessment Report	(*30% of the Total Implementation Cost*)
Milestone 3 - Completion and State approval of the following Deliverables: (See Contract Section A.13.) Deliverable #14 Site Implementation Remaining RMHIs Deliverable #15 Training Services Remaining RMHIs Deliverable #16 Implementation Assessment Report Remaining RMHIs Deliverable #17 Final Project Report	$ Number (*45% of the Total Implementation Cost*)
Monthly rental fee per AMDC	$ Number
Note: The Contractor shall not be compensated for travel time to the primary location of service provision.	

c. The Contractor shall be compensated for changes requested and performed pursuant to Contract Section A.14, without a formal amendment of this Contract based upon the payment rates detailed in the schedule below and as agreed pursuant to Section C.3.b., PROVIDED THAT compensation to the Contractor for such "change order" work shall not exceed seven percent (7%) of the sum of milestone payment rates detailed in Section C.3.b., above (which is the total cost for the milestones and associated deliverables set forth in Contract Sections A.3., through A.29.). If, at any point during the Term, the State determines that the cost of necessary "change order" work would exceed the maximum amount, the State may amend this contract to address the need.

Goods or Services Description	**Amount** (per compensable increment)
Change Order Work (See Contract Section A.14)	$ Amount per hour
Note: The Contractor shall not be compensated for travel time to the primary location of service provision.	

d. The monthly rental fees shall cover the equipment rental, as well as support and maintenance services for all hardware and software provided.
e. No rental fee detailed above shall be effective or applicable prior to the date that Milestone 2, as identified above, is complete and the system goes live at the Pilot Site.
f. Following the Pilot Site implementation, the total rental payment per month shall be calculated by multiplying the monthly rental fee and the number of AMDCs operational at the end of the month.
g. All rental fees shall be paid in arrears, and shall be prorated for a partial period to which the fee(s) may be applicable.

C.4. Travel Compensation. The Contractor shall not be compensated or reimbursed for travel time, travel expenses, meals, or lodging.

C.5. Invoice Requirements. The Contractor shall invoice the State only for goods delivered and accepted by the State or services satisfactorily provided at the amounts stipulated in Section C.3., above. Contractor shall submit invoices and necessary supporting documentation, no more frequently than once a month, and no later than thirty (30) days after goods or services have been provided to the following address:

Tennessee Department of Mental Health and Substance Abuse Services
Fiscal Services
Andrew Jackson Building, 6th Floor
500 Deaderick Street
Nashville, TN 37243

a. Each invoice, on Contractor's letterhead, shall clearly and accurately detail all of the following information (calculations must be extended and totaled correctly):

(1) Invoice number (assigned by the Contractor);
(2) Invoice date;
(3) Contract number (assigned by the State);
(4) Customer account name: Tennessee Department of Mental Health and Substance Abuse Services (TDMHSAS)
(5) Customer account number (assigned by the Contractor to the above-referenced Customer);
(6) Contractor name;
(7) Contractor Tennessee Edison registration ID number;
(8) Contractor contact for invoice questions (name, phone, or email);
(9) Contractor remittance address;
(10) Description of delivered goods or services provided and invoiced, including identifying information as applicable;
(11) Number of delivered or completed units, increments, hours, or days as applicable, of each good or service invoiced;
(12) Applicable payment methodology (as stipulated in Section C.3.) of each good or service invoiced;
(13) Amount due for each compensable unit of good or service; and
(14) Total amount due for the invoice period.

b. Contractor's invoices shall:

(1) Only include charges for goods delivered or services provided as described in Section A and in accordance with payment terms and conditions set forth in Section C;
(2) Only be submitted for goods delivered or services completed and shall not include any charge for future goods to be delivered or services to be performed;
(3) Not include Contractor's taxes, which includes without limitation Contractor's sales and use tax, excise taxes, franchise taxes, real or personal property taxes, or income taxes; and
(4) Include shipping or delivery charges only as authorized in this Contract.

c. The timeframe for payment (or any discounts) begins only when the State is in receipt of an invoice that meets the minimum requirements of this Section C.5.

C.6. Payment of Invoice. A payment by the State shall not prejudice the State's right to object to or question any payment, invoice, or other matter. A payment by the State shall not be construed as acceptance of goods delivered, any part of the services provided, or as approval of any amount invoiced.

C.7. Invoice Reductions. The Contractor's invoice shall be subject to reduction for amounts included in any invoice or payment that is determined by the State, on the basis of audits conducted in accordance with the terms of this Contract, to not constitute proper compensation for goods delivered or services provided.

C.8. Deductions. The State reserves the right to deduct from amounts, which are or shall become due and payable to the Contractor under this or any contract between the Contractor and the State of Tennessee, any amounts that are or shall become due and payable to the State of Tennessee by the Contractor.

C.9. Prerequisite Documentation. The Contractor shall not invoice the State under this Contract until the State has received the following, properly completed documentation.

a. The Contractor shall complete, sign, and present to the State the "Authorization Agreement for Automatic Deposit Form" provided by the State. By doing so, the Contractor acknowledges and agrees that, once this form is received by the State, payments to the Contractor, under this or any other contract the Contractor has with the State of Tennessee, may be made by ACH; and

b. The Contractor shall complete, sign, and return to the State the State-provided W-9 form. The taxpayer identification number on the W-9 form must be the same as the Contractor's Federal Employer Identification Number or Social Security Number referenced in the Contractor's Edison registration information.

D. MANDATORY TERMS AND CONDITIONS:

D.1. Required Approvals. The State is not bound by this Contract until it is duly approved by the Parties and all appropriate State officials in accordance with applicable Tennessee laws and regulations. Depending upon the specifics of this Contract, this may include approvals by the Commissioner of Finance and Administration, the Commissioner of Human Resources, the Comptroller of the Treasury, and the Chief Procurement Officer. Approvals shall be evidenced by a signature or electronic approval.

D.2. Communications and Contacts. All instructions, notices, consents, demands, or other communications required or contemplated by this Contract shall be in writing and shall be made by certified, first class mail, return receipt requested and postage prepaid, by overnight courier service with an asset tracking system, or by email or facsimile transmission with recipient confirmation. All communications, regardless of method of transmission, shall be addressed to the respective Party at the appropriate mailing address, facsimile number, or email address as stated below or any other address provided in writing by a Party.

The State:
Christopher Romaine
Department of General Services
Central Procurement Office
312 Rosa L. Parks Ave., Nashville, TN 37243
615-253-5613
Christopher.Romaine@tn.gov

The Contractor:

Contractor Contact Name & Title
Contractor Name
Address
Email Address
Telephone # Number
FAX # Number

All instructions, notices, consents, demands, or other communications shall be considered effective upon receipt or recipient confirmation as may be required.

D.3. Modification and Amendment. This Contract may be modified only by a written amendment signed by all Parties and approved by all applicable State officials.

D.4. Subject to Funds Availability. The Contract is subject to the appropriation and availability of State or federal funds. In the event that the funds are not appropriated or are otherwise unavailable, the State reserves the right to terminate this Contract upon written notice to the Contractor. The State's exercise of its right to terminate this Contract shall not constitute a breach of Contract by the State. Upon receipt of the written notice, the Contractor shall cease all work associated with the Contract. If the State terminates this Contract due to lack of funds availability, the Contractor shall be entitled to compensation for all conforming goods requested and accepted by the State and for all satisfactory and authorized services completed as of the termination date. Should the State exercise its right to terminate this Contract due to unavailability of funds, the Contractor shall have no right to recover from the State any actual, general, special, incidental, consequential, or any other damages of any description or amount.

D.5. Termination for Convenience. The State may terminate this Contract for convenience without cause and for any reason. The State shall give the Contractor at least thirty (30) days written notice before the termination date. The Contractor shall be entitled to compensation for all conforming goods delivered and accepted by the State or for satisfactory, authorized services completed as of the termination date. In no event shall the State be liable to the Contractor for compensation for any goods neither requested nor accepted by the State or for any services neither requested by the State nor satisfactorily performed by the Contractor. In no event shall the State's exercise of its right to terminate this Contract for convenience relieve the Contractor of any liability to the State for any damages or claims arising under this Contract.

D.6. Termination for Cause. If the Contractor fails to properly perform its obligations under this Contract in a timely or proper manner, or if the Contractor materially violates any terms of this Contract ("Breach Condition"),the State shall have the right to immediately terminate the Contract and withhold payments in excess of compensation for completed services or provided goods. Notwithstanding the above, the Contractor shall not be relieved of liability to the State for damages sustained by virtue of any Breach Condition and the State may seek other remedies allowed at law or in equity for breach of this Contract.

D.7. Assignment and Subcontracting. The Contractor shall not assign this Contract or enter into a subcontract for any of the goods or services provided under this Contract without the prior written approval of the State. Notwithstanding any use of the approved subcontractors, the Contractor shall be the prime contractor and responsible for compliance with all terms and conditions of this Contract. The State reserves the right to request additional information or impose additional terms and conditions before approving an assignment of this Contract in whole or in part or the use of subcontractors in fulfilling the Contractor's obligations under this Contract.

D.8. Conflicts of Interest. The Contractor warrants that no part of the Contractor's compensation shall be paid directly or indirectly to an employee or official of the State of Tennessee as wages, compensation, or gifts in exchange for acting as an officer, agent, employee, subcontractor, or consultant to the Contractor in connection with any work contemplated or performed under this Contract.

The Contractor acknowledges, understands, and agrees that this Contract shall be null and void if the Contractor is, or within the past six (6) months has been, an employee of the State of Tennessee or if the Contractor is an entity in which a controlling interest is held by an individual who is, or within the past six (6) months has been, an employee of the State of Tennessee.

D.9. Nondiscrimination. The Contractor hereby agrees, warrants, and assures that no person shall be excluded from participation in, be denied benefits of, or be otherwise subjected to discrimination in the performance of this Contract or in the employment practices of the Contractor on the grounds of handicap or disability, age, race, creed, color, religion, sex, national origin, or any other classification protected by federal or state law. The Contractor shall, upon request, show proof of nondiscrimination and shall post in conspicuous places, available to all employees and applicants, notices of nondiscrimination.

D.10. Prohibition of Illegal Immigrants. The requirements of Tenn. Code Ann. § 12-3-309 addressing the use of illegal immigrants in the performance of any contract to supply goods or services to the state of Tennessee, shall be a material provision of this Contract, a breach of which shall be grounds for monetary and other penalties, up to and including termination of this Contract.

a. The Contractor agrees that the Contractor shall not knowingly utilize the services of an illegal immigrant in the performance of this Contract and shall not knowingly utilize the services of any subcontractor who will utilize the services of an illegal immigrant in the performance of this Contract. The Contractor shall reaffirm this attestation, in writing, by submitting to the State a completed and signed copy of the document at Attachment 2, semi-annually during the Term. If the Contractor is a party to more than one contract with the State, the Contractor may submit one attestation that applies to all contracts with the State. All Contractor attestations shall be maintained by the Contractor and made available to State officials upon request.

b. Prior to the use of any subcontractor in the performance of this Contract, and semi-annually thereafter, during the Term, the Contractor shall obtain and retain a current, written attestation that the subcontractor shall not knowingly utilize the services of an illegal immigrant to perform work under this Contract and shall not knowingly utilize the services of any subcontractor who will utilize the services of an illegal immigrant to perform work under this Contract. Attestations obtained from subcontractors shall be maintained by the Contractor and made available to State officials upon request.

c. The Contractor shall maintain records for all personnel used in the performance of this Contract. Contractor's records shall be subject to review and random inspection at any reasonable time upon reasonable notice by the State.

d. The Contractor understands and agrees that failure to comply with this section will be subject to the sanctions of Tenn. Code Ann. § 12-3-309 for acts or omissions occurring after its effective date.

e. For purposes of this Contract, "illegal immigrant" shall be defined as any person who is not: (i) a United States citizen; (ii) a Lawful Permanent Resident; (iii) a person whose physical presence in the United States is authorized; (iv) allowed by the federal Department of Homeland Security and who, under federal immigration laws or regulations, is authorized to be employed in the U.S.; or (v) is otherwise authorized to provide services under the Contract.

D.11. Records. The Contractor shall maintain documentation for all charges under this Contract. The books, records, and documents of the Contractor, for work performed or money received under this Contract, shall be maintained for a period of five (5) full years from the date of the final payment and shall be subject to audit at any reasonable time and upon reasonable notice by the State, the Comptroller of the Treasury, or their duly appointed representatives. The financial statements shall be prepared in accordance with generally accepted accounting principles.

D.12. Monitoring. The Contractor's activities conducted and records maintained pursuant to this Contract shall be subject to monitoring and evaluation by the State, the Comptroller of the Treasury, or their duly appointed representatives.

D.13. Progress Reports. The Contractor shall submit brief, periodic, progress reports to the State as requested.

D.14. Strict Performance. Failure by any Party to this Contract to require, in any one or more cases, the strict performance of any of the terms, covenants, conditions, or provisions of this Contract shall not be construed as a waiver or relinquishment of any term, covenant, condition, or provision. No term or condition of this Contract shall be held to be waived, modified, or deleted except by a written amendment signed by the Parties.

D.15. Independent Contractor. The Parties shall not act as employees, partners, joint venturers, or associates of one another. The Parties are independent contracting entities. Nothing in this Contract shall be construed to create an employer/employee relationship or to allow either Party to exercise control or direction over the manner or method by which the other transacts its business affairs or provides its usual services. The employees or agents of one Party are not employees or agents of the other Party.

D.16 Patient Protection and Affordable Care Act. The Contractor agrees that it will be responsible for compliance with the Patient Protection and Affordable Care Act ("PPACA") with respect to itself and its employees, including any obligation to report health insurance coverage, provide health insurance coverage, or pay any financial assessment, tax, or penalty for not providing health insurance. The Contractor shall indemnify the State and hold it harmless for any costs to the State arising from Contractor's failure to fulfill its PPACA responsibilities for itself or its employees.

D.17. Limitation of State's Liability. The State shall have no liability except as specifically provided in this Contract. In no event will the State be liable to the Contractor or any other party for any lost revenues, lost profits, loss of business, decrease in the value of any securities or cash position, time, money, goodwill, or any indirect, special, incidental, punitive, exemplary or consequential damages of any nature,

whether based on warranty, contract, statute, regulation, tort (including but not limited to negligence), or any other legal theory that may arise under this Contract or otherwise. The State's total liability under this Contract (including any exhibits, schedules, amendments or other attachments to the Contract) or otherwise shall under no circumstances exceed the Maximum Liability. This limitation of liability is cumulative and not per incident.

D.18. Limitation of Contractor's Liability. In accordance with Tenn. Code Ann. § 12-3-701, the Contractor's liability for all claims arising under this Contract shall be limited to an amount equal to two (2) times the Maximum Liability amount detailed in Section C.1. and as may be amended, PROVIDED THAT in no event shall this Section limit the liability of the Contractor for: (i) intellectual property or any Contractor indemnity obligations for infringement for third-party intellectual property rights; (ii) any claims covered by any specific provision in the Contract providing for liquidated damages; or (iii) any claims for intentional torts, criminal acts, fraudulent conduct, or acts or omissions that result in personal injuries or death.

D.19. Hold Harmless. The Contractor agrees to indemnify and hold harmless the State of Tennessee as well as its officers, agents, and employees from and against any and all claims, liabilities, losses, and causes of action which may arise, accrue, or result to any person, firm, corporation, or other entity which may be injured or damaged as a result of acts, omissions, or negligence on the part of the Contractor, its employees, or any person acting for or on its or their behalf relating to this Contract. The Contractor further agrees it shall be liable for the reasonable cost of attorneys for the State to enforce the terms of this Contract.

In the event of any suit or claim, the Parties shall give each other immediate notice and provide all necessary assistance to respond. The failure of the State to give notice shall only relieve the Contractor of its obligations under this Section to the extent that the Contractor can demonstrate actual prejudice arising from the failure to give notice. This Section shall not grant the Contractor, through its attorneys, the right to represent the State in any legal matter, as the right to represent the State is governed by Tenn. Code Ann. § 8-6-106.

D.20. HIPAA Compliance. The State and Contractor shall comply with obligations under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA"), Health Information Technology for Economic and Clinical Health ("HITECH") Act and any other relevant laws and regulations regarding privacy (collectively the "Privacy Rules"). The obligations set forth in this Section shall survive the termination of this Contract.

a. Contractor warrants to the State that it is familiar with the requirements of the Privacy Rules, and will comply with all applicable requirements in the course of this Contract.

b. Contractor warrants that it will cooperate with the State, including cooperation and coordination with State privacy officials and other compliance officers required by the Privacy Rules, in the course of performance of the Contract so that both parties will be in compliance with the Privacy Rules.

c. The State and the Contractor will sign documents, including but not limited to business associate agreements, as required by the Privacy Rules and that are reasonably necessary to keep the State and Contractor in compliance with the Privacy Rules. This provision shall not apply if information received or delivered by the parties under this Contract is NOT "protected health information" as defined by the Privacy Rules, or if the Privacy Rules permit the parties to receive or deliver the information without entering into a business associate agreement or signing another document.

d. The Contractor will indemnify the State and hold it harmless for any violation by the Contractor or its subcontractors of the Privacy Rules. This includes the costs of responding to a breach of protected health information, the costs of responding to a government enforcement action related to the breach, and any fines, penalties, or damages paid by the State because of the violation.

D.21. Tennessee Consolidated Retirement System. Subject to statutory exceptions contained in Tenn. Code Ann. §§ 8-36-801, *et seq*., the law governing the Tennessee Consolidated Retirement System ("TCRS"), provides that if a retired member of TCRS, or of any superseded system administered by TCRS, or of any

local retirement fund established under Tenn. Code Ann. §§ 8-35-101, *et seq.*, accepts State employment, the member's retirement allowance is suspended during the period of the employment. Accordingly and notwithstanding any provision of this Contract to the contrary, the Contractor agrees that if it is later determined that the true nature of the working relationship between the Contractor and the State under this Contract is that of "employee/employer" and not that of an independent contractor, the Contractor, if a retired member of TCRS, may be required to repay to TCRS the amount of retirement benefits the Contractor received from TCRS during the Term.

D.22. Tennessee Department of Revenue Registration. The Contractor shall comply with all applicable registration requirements contained in Tenn. Code Ann. §§ 67-6-601 – 608. Compliance with applicable registration requirements is a material requirement of this Contract.

D.23. Debarment and Suspension. The Contractor certifies, to the best of its knowledge and belief, that it, its current and future principals, its current and future subcontractors and their principals:

a. are not presently debarred, suspended, proposed for debarment, declared ineligible, or voluntarily excluded from covered transactions by any federal or state department or agency;

b. have not within a three (3) year period preceding this Contract been convicted of, or had a civil judgment rendered against them from commission of fraud, or a criminal offense in connection with obtaining, attempting to obtain, or performing a public (federal, state, or local) transaction or grant under a public transaction; violation of federal or state antitrust statutes or commission of embezzlement, theft, forgery, bribery, falsification, or destruction of records, making false statements, or receiving stolen property;

c. are not presently indicted or otherwise criminally or civilly charged by a government entity (federal, state, or local) with commission of any of the offenses detailed in section b. of this certification; and

d. have not within a three (3) year period preceding this Contract had one or more public transactions (federal, state, or local) terminated for cause or default.

The Contractor shall provide immediate written notice to the State if at any time it learns that there was an earlier failure to disclose information or that due to changed circumstances, its principals or the principals of its subcontractors are excluded or disqualified.

D.24. Force Majeure. "Force Majeure Event" means fire, flood, earthquake, elements of nature or acts of God, wars, riots, civil disorders, rebellions or revolutions, acts of terrorism or any other similar cause beyond the reasonable control of the Party except to the extent that the non-performing Party is at fault in failing to prevent or causing the default or delay, and provided that the default or delay cannot reasonably be circumvented by the non-performing Party through the use of alternate sources, workaround plans or other means. A strike, lockout or labor dispute shall not excuse either Party from its obligations under this Contract. Except as set forth in this Section, any failure or delay by a Party in the performance of its obligations under this Contract arising from a Force Majeure Event is not a default under this Contract or grounds for termination. The non-performing Party will be excused from performing those obligations directly affected by the Force Majeure Event, and only for as long as the Force Majeure Event continues, provided that the Party continues to use diligent, good faith efforts to resume performance without delay. The occurrence of a Force Majeure Event affecting Contractor's representatives, suppliers, subcontractors, customers or business apart from this Contract is not a Force Majeure Event under this Contract. Contractor will promptly notify the State of any delay caused by a Force Majeure Event (to be confirmed in a written notice to the State within one (1) day of the inception of the delay) that a Force Majeure Event has occurred, and will describe in reasonable detail the nature of the Force Majeure Event. If any Force Majeure Event results in a delay in Contractor's performance longer than forty-eight (48) hours, the State may, upon notice to Contractor: (a) cease payment of the fees until Contractor resumes performance of the affected obligations; or (b) immediately terminate this Contract or any purchase order, in whole or in part, without further payment except for fees then due and payable.

Contractor will not increase its charges under this Contract or charge the State any fees other than those provided for in this Contract as the result of a Force Majeure Event.

D.25. State and Federal Compliance. The Contractor shall comply with all applicable state and federal laws and regulations in the performance of this Contract.

D.26. Governing Law. This Contract shall be governed by and construed in accordance with the laws of the State of Tennessee. The Tennessee Claims Commission or the state or federal courts in Tennessee shall be the venue for all claims, disputes, or disagreements arising under this Contract. The Contractor acknowledges and agrees that any rights, claims, or remedies against the State of Tennessee or its employees arising under this Contract shall be subject to and limited to those rights and remedies available under Tenn. Code Ann. §§ 9-8-101 - 407.

D.27. Entire Agreement. This Contract is complete and contains the entire understanding between the Parties relating to its subject matter, including all the terms and conditions of the Parties' agreement. This Contract supersedes any and all prior understandings, representations, negotiations, and agreements between the Parties, whether written or oral.

D.28. Severability. If any terms and conditions of this Contract are held to be invalid or unenforceable as a matter of law, the other terms and conditions of this Contract shall not be affected and shall remain in full force and effect. The terms and conditions of this Contract are severable.

D.29. Headings. Section headings of this Contract are for reference purposes only and shall not be construed as part of this Contract.

D.30. Incorporation of Additional Documents. Each of the following documents is included as a part of this Contract by reference. In the event of a discrepancy or ambiguity regarding the Contractor's duties, responsibilities, and performance under this Contract, these items shall govern in order of precedence below:

a. any amendment to this Contract, with the latter in time controlling over any earlier amendments;
b. this Contract with any attachments or exhibits (excluding the items listed at subsections c. through f., below), which includes Attachment 1 – System Requirements, Attachment 2 – Attestation Re: Personnel Used in Contract Performance, Attachment 3 – Letter of Diversity Commitment, and Attachment 4 – State of Tennessee Enterprise Architecture,
c. any clarifications of or addenda to the Contractor's proposal seeking this Contract;
d. the State solicitation, as may be amended, requesting responses in competition for this Contract;
e. any technical specifications provided to proposers during the procurement process to award this Contract; and
f. the Contractor's response seeking this Contract.

E. SPECIAL TERMS AND CONDITIONS:

E.1. Conflicting Terms and Conditions. Should any of these special terms and conditions conflict with any other terms and conditions of this Contract, the special terms and conditions shall be subordinate to the Contract's other terms and conditions.

E. 2. Ownership of Software and Work Products.

a. Definitions.

(1) "Contractor-Owned Software," shall mean commercially available software the rights to which are owned by Contractor, including but not limited to commercial "off-the-shelf" software which is not developed using State's money or resources.

(2) "Custom-Developed Application Software," shall mean customized application software developed by Contractor solely for State.

(3) "Rights Transfer Application Software," shall mean any pre-existing application software owned by Contractor or a third party, provided to State and to which Contractor will grant and assign, or will facilitate the granting and assignment of, all rights, including the source code, to State.

(4) "Third-Party Software," shall mean software not owned by the State or the Contractor.

(5) "Work Product," shall mean all deliverables exclusive of hardware, such as software, software source code, documentation, planning, etc., that are created, designed, developed, or documented by the Contractor exclusively for the State during the course of the project using State's money or resources, including Custom-Developed Application Software. If the deliverables under this Contract include Rights Transfer Application Software, the definition of Work Product shall also include such software. Work Product shall not include Contractor-Owned Software or Third-Party Software.

b. Rights and Title to the Software

(1) All right, title and interest in and to the Contractor-Owned Software shall at all times remain with Contractor, subject to any license granted under this Contract.

(2) All right, title and interest in and to the Work Product, and to modifications thereof made by State, including without limitation all copyrights, patents, trade secrets and other intellectual property and other proprietary rights embodied by and arising out of the Work Product, shall belong to State. To the extent such rights do not automatically belong to State, Contractor hereby assigns, transfers, and conveys all right, title and interest in and to the Work Product, including without limitation the copyrights, patents, trade secrets, and other intellectual property rights arising out of or embodied by the Work Product. Contractor and its employees, agents, contractors or representatives shall execute any other documents that State or its counsel deem necessary or desirable to document this transfer or allow State to register its claims and rights to such intellectual property rights or enforce them against third parties.

(3) All right, title and interest in and to the Third-Party Software shall at all times remain with the third party, subject to any license granted under this Contract.

c. The Contractor may use for its own purposes the general knowledge, skills, experience, ideas, concepts, know-how, and techniques obtained and used during the course of performing under this Contract. The Contractor may develop for itself, or for others, materials which are similar to or competitive with those that are produced under this Contract.

E.3. Software License Warranty. Contractor grants a license to the State to use all software provided under this Contract in the course of the State's business and purposes.

E.4. Software Support and Maintenance Warranty. Contractor shall provide to the State all software upgrades, modifications, bug fixes, or other improvements in its software that it makes generally available to its customers.

IN WITNESS WHEREOF,

CONTRACTOR LEGAL ENTITY NAME:

CONTRACTOR SIGNATURE **DATE**

PRINTED NAME AND TITLE OF CONTRACTOR SIGNATORY (above)

DEPARTMENT OF MENTAL HEALTH AND SUBSTANCE ABUSE SERVICES:

NAME & TITLE **DATE**

#	System Requirement Description
1	Must provide assistance in evaluation of medication room/nursing station geography in planning for installation of appropriate size and number of cabinets for each RMHI: with consideration for factors such as appropriate ventilation, controlled room temperature, lighting, electrical and network connectivity.
2	Must provide a schematic configuration with the dimensions of the proposed cabinets solution for each patient unit and their appropriate placement in each medication room on the units.
3	Must provide a staff person to collaborate with TDMHSAS on creating a written implementation plan that includes the following components as well as the level of support to be provided during each phase: a) Installation and set-up of equipment, interfaces and orders; b) Testing and verification of system performance and data accuracy; c) On-site employee training ; d) An approved roll-out schedule for each RMHI to be coordinated with Pharmacy, Nursing, and IT management at each facility; e) An agreed upon timeframe to complete the project.
4	Must provide written details of the customer support process, including projected response time to address all reported problems and estimated time of arrival on-site of service technicians when needed. AMDC software support and technical support must be available 24/7 with call back response not to exceed 30 minutes.
5	System must be able to batch NDC codes per medication allowing multiple NDCs per drug allowing for a mix of manufacturers in the same bin.
6	Must have medication profiling system to view patient-specific medication orders, administration times, and listed allergies at the AMDC.
7	Must provide process for user to obtain medications not yet verified by the pharmacy. When a medication that has not been reviewed and approved by a pharmacist needs to be accessed from the AMDC, the nurse must be prompted to describe the reason for the override.
8	Must provide a secure medication return bin installed as part of the AMDC system, along with process at the AMDC screen for the nurse to enter reason for return.
9	Drawer and bin configuration must allow pharmacy to adjust each AMDC's drawer/system configuration to meet changing medication needs over time without requiring vendor intervention.
10	Configuration settings for devices, users, and formulary items must be available at the following levels: enterprise wide, individual Regional Mental Health Institute, or individual cabinet.
11	Must have system alert for the nurse if attempting to remove medication outside of administration time range allowed by hospital, or if attempting to remove a medication that is more or less than the ordered quantity.
12	System must display an alarm if a drawer in the cabinet is left open for a configurable, defined time period.
13	AMDCs must log the user off automatically after a configurable, defined time period.
14	Failure of one bin or drawer to operate does not disable the use of other AMDC parts.
15	Patient’s medication orders must be searchable from any AMDC in the hospital.
16	Vendor must provide a recommendation for cabinet capacity and configuration requirements based on pharmaceutical statistics for each RMHI.

17	System must have the ability to search for medications on both generic and brand names.
18	System must have capability to customize drug names to ensure consistency with the Medication Administration Record (MAR).
19	System must flag or identify patients with the same last name found on a searched list or within the same unit.
20	The system must be able to track medication lot numbers and expiration dates.
21	Must have manual process to access medications stored in the AMDC in the event of a system failure.
22	Must have capability of increased security for controlled substance administering, waste and return.
23	Must allow nurses on each unit to inventory only those controlled medications that have been accessed at the AMDC since the last count.
24	Must have capacity to manage par levels, monitor critically low stock levels and out of stock items by pharmacy staff.
25	Must have customizable security level access for multiple user roles within the system.
26	Must offer unlimited number of security based customizable over-ride list categories.
27	Must have bar code scanner for stocking and restocking confirmation.
28	HL7 interfaces must be able to handle error conditions and create log files which shall be maintained for a specified period of time.
29	System must provide analytical tools that support drill down and dashboard functions for tracking, delivering, and dispensing of medications.
30	Must have single server to support RMHI's in multiple time zones.
31	Cabinets and drawers must have proven durability.
32	System must provide easily accessible, searchable on-screen help pertinent to current screen display.
33	Must interface with our pharmacy system using HL7 using agreed upon data exchange requirements.
34	All AMDCs will be configured and implemented on the State network in compliance with State Technology Standards and Enterprise Information Security Policies. Server hosted in the State's data center will be configured in compliance with State Technology Standards and Enterprise Information Security Policies.
35	The vendor will utilize the State's SSL VPN solution for remote access. All connections and transmissions to and from the State network must be encrypted.
36	System must provide both a typed login/password, as well as biometric user identification which uses technology that is NIST and FIPS 201 certified, to access AMDC system.
37	System software upgrades requiring corresponding hardware upgrades shall be provided and installed at no additional cost to the State and in conformity with the Tennessee Enterprise Technology Architecture Standards.
38	AMDC System must have patient safety technology to guide user to the correct dispensing bin for accessing or restocking medications with the use of lights or other guidance features.
39	Must provide capacity for on-screen and physical keyboard access with touch screen functions at all AMDC systems with keyboard protected from spills and easily cleaned with alcohol based cleaners without causing damage.

40	AMDCs must be able to connect to network printers.
41	Nurse must be able to search all AMDCs throughout the hospital for a medication if the medication is not available in the unit AMDC.
42	Software must provide for the sorting and filtering of patient information based on patient profile data.
43	System must provide medication nurse messages that are customizable on content, color, and flashing.
44	System must prompt medication nurse to refer to patient chart if allergy status of patient is unknown.
45	Patient allergy messages must be displayed on the monitor and require interaction when a medication administering override is entered.
46	Authorized user must have ability to assign time-limited, temporary passwords from a cabinet.
47	Must have ability to access “drug information database” from the internet at every cabinet location.
48	Must have ability to track removal of partial quantity of a whole unit. e.g., Multi-dose vial or Bulk Liquid
49	Authorized staff must be able to access system-wide information and generate reports from the AMDC system from any workstation located within the State network.
50	System must provide standard report on attempts to access non-indicated medication compartments.
51	System must have the capability to automatically generate scheduled reports.
52	System must be able to generate reports up to 60-days without having to access an archive for the data. Allow for three years of data on the live system and be able to send the report to any network printer within TDMHSAS network. Records must be electronically accessible for up to ten years.
53	Database must be configured to allow unlimited historical data to be kept without negatively impacting performance.
54	System users must be able to create custom reports without vendor interaction.
55	System must include 10 custom built reports at no extra cost to TDMHSAS.
56	System must be able to export reports in a Microsoft Excel 2010 compatible format.

(Fill out only by selected Contractor)

ATTESTATION RE PERSONNEL USED IN CONTRACT PERFORMANCE

SUBJECT CONTRACT NUMBER:	
CONTRACTOR LEGAL ENTITY NAME:	
FEDERAL EMPLOYER IDENTIFICATION NUMBER (or Social Security number)	

The Contractor, identified above, does hereby attest, certify, warrant, and assure that Contractor shall not knowingly utilize the services of an illegal immigrant in the performance of this Contract and shall not knowingly utilize the services of any subcontractor who will utilize the services of an illegal immigrant in the performance of this Contract.

CONTRACTOR SIGNATURE

NOTICE: This attestation MUST be signed by an individual empowered to contractually bind Contractor. If said individual is not the chief executive or president, this document shall attach evidence showing the individual's authority to contractually bind Contractor.

PRINTED NAME AND TITLE OF SIGNATORY

DATE OF ATTESTATION

SAMPLE LETTER OF DIVERSITY COMMITMENT

(Company Letterhead/Logo)
(Address)
(Date)

(Salutation),

(Company Name) is committed to achieving or surpassing a goal of (numeral) percent spend with certified diversity business enterprise firms on State of Tennessee contract # (Edison document #). Diversity businesses are defined as those that are owned by minority, women, small business and Tennessee service-disabled veterans which are certified by the Governor's Office of Diversity Business Enterprise (Go-DBE).

We confirm our commitment of (percentage) participation on the (Contract) by using the following diversity businesses:

Name and ownership characteristics (i.e., ethnicity, gender, Tennessee service-disabled veteran) of anticipated diversity subcontractors and suppliers:
_____

(ii) Participation estimates (expressed as a percent of the total contract value to be dedicated to diversity subcontractors and suppliers):
_____%.

(iii) Description of anticipated services to be performed by diversity subcontractors and suppliers:

_____

_____

We accept that our commitment to diversity advances the State's efforts to expand opportunity of diversity businesses to do business with the State as contractors and sub-contractors.

Further, we commit to:
Using applicable reporting tools that allow the State to track and report purchases from businesses owned by minority, women, Tennessee service-disabled veterans and small business.

Reporting quarterly to the Go-DBE office the dollars spent with certified diversity businesses owned by minority, women, Tennessee service-disabled veterans and small business accomplished under contract # (Edison number).

(Company Name) is committed to working with the Go-DBE office to accomplish this goal.

Regards,

(Company authority – signature and title)

Place holder for Tennessee Enterprise Architecture: reference RFQ Section 1.3.2.

REQUEST FOR CONFIDENTIAL DOCUMENTS

In order to receive the confidential documents described in the Solicitation, the State must receive a Notice of Intent to Propose (filed separately) and a signature on the attached Confidentiality Agreement by an officer of the prospective respondent who is authorized to bind the company.

CONFIDENTIALITY AGREEMENT

_____, a Prospective Respondent on a procurement with the State of Tennessee (hereinafter "Prospective Respondent"), will be provided with copies of the following documents for the purposes of preparing a response to this procurement.

1. Edison Business Partner Interfaces – Technical Quick Start Guide

2. Enterprise Technology Architecture Standard Products

In consideration for access to these documents, Prospective Respondent agrees as follows:

1. These documents are confidential and proprietary and are not public records of the State of Tennessee.

2. These documents, or copies thereof, will only be disclosed to authorized employees and contractors of Prospective Respondent who need access to them for the purpose of preparing a response to the procurement. All individuals entrusted with these documents, or the information contained therein, will be notified of the confidentiality restrictions.

3. Prospective Respondent will maintain reasonable security procedures to protect paper and electronic copies of these documents.

4. If Prospective Respondent chooses not to offer a response or if the response does not result in a contract with the State, the Prospective Respondent will destroy all copies of the documents within a reasonable time. If requested by the State, Prospective Respondent will certify in writing that the confidential documents were destroyed.

5. If Prospective Respondent enters into a contract with the State based on this procurement, this confidentiality agreement will expire upon signature of the contract, and the confidentiality provisions of the contract will control.

6. Prospective Respondent agrees that unauthorized release of the documents would cause such harm to the State that injunctive relief would be an appropriate remedy. If any court rules that Prospective Respondent has breached this confidentiality agreement, Prospective Respondent shall reimburse the State for its cost of litigation, including attorney's fees, as well as any damages awarded by the court.

7. This confidentiality agreement shall be interpreted under the laws of the State of Tennessee.

_____
(signature)

_____
(name of company)

Signature of this document constitutes certification that the person signing the document has the authority to bind the company.

_____

for State of Tennessee

WESTERN MENTAL HEALTH INSTITUTE MEDICATION ROOM
(6 of these)



MEMPHIS MENTAL HEALTH INSTITUTE MEDICATION ROOM
(2 of these)



MOCCASIN BEND
MENTAL HEALTH
INSTITUTE
MEDICATION ROOM
(6 of these)



MIDDLE TENNESSEE MENTAL HEALTH INSTITUTE MEDICATION ROOM (7 of these)





MIDDLE TENNESSEE MENTAL HEALTH INSTITUTE
MEDICATION ROOM
FORENSICS BUILDING
(2 of these)

DRUG USAGE INFORMATION

The following information is to be used by the vendor to help determine an estimate for the needed drawers and configuration for each Automated Medication Dispensing Cabinet (AMDC). In addition to the drug usage information below, please include drawers, configuration and pricing for an additional cabinet per RMHI assuming similar storage capacity to those below.

Drugs used in average month by RMHI, by unit
Totals are per drug unit (pill/mL/gram)

WMHI Tablets dispensed in a typical month. WMHI has 6 units.

Sum of Quantity Dispensed		
Patient Unit	Drug Name	Total
501	ACETAMINOPHEN-COD #3 TABLET	60
	AMANTADINE 100 MG CAPSULE	16
	AMLODIPINE BESYLATE 10 MG T	36
	AMLODIPINE BESYLATE 2.5 MG	7
	AMLODIPINE BESYLATE 5 MG TA	34
	ASPIRIN EC 81 MG TABLET	77
	BENZTROPINE 2 MG/2 ML AMPUL	10
	BENZTROPINE MES 0.5 MG TAB	34
	BENZTROPINE MES 1 MG TABLET	329
	BENZTROPINE MES 2 MG TABLET	129
	BICILLIN LA 2,400,000 UNITS	4
	BUPROPION HCL SR 100 MG TAB	7
	BUPROPION SR 150 MG TABLET	7
	BUSPIRONE HCL 10 MG TABLET	14
	CHLORASEPTIC SORE THROAT LO	36
	CHLORPROMAZINE 100 MG TABLE	1
	CHLORPROMAZINE 25 MG/ML AMP	0
	CITALOPRAM HBR 20 MG TABLET	75
	CLONAZEPAM 0.5 MG DIS TABLE	4
	CLONAZEPAM 0.5 MG TABLET	30
	CLONAZEPAM 1 MG TABLET	30
	CLONIDINE HCL 0.1 MG TABLET	99
	CLONIDINE HCL 0.2 MG TABLET	54
	CLOPIDOGREL 75 MG TABLET	1
	CLOZAPINE 100 MG TABLET	10
	CLOZAPINE 200 MG TABLET	4
	CLOZAPINE 25 MG TABLET	48

	CYCLOBENZAPRINE 10 MG TABLE	18
	DIPHENHYDRAMINE 50 MG CAPSU	161
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIPHENOXYLATE-ATROPINE TABL	20
	DIVALPROEX SOD DR 250 MG TA	77
	DIVALPROEX SOD DR 500 MG TA	526
	DOK 100 MG CAPSULE	102
	ESCITALOPRAM 10 MG TABLET	4
	FLUOXETINE HCL 20 MG CAPSUL	93
	FLUPHENAZINE 1 MG TABLET	92
	FLUPHENAZINE 10 MG TABLET	86
	FLUPHENAZINE 2.5 MG/ML VIAL	0
	FLUPHENAZINE 5 MG TABLET	10
	FLUPHENAZINE DEC 25 MG/ML V	10
	FUROSEMIDE 20 MG TABLET	3
	GABAPENTIN 300 MG CAPSULE	230
	GLIMEPIRIDE 4 MG TABLET	64
	HALOPERIDOL 10 MG TABLET	475
	HALOPERIDOL 2 MG TABLET	15
	HALOPERIDOL 5 MG TABLET	17
	HALOPERIDOL DEC 100 MG/ML V	17
	HALOPERIDOL LAC 2 MG/ML CON	0
	HALOPERIDOL LAC 5 MG/ML VIA	25
	HYDROCORTISONE 1% CREAM	28
	HYDROXYZINE PAM 25 MG CAP	224
	IBUPROFEN 400 MG TABLET	32
	IBUPROFEN 600 MG TABLET	83
	KLOR-CON 10 MEQ TABLET	14
	KLOR-CON 20 MEQ PACKET	2
	LANTUS 100 UNITS/ML VIAL	20
	LEVOTHYROXINE 100 MCG TABLE	3
	LEVOTHYROXINE 75 MCG TABLET	7
	LISINOPRIL 20 MG TABLET	20
	LITHIUM CARBONATE 300 MG CA	19
	LOPERAMIDE 2 MG CAPSULE	0
	LORATADINE 10 MG TABLET	13
	LORAZEPAM 0.5 MG TABLET	4
	LORAZEPAM 1 MG TABLET	0
	LORAZEPAM 2 MG TABLET	0
	LORAZEPAM 2 MG/ML VIAL	25
	MAG-AL PLUS SUSPENSION	600
	MAPAP 325 MG TABLET	200
	MEGESTROL ACET 40 MG/ML SUS	0

	METFORMIN HCL 500 MG TABLET	87
	METOPROLOL TARTRATE 25 MG T	27
	MILK OF MAGNESIA SUSPENSION	1500
	MIRTAZAPINE 15 MG TABLET	7
	MUCINEX ER 600 MG TABLET	26
	NAPROXEN 500 MG TABLET	7
	NICOTINE 21 MG/24HR PATCH	14
	NOVOLOG 100 UNIT/ML VIAL	0
	OLANZAPINE 10 MG TABLET	11
	OLANZAPINE 10 MG VIAL	0
	OLANZAPINE 20 MG TABLET	8
	OMEPRAZOLE DR 20 MG CAPSULE	182
	OXCARBAZEPINE 300 MG TABLET	14
	PAROXETINE HCL 20 MG TABLET	13
	PHENERGAN 25 MG/ML AMPUL	6
	POLYETHYLENE GLYCOL 3350 PO	33
	PROCTOSOL-HC 2.5% CREAM	28.35
	PROMETHAZINE 25 MG TABLET	14
	PROPRANOLOL 20 MG TABLET	1
	QUETIAPINE FUMARATE 50 MG T	7
	RANITIDINE 150 MG TABLET	53
	RISPERIDONE 1 MG TABLET	14
	RISPERIDONE 2 MG TABLET	15
	SERTRALINE HCL 50 MG TABLET	42
	SIMETHICONE 80 MG TAB CHEW	49
	SIMVASTATIN 20 MG TABLET	7
	SULFAMETHOXAZOLE-TMP DS TAB	14
	TOPROL XL 50 MG TABLET	78
	TRAZODONE 100 MG TABLET	34
	TRAZODONE 50 MG TABLET	17
	TUBERSOL 5T UNITS/0.1 ML VI	3
	TUMS TABLET CHEWABLE	10
	VENLAFAXINE HCL ER 150 MG C	16
	VENLAFAXINE HCL ER 75 MG CA	8
	VIT D2 1.25 MG (50,000 UNIT	1
	VITAMIN E 400 UNIT CAPSULE	16
501 Total		6882.35
511	ACETAMINOPHEN-COD #3 TABLET	60
	ALBUTEROL 0.083% INHAL SOLN	30
	AMOX TR-K CLV 500-125 MG TA	1
	ARTIFICIAL TEARS DROPS	0
	ASPIRIN EC 81 MG TABLET	20
	AZITHROMYCIN 250 MG TABLET	8

	BENZTROPINE 2 MG/2 ML AMPUL	18
	BENZTROPINE MES 0.5 MG TAB	71
	BENZTROPINE MES 1 MG TABLET	123
	BENZTROPINE MES 2 MG TABLET	14
	BETHANECHOL 25 MG TABLET	21
	BUSPIRONE HCL 10 MG TABLET	6
	CARVEDILOL 3.125 MG TABLET	14
	CEPHALEXIN 250 MG CAPSULE	8
	CHLORDIAZEPOXIDE 25 MG CAPS	30
	CHLORPROMAZINE 25 MG/ML AMP	50
	CITALOPRAM HBR 20 MG TABLET	21
	CLONAZEPAM 0.5 MG TABLET	90
	CLONAZEPAM 1 MG TABLET	90
	CLONIDINE HCL 0.1 MG TABLET	21
	CLOZAPINE 100 MG TABLET	9
	CLOZAPINE 200 MG TABLET	4
	CLOZAPINE 25 MG TABLET	26
	CYANOCOBALAMIN 1,000 MCG/ML	0
	DEEP SEA 0.65% NOSE SPRAY	0
	DIAZEPAM 5 MG TABLET	10
	DIPHENHYDRAMINE 25 MG CAPSU	10
	DIPHENHYDRAMINE 50 MG/ML VI	0
	DIPHENOXYLATE-ATROPINE TABL	0
	DIVALPROEX SOD DR 250 MG TA	3
	DIVALPROEX SOD DR 500 MG TA	108
	FLUCONAZOLE 150 MG TABLET	2
	FLUOXETINE HCL 20 MG CAPSUL	51
	FOLIC ACID 1 MG TABLET	30
	FUROSEMIDE 40 MG TABLET	8
	GABAPENTIN 300 MG CAPSULE	100
	GEODON 20 MG VIAL	10
	GLIMEPIRIDE 2 MG TABLET	14
	HALOPERIDOL 10 MG TABLET	113
	HALOPERIDOL 2 MG TABLET	15
	HALOPERIDOL 5 MG TABLET	98
	HALOPERIDOL DEC 100 MG/ML V	30
	HALOPERIDOL LAC 5 MG/ML VIA	100
	HYDROCHLOROTHIAZIDE 25 MG T	28
	HYDROCORTISONE 1% CREAM	56
	HYDROXYZINE PAM 25 MG CAP	154
	IBUPROFEN 400 MG TABLET	45

	KETOROLAC 60 MG/2 ML VIAL	2
	KLOR-CON 10 MEQ TABLET	2
	LAMOTRIGINE 25 MG TABLET	14
	LANTUS 100 UNITS/ML VIAL	20
	LEVOTHYROXINE 75 MCG TABLET	1
	LISINOPRIL 10 MG TABLET	7
	LISINOPRIL 20 MG TABLET	30
	LITHIUM CARBONATE ER 300 MG	21
	LITHIUM ER 450 MG TABLET	2
	LORATADINE 10 MG TABLET	8
	LORAZEPAM 1 MG TABLET	0
	LORAZEPAM 2 MG TABLET	30
	LORAZEPAM 2 MG/ML VIAL	50
	LOVASTATIN 20 MG TABLET	14
	MAG64 DR 64 MG TABLET	52
	MAG-AL PLUS SUSPENSION	1200
	MAPAP 325 MG TABLET	200
	MEGESTROL 40 MG TABLET	21
	MELOXICAM 7.5 MG TABLET	16
	METFORMIN HCL 500 MG TABLET	14
	MILK OF MAGNESIA SUSPENSION	600
	MINERAL OIL	473
	MUPIROCIN 2% OINTMENT	44
	NEOMYCIN-POLYMYXIN-HC EAR S	10
	NICOTINE 21 MG/24HR PATCH	7
	NOVOLIN R 100 UNITS/ML VIAL	0
	NOVOLOG 100 UNIT/ML VIAL	10
	OLANZAPINE 10 MG VIAL	0
	OMEPRAZOLE DR 20 MG CAPSULE	30
	OXCARBAZEPINE 300 MG TABLET	1
	PHENYTOIN SOD EXT 100 MG CA	80
	PROCTOSOL-HC 2.5% CREAM	85.05
	PROPRANOLOL 20 MG TABLET	5
	QUETIAPINE FUMARATE 100 MG	7
	RANITIDINE 150 MG TABLET	1
	RISPERIDONE 3 MG TABLET	21
	SENSI-CARE PROTECTIVE OINTM	113
	SERTRALINE HCL 50 MG TABLET	28
	SPIRONOLACTONE 25 MG TABLET	7
	SYMBICORT 160-4.5 MCG INHAL	60
	TAB-A-VITE TABLET	142
	TAMSULOSIN HCL 0.4 MG CAPSU	8
	THIAMINE 200 MG/2 ML VIAL	0

	TIMOLOL 0.5% EYE DROPS	10
	TINACTIN 1% AEROSOL POWDER	133
	TRAZODONE 100 MG TABLET	49
	TRAZODONE 50 MG TABLET	79
	TRIPLE ANTIBIOTIC OINTMENT	0
	TUBERSOL 5T UNITS/0.1 ML VI	5
	VENLAFAXINE HCL ER 150 MG C	8
	VENLAFAXINE HCL ER 75 MG CA	28
	VENTOLIN HFA 90 MCG INHALER	8
	VITAMIN B-1 50 MG TABLET	32
	WATER FOR INJECTION VIAL	200
511 Total		5708.05
521	ACYCLOVIR 200 MG CAPSULE	111
	ALPHAGAN P 0.1% DROPS	10
	AMANTADINE 100 MG CAPSULE	60
	AMLODIPINE BESYLATE 10 MG T	6
	AMLODIPINE BESYLATE 5 MG TA	30
	ANUCORT-HC 25 MG SUPPOSITOR	6
	ARTIFICIAL TEARS DROPS	15
	ASPIRIN EC 81 MG TABLET	62
	BENZOYL PEROXIDE 10% GEL	42.5
	BENZTROPINE 2 MG/2 ML AMPUL	0
	BENZTROPINE MES 1 MG TABLET	327
	BENZTROPINE MES 2 MG TABLET	370
	CHLORASEPTIC SORE THROAT LO	18
	CHLORHEXIDINE 0.12% RINSE	473
	CITALOPRAM HBR 20 MG TABLET	110
	CLONAZEPAM 0.5 MG TABLET	90
	CLONAZEPAM 1 MG TABLET	120
	CLOZAPINE 100 MG TABLET	1
	CLOZAPINE 200 MG TABLET	119
	COUMADIN 5 MG TABLET	14
	DESMOPRESSIN ACETATE 0.2 MG	2
	DIVALPROEX SOD DR 250 MG TA	1
	DIVALPROEX SOD DR 500 MG TA	512
	DOK 100 MG CAPSULE	207
	FLUPHENAZINE 10 MG TABLET	61
	FLUPHENAZINE 5 MG TABLET	122
	FLUPHENAZINE DEC 25 MG/ML V	10
	FLUTICASONE PROP 50 MCG SPR	32
	GEMFIBROZIL 600 MG TABLET	61
	HALOPERIDOL 10 MG TABLET	246
	HALOPERIDOL 2 MG TABLET	17

	HALOPERIDOL 5 MG TABLET	22
	HALOPERIDOL DEC 100 MG/ML V	40
	HALOPERIDOL LAC 2 MG/ML CON	120
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HYDROCHLOROTHIAZIDE 25 MG T	30
	HYDROCORTISONE 1% CREAM	112
	HYDROXYZINE PAM 25 MG CAP	20
	IBUPROFEN 400 MG TABLET	6
	IBUPROFEN 600 MG TABLET	20
	LEVOTHYROXINE 125 MCG TABLE	85
	LEVOTHYROXINE 25 MCG TABLET	145
	LEVOTHYROXINE 75 MCG TABLET	37
	LISINOPRIL 10 MG TABLET	61
	LISINOPRIL 20 MG TABLET	37
	LITHIUM CARBONATE 300 MG CA	302
	LITHIUM CARBONATE ER 300 MG	120
	LORATADINE 10 MG TABLET	72
	LORAZEPAM 1 MG TABLET	30
	LORAZEPAM 2 MG TABLET	0
	LORAZEPAM 2 MG/ML VIAL	0
	MAG-AL PLUS SUSPENSION	900
	MAPAP 325 MG TABLET	200
	METFORMIN HCL 500 MG TABLET	69
	MILK OF MAGNESIA SUSPENSION	300
	MINERAL OIL	0
	NEOMYCIN-POLYMYXIN-HC EAR S	10
	NICOTINE 21 MG/24HR PATCH	7
	OLANZAPINE 10 MG TABLET	122
	OLANZAPINE 20 MG TABLET	14
	OMEPRAZOLE DR 20 MG CAPSULE	54
	OXCARBAZEPINE 300 MG TABLET	120
	PRAVASTATIN SODIUM 20 MG TA	32
	PREDNISONE 20 MG TABLET	1
	QUETIAPINE FUMARATE 200 MG	1
	QUETIAPINE FUMARATE 300 MG	139
	RANITIDINE 150 MG TABLET	60
	RISPERIDONE 3 MG TABLET	84
	SELENIUM SULFIDE 2.5% LOTIO	240
	SIMVASTATIN 20 MG TABLET	30
	TAMSULOSIN HCL 0.4 MG CAPSU	28
	TIMOLOL 0.5% EYE DROPS	10
	TINACTIN 1% AEROSOL POWDER	266
	TRAZODONE 100 MG TABLET	35

	TRAZODONE 50 MG TABLET	26
	TRIAMCINOLONE 0.1% CREAM	400
	TUBERSOL 5T UNITS/0.1 ML VI	1
	WATER FOR INJECTION VIAL	60
	ZIPRASIDONE HCL 80 MG CAPSU	59
521 Total		7782.5
561	ALLOPURINOL 100 MG TABLET	30
	AMANTADINE 100 MG CAPSULE	116
	AMLODIPINE BESYLATE 10 MG T	112
	AMLODIPINE BESYLATE 5 MG TA	30
	AMPICILLIN TR 250 MG CAPSUL	80
	ANALGESIC BALM	56
	ARTIFICIAL TEARS DROPS	15
	ASPIRIN EC 81 MG TABLET	203
	BENZTROPINE MES 0.5 MG TAB	62
	BENZTROPINE MES 1 MG TABLET	384
	BENZTROPINE MES 2 MG TABLET	120
	BETHANECHOL 25 MG TABLET	90
	BUSPIRONE HCL 10 MG TABLET	147
	BUSPIRONE HCL 5 MG TABLET	165
	CARBAMAZEPINE 200 MG TABLET	71
	CARVEDILOL 25 MG TABLET	33
	CHLORPROMAZINE 200 MG TABLE	60
	CHLORPROMAZINE 25 MG TABLET	10
	CHLORPROMAZINE 25 MG/ML AMP	25
	CHLORPROMAZINE 50 MG TABLET	10
	CITALOPRAM HBR 20 MG TABLET	57
	CLONAZEPAM 0.5 MG DIS TABLE	90
	CLONAZEPAM 0.5 MG TABLET	90
	CLONAZEPAM 1 MG DIS TABLET	4
	CLONAZEPAM 2 MG ODT	90
	CLONIDINE HCL 0.1 MG TABLET	60
	CLOZAPINE 100 MG TABLET	59
	CLOZAPINE 200 MG TABLET	75
	CLOZAPINE 25 MG TABLET	116
	DEBROX EAR DROPS	15
	DESMOPRESSIN 0.01% SOLUTION	5
	DESMOPRESSIN ACETATE 0.2 MG	122
	DILTIAZEM ER 240 MG CAPSULE	30
	DIPHENHYDRAMINE 50 MG CAPSU	9
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	231

	DIVALPROEX SOD DR 500 MG TA	1151
	DOK 100 MG CAPSULE	151
	DOXYCYCLINE HYCLATE 100 MG	4
	ESCITALOPRAM 10 MG TABLET	84
	FERROUS SULFATE 325 MG TABL	10
	FISH OIL 1,000 MG SOFTGEL	29
	FLUDROCORTISONE 0.1 MG TABL	119
	FLUOXETINE HCL 10 MG CAPSUL	30
	FLUOXETINE HCL 20 MG CAPSUL	60
	FLUPHENAZINE 10 MG TABLET	439
	FLUPHENAZINE 5 MG TABLET	82
	FUROSEMIDE 40 MG TABLET	76
	GABAPENTIN 300 MG CAPSULE	640
	GEMFIBROZIL 600 MG TABLET	119
	GLIMEPIRIDE 2 MG TABLET	71
	HALOPERIDOL 10 MG TABLET	31
	HALOPERIDOL 5 MG TABLET	10
	HALOPERIDOL DEC 100 MG/ML V	10
	HALOPERIDOL LAC 5 MG/ML VIA	25
	HYDROCHLOROTHIAZIDE 12.5 MG	43
	HYDROCORTISONE 1% CREAM	28
	HYDROXYZINE PAM 25 MG CAP	270
	ISOSORBIDE DN 10 MG TABLET	41
	LACTULOSE 20 GM/30 ML SOLUT	1200
	LANTUS 100 UNITS/ML VIAL	20
	LEVOTHYROXINE 100 MCG TABLE	88
	LEVOTHYROXINE 125 MCG TABLE	128
	LEVOTHYROXINE 25 MCG TABLET	170
	LEVOTHYROXINE 75 MCG TABLET	95
	LISINOPRIL 10 MG TABLET	60
	LISINOPRIL 20 MG TABLET	154
	LISINOPRIL 5 MG TABLET	30
	LITHIUM CARBONATE 300 MG CA	19
	LITHIUM CARBONATE ER 300 MG	249
	LITHIUM ER 450 MG TABLET	23
	LORATADINE 10 MG TABLET	34
	LORAZEPAM 0.5 MG TABLET	60
	LORAZEPAM 1 MG TABLET	90
	LORAZEPAM 2 MG TABLET	30
	LORAZEPAM 2 MG/ML VIAL	25
	LOSARTAN POTASSIUM 50 MG TA	28
	LUMIGAN 0.01% EYE DROPS	5
	MAG-AL PLUS SUSPENSION	900

	MAPAP 325 MG TABLET	494
	MELOXICAM 7.5 MG TABLET	61
	METFORMIN HCL 500 MG TABLET	494
	METOPROLOL TARTRATE 50 MG T	29
	MILK OF MAGNESIA SUSPENSION	600
	MINOXIDIL 2.5 MG TABLET	360
	MONTELUKAST SOD 10 MG TABLE	1
	NEOMYCIN-POLYMYXIN-HC EAR S	10
	NITROFURANTOIN MCR 50 MG CA	30
	NOVOLIN 70-30 100 UNIT/ML V	20
	NOVOLOG 100 UNIT/ML VIAL	10
	OLANZAPINE 10 MG TABLET	127
	OLANZAPINE 20 MG TABLET	60
	OLANZAPINE ODT 20 MG TABLET	50
	OMEPRAZOLE DR 20 MG CAPSULE	413
	OXCARBAZEPINE 150 MG TABLET	53
	OXCARBAZEPINE 300 MG TABLET	53
	OYSTER SHELL CALCIUM 500+D	120
	PHENYTOIN SOD EXT 100 MG CA	145
	POLYETHYLENE GLYCOL 3350 PO	60
	PROPRANOLOL 10 MG TABLET	60
	QUETIAPINE FUMARATE 100 MG	159
	QUETIAPINE FUMARATE 200 MG	150
	QUETIAPINE FUMARATE 25 MG T	29
	QUETIAPINE FUMARATE 300 MG	71
	QUETIAPINE FUMARATE 50 MG T	28
	RANITIDINE 150 MG TABLET	413
	RISPERIDONE 0.5 MG TABLET	4
	RISPERIDONE 1 MG TABLET	28
	RISPERIDONE 1 MG/ML SOLUTIO	120
	RISPERIDONE 2 MG TABLET	60
	RISPERIDONE 4 MG TABLET	2
	SELENIUM SULFIDE 2.5% LOTIO	120
	SENNA-TIME S TABLET	184
	SENSI-CARE PROTECTIVE OINTM	113
	SIMVASTATIN 10 MG TABLET	61
	SIMVASTATIN 20 MG TABLET	90
	SIMVASTATIN 40 MG TABLET	95
	SLO-NIACIN 500 MG TABLET	52
	SPIRONOLACTONE 25 MG TABLET	39
	SULFAMETHOXAZOLE-TMP DS TAB	15
	SYMBICORT 160-4.5 MCG INHAL	120
	TAB-A-VITE TABLET	217

	TAMSULOSIN HCL 0.4 MG CAPSU	150
	TERAZOSIN 1 MG CAPSULE	60
	TERAZOSIN 5 MG CAPSULE	29
	TOPIRAMATE 100 MG TABLET	31
	TRAZODONE 100 MG TABLET	31
	TRAZODONE 50 MG TABLET	45
	TRIHEXYPHENIDYL 2 MG TABLET	27
	TRIHEXYPHENIDYL 5 MG TABLET	118
	TUMS TABLET CHEWABLE	119
	VALPROIC ACID 250 MG/5 ML S	2365
	VENTOLIN HFA 90 MCG INHALER	8
	VIT D2 1.25 MG (50,000 UNIT	3
	VITAMIN D3 5,000 UNIT SOFTG	99
	ZIPRASIDONE HCL 80 MG CAPSU	29
	ZOLPIDEM TARTRATE 5 MG TABL	60
561 Total		18422
571	ACETAMINOPHEN-COD #3 TABLET	20
	ALBUTEROL 0.083% INHAL SOLN	0
	AMLODIPINE BESYLATE 2.5 MG	31
	AMLODIPINE BESYLATE 5 MG TA	6
	ARTIFICIAL TEARS DROPS	75
	ATENOLOL 25 MG TABLET	30
	AZITHROMYCIN 250 MG TABLET	6
	BENZTROPINE 2 MG/2 ML AMPUL	0
	BENZTROPINE MES 0.5 MG TAB	57
	BENZTROPINE MES 1 MG TABLET	504
	BENZTROPINE MES 2 MG TABLET	346
	BISACODYL EC 5 MG TABLET	8
	BUPROPION SR 150 MG TABLET	205
	CARBAMAZEPINE 100 MG TAB CH	120
	CARBAMAZEPINE 200 MG TABLET	591
	CARBIDOPA-LEVODOPA 25-100 T	21
	CEPHALEXIN 250 MG CAPSULE	61
	CHLORASEPTIC SORE THROAT LO	36
	CHLORPROMAZINE 100 MG TABLE	151
	CHLORPROMAZINE 200 MG TABLE	460
	CHLORPROMAZINE 25 MG/ML AMP	175
	CHLORPROMAZINE 50 MG TABLET	119
	CIPRODEX OTIC SUSPENSION	7.5
	CITALOPRAM HBR 20 MG TABLET	61
	CLINDAMYCIN HCL 150 MG CAPS	30
	CLONAZEPAM 0.5 MG DIS TABLE	60

	CLONAZEPAM 0.5 MG TABLET	300
	CLONAZEPAM 1 MG TABLET	450
	CLONAZEPAM 2 MG ODT	30
	CLONAZEPAM 2 MG TABLET	60
	CLONIDINE HCL 0.1 MG TABLET	209
	CLOZAPINE 100 MG TABLET	79
	CLOZAPINE 200 MG TABLET	81
	CLOZAPINE 25 MG TABLET	60
	DEEP SEA 0.65% NOSE SPRAY	132
	DILTIAZEM ER 120 MG CAPSULE	61
	DIPHENHYDRAMINE 25 MG CAPSU	41
	DIPHENHYDRAMINE 50 MG CAPSU	175
	DIVALPROEX SOD DR 250 MG TA	325
	DIVALPROEX SOD DR 500 MG TA	262
	DOK 100 MG CAPSULE	378
	DONEPEZIL HCL 10 MG TABLET	60
	FISH OIL 1,000 MG SOFTGEL	62
	FLUCONAZOLE 50 MG TABLET	6
	FLUOXETINE 20 MG/5 ML SOLUT	300
	FLUOXETINE HCL 10 MG CAPSUL	24
	FLUOXETINE HCL 20 MG CAPSUL	30
	FLUPHENAZINE 5 MG TABLET	41
	FOLIC ACID 1 MG TABLET	7
	GABAPENTIN 300 MG CAPSULE	180
	GABAPENTIN 400 MG CAPSULE	1
	GEMFIBROZIL 600 MG TABLET	60
	GLIMEPIRIDE 2 MG TABLET	124
	GOLYTELY SOLUTION	4000
	GUAIFENESIN 100 MG/5 ML SYR	200
	HALOPERIDOL 10 MG TABLET	135
	HALOPERIDOL 5 MG TABLET	107
	HALOPERIDOL DEC 100 MG/ML V	20
	HALOPERIDOL LAC 2 MG/ML CON	480
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HYDROCHLOROTHIAZIDE 25 MG T	51
	IBUPROFEN 400 MG TABLET	2
	LACTULOSE 20 GM/30 ML SOLUT	900
	LANTUS 100 UNITS/ML VIAL	10
	LEVOTHYROXINE 100 MCG TABLE	341
	LEVOTHYROXINE 125 MCG TABLE	90
	LEVOTHYROXINE 25 MCG TABLET	266
	LEVOTHYROXINE 75 MCG TABLET	140
	LISINOPRIL 10 MG TABLET	37

	LISINOPRIL 20 MG TABLET	164
	LITHIUM CARBONATE ER 300 MG	72
	LITHIUM CITRATE 8 MEQ/5 ML	300
	LITHIUM ER 450 MG TABLET	195
	LORATADINE 10 MG TABLET	57
	LORAZEPAM 2 MG TABLET	60
	LORAZEPAM 2 MG/ML VIAL	50
	LOSARTAN POTASSIUM 50 MG TA	30
	LOVASTATIN 20 MG TABLET	30
	MAPAP 325 MG TABLET	100
	MEGESTROL ACET 40 MG/ML SUS	720
	MELOXICAM 7.5 MG TABLET	14
	METFORMIN HCL 500 MG TABLET	430
	METOCLOPRAMIDE 10 MG TABLET	72
	MILK OF MAGNESIA SUSPENSION	2400
	MINERAL OIL	0
	MONTELUKAST SOD 10 MG TABLE	32
	NICOTINE 21 MG/24HR PATCH	6
	NITROFURANTOIN MCR 50 MG CA	18
	NORVIR 100 MG TABLET	31
	NOVOLIN 70-30 100 UNIT/ML V	20
	NOVOLIN R 100 UNITS/ML VIAL	0
	NOVOLOG 100 UNIT/ML VIAL	10
	OFLOXACIN 0.3% EAR DROPS	10
	OLANZAPINE 10 MG TABLET	97
	OLANZAPINE 10 MG VIAL	0
	OLANZAPINE 5 MG TABLET	182
	OLANZAPINE ODT 10 MG TABLET	27
	OLANZAPINE ODT 5 MG TABLET	12
	OMEPRAZOLE DR 20 MG CAPSULE	417
	OXYBUTYNIN 5 MG TABLET	47
	OYSTER SHELL CALCIUM 500 MG	7
	OYSTER SHELL CALCIUM 500+D	121
	PAROXETINE HCL 20 MG TABLET	71
	PHENOBARBITAL 64.8 MG TABLE	40
	PHENYTOIN SOD EXT 100 MG CA	299
	PHILLIPS' COLON HEALTH CAPS	29
	POLYETHYLENE GLYCOL 3350 PO	288
	PREZISTA 800 MG TABLET	31
	PROMETHAZINE 25 MG TABLET	6
	PROPRANOLOL 20 MG TABLET	91
	QUETIAPINE FUMARATE 400 MG	118
	RANITIDINE 150 MG TABLET	429

	RISPERDAL CONSTA 50 MG SYR	2
	RISPERIDONE 2 MG TABLET	60
	SELENIUM SULFIDE 2.5% LOTIO	120
	SENNA-TIME S TABLET	60
	SIMVASTATIN 20 MG TABLET	110
	SIMVASTATIN 40 MG TABLET	64
	TAB-A-VITE TABLET	91
	TOPIRAMATE 100 MG TABLET	305
	TOPIRAMATE 25 MG TABLET	160
	TRAZODONE 100 MG TABLET	224
	TRAZODONE 50 MG TABLET	36
	TRUVADA 200 MG-300 MG TABLE	27
	VALPROIC ACID 250 MG/5 ML S	2838
	VENLAFAXINE HCL ER 150 MG C	22
	VITAMIN B-6 50 MG TABLET	53
571 Total		24802.5
581	AMLODIPINE BESYLATE 10 MG T	8
	ANALGESIC BALM	28
	ARTIFICIAL TEARS DROPS	30
	ASPIRIN EC 81 MG TABLET	60
	ATENOLOL 25 MG TABLET	57
	BENZOYL PEROXIDE 10% GEL	85
	BENZTROPINE MES 0.5 MG TAB	239
	BENZTROPINE MES 1 MG TABLET	759
	BENZTROPINE MES 2 MG TABLET	77
	BISACODYL EC 5 MG TABLET	116
	CARBAMAZEPINE 200 MG TABLET	420
	CHLORHEXIDINE 0.12% RINSE	946
	CHLORPROMAZINE 100 MG TABLE	178
	CHLORPROMAZINE 200 MG TABLE	41
	CITALOPRAM HBR 20 MG TABLET	109
	CLONAZEPAM 0.5 MG TABLET	30
	CLONAZEPAM 1 MG TABLET	300
	CLONAZEPAM 2 MG TABLET	146
	CLONIDINE HCL 0.1 MG TABLET	115
	CLOTRIMAZOLE 1% CREAM	45
	CLOZAPINE 100 MG TABLET	62
	CLOZAPINE 200 MG TABLET	121
	CLOZAPINE 25 MG TABLET	120
	DILTIAZEM ER 120 MG CAPSULE	58
	DIPHENHYDRAMINE 25 MG CAPSU	101
	DIPHENHYDRAMINE 50 MG CAPSU	31
	DIVALPROEX SOD DR 250 MG TA	230

	DIVALPROEX SOD DR 500 MG TA	1153
	DOK 100 MG CAPSULE	473
	FERROUS SULFATE 325 MG TABL	20
	FINASTERIDE 5 MG TABLET	30
	FISH OIL 1,000 MG SOFTGEL	176
	FLUPHENAZINE 10 MG TABLET	273
	FLUPHENAZINE 5 MG TABLET	87
	FLUPHENAZINE DEC 25 MG/ML V	10
	GABAPENTIN 300 MG CAPSULE	22
	GEMFIBROZIL 600 MG TABLET	133
	GLIMEPIRIDE 4 MG TABLET	2
	HALOPERIDOL 10 MG TABLET	596
	HALOPERIDOL 5 MG TABLET	1
	HALOPERIDOL DEC 100 MG/ML V	35
	HALOPERIDOL LAC 2 MG/ML CON	240
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HYDROCHLOROTHIAZIDE 12.5 MG	12
	HYDROCORTISONE 1% CREAM	56
	HYDROXYZINE PAM 25 MG CAP	34
	IBUPROFEN 400 MG TABLET	37
	LACTULOSE 20 GM/30 ML SOLUT	4200
	LAMOTRIGINE 100 MG TABLET	60
	LAMOTRIGINE 25 MG TABLET	187
	LANTUS 100 UNITS/ML VIAL	10
	LEVOTHYROXINE 100 MCG TABLE	116
	LEVOTHYROXINE 125 MCG TABLE	144
	LEVOTHYROXINE 25 MCG TABLET	59
	LEVOTHYROXINE 75 MCG TABLET	106
	LISINOPRIL 2.5 MG TABLET	30
	LISINOPRIL 20 MG TABLET	158
	LITHIUM CARBONATE 300 MG CA	149
	LITHIUM CARBONATE ER 300 MG	293
	LITHIUM ER 450 MG TABLET	294
	LORATADINE 10 MG TABLET	82
	LORAZEPAM 1 MG TABLET	30
	LORAZEPAM 2 MG TABLET	0
	LORAZEPAM 2 MG/ML VIAL	0
	MAG-AL PLUS SUSPENSION	900
	MAPAP 325 MG TABLET	100
	METFORMIN HCL 500 MG TABLET	378
	METOPROLOL TARTRATE 25 MG T	30
	MIRTAZAPINE 15 MG TABLET	30
	MONTELUKAST SOD 10 MG TABLE	118

	NAPROXEN 500 MG TABLET	82
	NEOMYCIN-POLYMYXIN-HC EAR S	20
	NIASPAN ER 500 MG TABLET	60
	NOVOLOG 100 UNIT/ML VIAL	10
	OLANZAPINE 10 MG TABLET	14
	OLANZAPINE 10 MG VIAL	4
	OLANZAPINE 20 MG TABLET	116
	OLANZAPINE 7.5 MG TABLET	14
	OLANZAPINE ODT 15 MG TABLET	60
	OMEPRAZOLE DR 20 MG CAPSULE	399
	OXCARBAZEPINE 150 MG TABLET	60
	OXCARBAZEPINE 300 MG TABLET	830
	OXYBUTYNIN 5 MG TABLET	90
	POLYETHYLENE GLYCOL 3350 PO	418
	PROPRANOLOL 10 MG TABLET	239
	PROPRANOLOL 20 MG TABLET	119
	QUETIAPINE FUMARATE 200 MG	105
	QUETIAPINE FUMARATE 300 MG	81
	QUETIAPINE FUMARATE 400 MG	207
	RANITIDINE 150 MG TABLET	302
	RISPERIDONE 1 MG TABLET	57
	RISPERIDONE 3 MG TABLET	60
	SENNA-TIME S TABLET	120
	SERTRALINE HCL 25 MG TABLET	27
	SERTRALINE HCL 50 MG TABLET	180
	SILVER SULFADIAZINE 1% CREA	50
	SIMVASTATIN 10 MG TABLET	1
	SIMVASTATIN 20 MG TABLET	72
	SIMVASTATIN 40 MG TABLET	58
	SULINDAC 150 MG TABLET	116
	TAB-A-VITE TABLET	71
	TAMSULOSIN HCL 0.4 MG CAPSU	1
	TERAZOSIN 1 MG CAPSULE	30
	TERAZOSIN 5 MG CAPSULE	60
	TRAZODONE 100 MG TABLET	60
	TRIHEXYPHENIDYL 2 MG TABLET	60
	TRIPLE ANTIBIOTIC OINTMENT	85.2
	VALPROIC ACID 250 MG/5 ML S	473
	VITAMIN D-2000 UNIT SOFTGEL	12
	VITAMIN D3 5,000 UNIT SOFTG	29
	WATER FOR INJECTION VIAL	120
581 Total		20348.2

MMHI Tablets dispensed in a typical month. MMHI has 2 units.

Sum of Quantity Dispensed		
Patient Unit	Drug Name	Total
3N	ACYCLOVIR 200 MG CAPSULE	10
	AMITRIPTYLINE HCL 50 MG TAB	4
	AMLODIPINE BESYLATE 10 MG T	8
	AMLODIPINE BESYLATE 5 MG TA	14
	AMOXICILLIN 250 MG CAPSULE	16
	ANTACID PLUS ANTI-GAS RELF	1065
	APLISOL 5T UNITS/0.1 ML VIA	5
	ASPIRIN EC 81 MG TABLET	7
	BENZTROPINE 2 MG/2 ML AMPUL	0
	BENZTROPINE MES 0.5 MG TAB	34
	BENZTROPINE MES 1 MG TABLET	164
	BENZTROPINE MES 2 MG TABLET	39
	BUPROPION HCL SR 150 MG TAB	28
	BUSPIRONE HCL 10 MG TABLET	28
	CARVEDILOL 3.125 MG TABLET	28
	CHLORDIAZEPOXIDE 25 MG CAPS	40
	CHLORPROMAZINE 200 MG TABLE	2
	CHLORPROMAZINE 25 MG/ML AMP	0
	CIPROFLOXACIN HCL 500 MG TA	4
	CITALOPRAM HBR 20 MG TABLET	67
	CLONAZEPAM 0.5 MG TABLET	96
	CLONAZEPAM 1 MG TABLET	4
	CLONIDINE 0.2 MG/DAY PATCH	1
	CLONIDINE HCL 0.1 MG TABLET	13
	DIPHENHYDRAMINE 25 MG CAPSU	42
	DIPHENHYDRAMINE 50 MG CAPSU	10
	DIPHENHYDRAMINE 50 MG/ML VI	0
	DIVALPROEX SOD DR 250 MG TA	82
	DIVALPROEX SOD DR 500 MG TA	139
	DIVALPROEX SOD ER 250 MG TA	36
	DIVALPROEX SOD ER 500 MG TA	70
	DOCUSATE SODIUM 100 MG CAPS	28
	DONEPEZIL HCL 10 MG TABLET	2
	DOXYCYCLINE HYCLATE 100 MG	8
	FLUOXETINE HCL 20 MG CAPSUL	29
	FLUPHENAZINE 10 MG TABLET	32
	FLUPHENAZINE 2.5 MG/ML VIAL	0
	FLUPHENAZINE 5 MG TABLET	9
	FOLIC ACID 1 MG TABLET	8

	GABAPENTIN 300 MG CAPSULE	84
	GABAPENTIN 600 MG TABLET	70
	GEODON 20 MG VIAL	0
	HALOPERIDOL 10 MG TABLET	113
	HALOPERIDOL 2 MG TABLET	130
	HALOPERIDOL 5 MG TABLET	94
	HALOPERIDOL DEC 100 MG/ML V	0
	HALOPERIDOL LAC 2 MG/ML CON	360
	HALOPERIDOL LAC 5 MG/ML VIA	25
	HYDROCHLOROTHIAZIDE 25 MG T	14
	HYDROCODON-ACETAMIN 5-325MG	41
	HYDROXYZINE PAM 25 MG CAP	12
	IBUPROFEN 200 MG TABLET	500
	ISENTRESS 400 MG TABLET	2
	LABETALOL HCL 200 MG TABLET	28
	LANTUS 100 UNITS/ML VIAL	10
	LEVETIRACETAM 500 MG TABLET	4
	LEVOFLOXACIN 250 MG TABLET	4
	LISINOPRIL 10 MG TABLET	10
	LISINOPRIL 20 MG TABLET	18
	LISINOPRIL 5 MG TABLET	31
	LITHIUM CARBONATE 300 MG CA	82
	LITHIUM CITRATE 8 MEQ/5 ML	0
	LOPERAMIDE 2 MG CAPSULE	2
	LORATADINE 10 MG TABLET	4
	LORAZEPAM 1 MG TABLET	130
	LORAZEPAM 2 MG/ML VIAL	25
	MAPAP 325 MG TABLET	600
	MELOXICAM 7.5 MG TABLET	8
	METAMUCIL POWDER	660
	METFORMIN HCL 500 MG TABLET	104
	MILK OF MAGNESIA SUSPENSION	1419
	MIRTAZAPINE 15 MG TABLET	47
	MIRTAZAPINE 30 MG TABLET	29
	MULTIVITAMIN	11
	MULTIVITAMINS CAPLET	15
	NICOTINE 14 MG/24HR PATCH	5
	NICOTINE 21 MG/24HR PATCH	9
	NICOTINE 7 MG/24HR PATCH	5
	NORVIR 100 MG TABLET	2
	NOVOLIN 70-30 100 UNIT/ML V	10
	NOVOLIN R 100 UNITS/ML VIAL	40

	OLANZAPINE 10 MG TABLET	30
	OLANZAPINE 10 MG VIAL	24
	OLANZAPINE 5 MG TABLET	28
	OLANZAPINE ODT 20 MG TABLET	23
	OMEPRAZOLE DR 20 MG CAPSULE	16
	OXCARBAZEPINE 600 MG TABLET	62
	PAROXETINE HCL 20 MG TABLET	0
	PHENYTOIN SOD EXT 100 MG CA	0
	PREZISTA 800 MG TABLET	2
	PROMETHAZINE 25 MG TABLET	5
	PROMETHAZINE 25 MG/ML AMPUL	0
	PROPRANOLOL 20 MG TABLET	93
	Q-TUSSIN 100 MG/5 ML SOLUT	118
	QUETIAPINE FUMARATE 100 MG	1
	QUETIAPINE FUMARATE 200 MG	32
	QUETIAPINE FUMARATE 300 MG	14
	RANITIDINE 150 MG TABLET	7
	RISPERIDONE 0.5 MG TABLET	6
	RISPERIDONE 1 MG TABLET	91
	RISPERIDONE 2 MG TABLET	30
	RISPERIDONE 3 MG TABLET	0
	RISPERIDONE 4 MG TABLET	45
	SERTRALINE HCL 100 MG TABLE	58
	SERTRALINE HCL 50 MG TABLET	44
	STRIBILD TABLET	0
	SULFAMETHOXAZOLE-TMP DS TAB	4
	THIAMINE 100 MG/ML VIAL	0
	TOPIRAMATE 25 MG TABLET	56
	TRAMADOL HCL 50 MG TABLET	0
	TRAZODONE 100 MG TABLET	101
	TRAZODONE 50 MG TABLET	97
	TRIPLE ANTIBIOTIC OINTMENT	144
	VALPROIC ACID 250 MG/5 ML S	1000
	VENLAFAXINE HCL ER 150 MG C	70
	VENLAFAXINE HCL ER 37.5 MG	2
	VENLAFAXINE HCL ER 75 MG CA	14
	VENTOLIN HFA 90 MCG INHALER	54
	VITAMIN B-1 100 MG TABLET	4
	WATER FOR INJECTION VIAL	240
	XARELTO 20 MG TABLET	14
	ZIPRASIDONE HCL 80 MG CAPSU	1
	ZOLPIDEM TARTRATE 10 MG TAB	29
3N Total		9488

3S	ABILIFY 10 MG TABLET	14
	ACYCLOVIR 200 MG CAPSULE	52
	AMLODIPINE BESYLATE 10 MG T	12
	AMLODIPINE BESYLATE 5 MG TA	56
	ANTACID PLUS ANTI-GAS RELF	3550
	APLISOL 5T UNITS/0.1 ML VIA	6
	ASPIRIN 325 MG TABLET	0
	ASPIRIN EC 81 MG TABLET	4
	AZITHROMYCIN 250 MG TABLET	8
	BENZTROPINE 2 MG/2 ML AMPUL	0
	BENZTROPINE MES 0.5 MG TAB	14
	BENZTROPINE MES 1 MG TABLET	114
	BENZTROPINE MES 2 MG TABLET	636
	BICILLIN LA 1,200,000 UNITS	4
	BUPROPION HCL SR 150 MG TAB	56
	BUSPIRONE HCL 5 MG TABLET	42
	CARVEDILOL 3.125 MG TABLET	4
	CHLORDIAZEPOXIDE 25 MG CAPS	117
	CHLORPROMAZINE 100 MG TABLE	35
	CHLORPROMAZINE 25 MG/ML AMP	0
	CHLORPROMAZINE 50 MG TABLET	17
	CITALOPRAM HBR 20 MG TABLET	220
	CLONAZEPAM 0.5 MG TABLET	20
	CLONAZEPAM 1 MG TABLET	30
	CLONIDINE HCL 0.1 MG TABLET	2
	CLOTRIMAZOLE 1% CREAM	28.35
	CYCLOBENZAPRINE 10 MG TABLE	6
	DIPHENHYDRAMINE 25 MG CAPSU	10
	DIPHENHYDRAMINE 50 MG CAPSU	36
	DIPHENHYDRAMINE 50 MG/ML VI	0
	DIPHENOXYLATE-ATROP 2.5-0.0	10
	DIVALPROEX SOD DR 250 MG TA	5
	DIVALPROEX SOD DR 500 MG TA	196
	DIVALPROEX SOD ER 500 MG TA	33
	DONEPEZIL HCL 10 MG TABLET	32
	DONEPEZIL HCL 5 MG TABLET	15
	FERROUS SULFATE 325 MG TABL	1
	FLUCONAZOLE 150 MG TABLET	1
	FLUOXETINE HCL 20 MG CAPSUL	191
	FLUPHENAZINE 2.5 MG/ML VIAL	0
	FLUPHENAZINE 5 MG TABLET	15
	FLUPHENAZINE DEC 25 MG/ML V	0
	FLUTICASONE PROP 50 MCG SPR	32

	FOLIC ACID 1 MG TABLET	17
	GABAPENTIN 300 MG CAPSULE	1
	GABAPENTIN 400 MG CAPSULE	4
	GOLYTELY SOLUTION	4000
	HALOPERIDOL 10 MG TABLET	254
	HALOPERIDOL 2 MG TABLET	47
	HALOPERIDOL 20 MG TABLET	2
	HALOPERIDOL 5 MG TABLET	207
	HALOPERIDOL DEC 100 MG/ML V	30
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HYDROCHLOROTHIAZIDE 25 MG T	14
	HYDROCODON-ACETAMIN 5-325MG	60
	HYDROCORTISONE 1% CREAM	28
	HYDROXYZINE PAM 25 MG CAP	58
	HYDROXYZINE PAM 50 MG CAP	151
	IBUPROFEN 200 MG TABLET	0
	INDOMETHACIN 25 MG CAPSULE	4
	JANTOVEN 2.5 MG TABLET	3
	KETOCONAZOLE 2% SHAMPOO	120
	LAMOTRIGINE 25 MG TABLET	28
	LANTUS 100 UNITS/ML VIAL	10
	LEVETIRACETAM 500 MG TABLET	8
	LEVOTHYROXINE 100 MCG TABLE	6
	LEVOTHYROXINE 25 MCG TABLET	2
	LISINOPRIL 10 MG TABLET	38
	LISINOPRIL 20 MG TABLET	14
	LITHIUM CARBONATE 300 MG CA	46
	LITHIUM CARBONATE ER 300 MG	56
	LITHIUM ER 450 MG TABLET	38
	LORATADINE 10 MG TABLET	4
	LORAZEPAM 0.5 MG TABLET	30
	LORAZEPAM 1 MG TABLET	24
	LORAZEPAM 2 MG/ML VIAL	25
	MAGNESIUM CITRATE	296
	MAPAP 325 MG TABLET	300
	MELOXICAM 7.5 MG TABLET	8
	METFORMIN HCL 500 MG TABLET	148
	METHYLPREDNISOLONE 4 MG DOS	42
	METOPROLOL TARTRATE 25 MG T	4
	METRONIDAZOLE 500 MG TABLET	2
	MILK OF MAGNESIA SUSPENSION	1419
	MIRTAZAPINE 15 MG TABLET	45

	MIRTAZAPINE 30 MG TABLET	1
	MULTIVITAMIN	15
	MULTIVITAMINS CAPLET	36
	MUPIROCIN 2% OINTMENT	44
	NAPROXEN 500 MG TABLET	21
	NEOMYCIN-POLY-HC EYE DROPS	7.5
	NICOTINE 14 MG/24HR PATCH	1
	NICOTINE 21 MG/24HR PATCH	17
	NIFEDIPINE ER 30 MG TABLET	4
	NOVOLIN R 100 UNITS/ML VIAL	30
	OLANZAPINE 10 MG TABLET	8
	OLANZAPINE 10 MG VIAL	6
	OLANZAPINE 20 MG TABLET	15
	OMEPRAZOLE DR 20 MG CAPSULE	28
	OXYCODONE-ACETAMINOPHEN 5-3	30
	PANTOPRAZOLE SOD DR 40 MG T	22
	PAROXETINE HCL 20 MG TABLET	1
	PHENYTOIN SOD EXT 100 MG CA	4
	PRAVASTATIN SODIUM 20 MG TA	8
	PRAZOSIN 1 MG CAPSULE	28
	PRENATAL TABLET	59
	PROMETHAZINE 25 MG TABLET	0
	PROMETHAZINE 25 MG/ML AMPUL	0
	QUETIAPINE FUMARATE 100 MG	10
	QUETIAPINE FUMARATE 200 MG	131
	QUETIAPINE FUMARATE 25 MG T	9
	QUETIAPINE FUMARATE 300 MG	72
	RANITIDINE 150 MG TABLET	6
	RISPERIDONE 0.5 MG TABLET	1
	RISPERIDONE 1 MG TABLET	32
	RISPERIDONE 2 MG TABLET	65
	RISPERIDONE 3 MG TABLET	28
	SELENIUM SULFIDE 2.5% LOTIO	120
	SERTRALINE HCL 100 MG TABLE	28
	SERTRALINE HCL 50 MG TABLET	94
	TENIVAC VIAL	0.5
	THIAMINE 100 MG/ML VIAL	50
	TOPIRAMATE 100 MG TABLET	16
	TOPIRAMATE 25 MG TABLET	24
	TRAZODONE 100 MG TABLET	101
	TRAZODONE 50 MG TABLET	86
	TRIHEXYPHENIDYL 5 MG TABLET	18
	TRIPLE ANTIBIOTIC OINTMENT	0

	VALPROIC ACID 250 MG CAPSUL	4
	VALPROIC ACID 250 MG/5 ML S	1000
	VENTOLIN HFA 90 MCG INHALER	36
	VITAMIN B-1 100 MG TABLET	18
	WARFARIN SODIUM 5 MG TABLET	4
	WATER FOR INJECTION VIAL	60
	ZITHROMAX 500 MG TABLET	0
	ZOLPIDEM TARTRATE 10 MG TAB	0
3S Total		15616.35

MBMHI Tablets dispensed in a typical month. MBMHI has 6 units.

Sum of Quantity Dispensed		
Patient Unit	Drug Name	Total
11	ABILIFY 10 MG TABLET	15
	ABILIFY 5 MG TABLET	16
	ACETAMINOPH (MAPAP) 325 MG	400
	ADVAIR 250-50 DISKUS	14
	ALLOPURINOL 100 MG TABLET	16
	AMANTADINE 100 MG CAPSULE	9
	AMITRIPTYLINE HCL 100 MG TA	24
	AMITRIPTYLINE HCL 25 MG TAB	4
	AMITRIPTYLINE HCL 50 MG TAB	1
	AMLODIPINE BESYLATE 5 MG TA	13
	AMOXICILLIN 500 MG CAPSULE	21
	ANALGESIC BALM	112
	APLISOL 5T UNITS/0.1 ML VIA	1
	ATENOLOL 25 MG TABLET	1
	BENZTROPINE MES 0.5 MG TAB	39
	BENZTROPINE MES 1 MG TABLET	40
	BENZTROPINE MES 2 MG TABLET	133
	BETASEPT 4% SURGICAL SCRUB	236
	BUPROPION HCL SR 100 MG TAB	15
	BUSPIRONE HCL 10 MG TABLET	84
	BUSPIRONE HCL 5 MG TABLET	118
	CARBAMAZEPINE 100 MG TAB CH	1
	CARBAMAZEPINE 200 MG TABLET	107
	CARVEDILOL 6.25 MG TABLET	34
	CHLORPHENIRAMINE 4 MG TAB	30
	CHLORPROMAZINE 100 MG TABLE	19
	CHLORPROMAZINE 200 MG TABLE	13
	CHLORPROMAZINE 50 MG TABLET	2
	CITALOPRAM HBR 20 MG TABLET	30
	CLONAZEPAM 1 MG TABLET	10
	CLONIDINE HCL 0.1 MG TABLET	9
	CLONIDINE HCL 0.2 MG TABLET	1
	CLOTRIMAZOLE 1% CREAM	30
	CLOZAPINE 100 MG TABLET	1
	CLOZAPINE 200 MG TABLET	94
	CLOZAPINE 50 MG TABLET	19
	COUMADIN 2.5 MG TABLET	13
	COUMADIN 3 MG TABLET	17
	COUMADIN 5 MG TABLET	23

	CYCLOBENZAPRINE 10 MG TABLE	3
	CYPROHEPTADINE 4 MG TABLET	10
	DEPAKOTE DR 500 MG TABLET	115
	DILANTIN 50 MG INFATAB	3
	DIPHENHYDRAMINE 12.5 MG/5 M	600
	DIPHENHYDRAMINE 25 MG CAPSU	30
	DIPHENHYDRAMINE 50 MG CAPSU	497
	DIPHENHYDRAMINE 50 MG/ML VI	51
	DIVALPROEX SOD DR 250 MG TA	1
	DIVALPROEX SOD DR 500 MG TA	487
	DIVALPROEX SOD ER 500 MG TA	56
	DIVALPROEX SOD. SPRK 125 MG	275
	DOCUSATE SOD UD 100 MG CAPS	21
	DONEPEZIL HCL 10 MG TABLET	20
	DOXYCYCLINE HYCLATE 100 MG	1
	FERROUS SULF EC 324 MG TABL	33
	FLUOXETINE HCL 20 MG CAPSUL	45
	FLUOXETINE HCL 40 MG CAPSUL	14
	FLUPHENAZINE 10 MG TABLET	15
	FLUPHENAZINE 5 MG TABLET	74
	FLUPHENAZINE DEC 25 MG/ML V	30
	FLUVOXAMINE MALEATE 100 MG	1
	FLUVOXAMINE MALEATE 50 MG T	3
	FUROSEMIDE 40 MG TABLET	30
	GABAPENTIN 300 MG CAPSULE	103
	GABAPENTIN 400 MG CAPSULE	3
	GABAPENTIN 600 MG TABLET	363
	GABAPENTIN 800 MG TABLET	87
	GEMFIBROZIL 600 MG TABLET	103
	GEODON 20 MG VIAL	6
	GLIMEPIRIDE 1 MG TABLET	45
	GLIMEPIRIDE 4 MG TABLET	1
	HALDOL 5 MG/ML AMPUL	30
	HALOPERIDOL 1 MG TABLET	2
	HALOPERIDOL 10 MG TABLET	210
	HALOPERIDOL 20 MG TABLET	36
	HALOPERIDOL 5 MG TABLET	229
	HUMULIN 70-30 VIAL	10
	HUMULIN R 100 UNITS/ML VIAL	10
	HURRICAINE 20% GEL	120
	HYDROCHLOROTHIAZIDE 12.5 MG	11
	HYDROCHLOROTHIAZIDE 25 MG T	15
	HYDROCODON-ACETAMINOPHEN 5-	1

	HYDROXYZINE PAM 50 MG CAP	1
	IBUPROFEN 400 MG TABLET	200
	IMIQUIMOD 5% CREAM PACKET	10
	KLOR-CON M20 TABLET	28
	LAMOTRIGINE 100 MG TABLET	109
	LAMOTRIGINE 25 MG TABLET	3
	LAMOTRIGINE 25 MG UD TAB	1
	LANTUS 100 UNITS/ML VIAL	10
	LEVETIRACETAM 500 MG TABLET	2
	LISINOPRIL 10 MG TABLET	2
	LISINOPRIL 20 MG TABLET	18
	LISINOPRIL 5 MG TABLET	68
	LITHIUM CARB 300 MG CAP	15
	LITHIUM CARB 600 MG CAP	14
	LOPERAMIDE 2 MG CAPSULE	30
	LORAZEPAM 1 MG TABLET	70
	LORAZEPAM 2 MG/ML VIAL	25
	LOVASTATIN 20 MG TABLET	2
	LOXAPINE 10 MG CAPSULE	0
	MAG-AL PLUS SUSPENSION	2400
	MELOXICAM 7.5 MG TABLET	2
	METAMUCIL PACKET S-F	39
	METFORMIN HCL 1000 MG TABL	33
	METFORMIN HCL 500 MG TABLET	101
	METOPROLOL TARTRATE 25 MG T	1
	METRONIDAZOLE 250 MG TABLET	1
	MINERIN CREME	454
	MIRTAZAPINE 15 MG TABLET	2
	MIRTAZAPINE 30 MG TABLET	32
	MULTIVITAMIN TABLET (THERA)	16
	NAPROXEN 375 MG TABLET	0
	NAPROXEN 500 MG TABLET	11
	NEOSPORIN OINTMENT UD	50
	NICOTINE 14 MG/24HR PATCH	7
	NICOTINE 21 MG/24HR PATCH	65
	OLANZAPINE 20 MG TABLET	1
	OMEPRAZOLE DR 20 MG CAPSULE	20
	OXCARBAZEPINE 300 MG TABLET	56
	OXCARBAZEPINE 600 MG TABLET	29
	PERPHENAZINE 8 MG TABLET	10
	PETROLATUM FOILPAC JELLY	150
	PHENYTOIN 125 MG/5 ML SUSP	237
	PHENYTOIN SOD EXT 100 MG CA	16

	POLYETHYLENE GLYCOL 3350 PO	255
	PRAVASTATIN SODIUM 20 MG TA	1
	PRAZOSIN 1 MG CAPSULE	50
	PROPRANOLOL 40 MG TABLET	14
	QUETIAPINE FUMARATE 100 MG	1
	QUETIAPINE FUMARATE 200 MG	14
	QUETIAPINE FUMARATE 25 MG T	95
	QUETIAPINE FUMARATE 300 MG	42
	QUETIAPINE FUMARATE 50 MG T	53
	RANITIDINE 150 MG TABLET	20
	RISPERIDONE 2 MG TABLET	1
	SERTRALINE HCL 100 MG TABLE	42
	SERTRALINE HCL 50 MG TABLET	59
	SORE THROAT LOZENGE	54
	SPIRIVA 18 MCG CP-HANDIHALE	30
	STRIBILD TABLET	12
	SUDOGEST 30 MG TABLET	20
	SULFAMETHOXAZOLE-TMP DS TAB	2
	TAMOXIFEN 10 MG TABLET	1
	TAMSULOSIN HCL 0.4 MG CAPSU	1
	TOPIRAMATE 100 MG TABLET	1
	TRAMADOL HCL 50 MG TABLET	3
	TRAZODONE 100 MG TABLET	63
	TRAZODONE 150 MG TABLET	31
	TRAZODONE 50 MG TABLET	4
	TRIAMCINOLONE 0.5% CREAM	15
	VENLAFAXINE HCL 75 MG TABLE	1
	VENLAFAXINE HCL ER 75 MG CA	85
	VENTOLIN HFA 90 MCG INHALER	64
	VERAPAMIL 80 MG TABLET	30
	WATER FOR INJECTION VIAL	60
	ZIPRASIDONE HCL 20 MG CAPSU	1
	ZIPRASIDONE HCL 40 MG CAPSU	32
	ZIPRASIDONE HCL 60 MG CAPSU	65
11 Total		11668
21	ACETAMINOPH (MAPAP) 325 MG	300
	ALBUTEROL 0.083% INHAL SOLN	30
	AMANTADINE 100 MG CAPSULE	43
	AMIODARONE HCL 200 MG TABLE	8
	AMLODIPINE BESYLATE 10 MG T	30
	ANALGESIC BALM	56
	APLISOL 5T UNITS/0.1 ML VIA	2
	ASPIRIN 81 MG CHEWABLE TABL	14

	ASPIRIN EC 325 MG TABLET	53
	ASPIRIN EC 81 MG TABLET	10
	ATENOLOL 50 MG TABLET	18
	BACITRACIN 500 UNIT/GM OINT	14
	BACLOFEN 10 MG TABLET	10
	BENZTROPINE MES 0.5 MG TAB	2
	BENZTROPINE MES 1 MG TABLET	85
	BENZTROPINE MES 2 MG TABLET	200
	BUPROPION HCL XL 150 MG TAB	29
	BUSPIRONE HCL 10 MG TABLET	1
	CARBAMAZEPINE 200 MG TABLET	465
	CARBIDOPA-LEVODOPA 25-100 T	23
	CARVEDILOL 6.25 MG TABLET	23
	CHLORPHENIRAMINE 4 MG TAB	20
	CHLORPROMAZINE 100 MG TABLE	29
	CHLORPROMAZINE 200 MG TABLE	113
	CHLORPROMAZINE 25 MG TABLET	2
	CITALOPRAM HBR 10 MG TABLET	14
	CITALOPRAM HBR 20 MG TABLET	14
	CLONAZEPAM 0.5 MG TABLET	7
	CLONAZEPAM 1 MG TABLET	6
	CLONIDINE HCL 0.1 MG TABLET	62
	CLONIDINE HCL 0.2 MG TABLET	1
	CLOZAPINE 100 MG TABLET	88
	CLOZAPINE 200 MG TABLET	5
	CLOZAPINE 25 MG TABLET	8
	CLOZAPINE 50 MG TABLET	7
	COMBIVENT RESPIMAT INHAL SP	12
	COUMADIN 2.5 MG TABLET	4
	COUMADIN 3 MG TABLET	0
	COUMADIN 5 MG TABLET	10
	CYANOCOBALAMIN 1,000 MCG/ML	1
	DEPAKOTE DR 250 MG TABLET	1
	DEPAKOTE DR 500 MG TABLET	48
	DIPHENHYDRAMINE 12.5 MG/5 M	900
	DIPHENHYDRAMINE 50 MG CAPSU	485
	DIPHENHYDRAMINE 50 MG/ML VI	100
	DIVALPROEX SOD DR 250 MG TA	1
	DIVALPROEX SOD DR 500 MG TA	651
	DOCUSATE SOD UD 100 MG CAPS	18
	DORZOLAMIDE-TIMOLOL EYE DRO	10
	DOXAZOSIN MESYLATE 2 MG TAB	13
	FENOFIBRATE 160 MG TABLET	3

	FERROUS SULF EC 324 MG TABL	7
	FIXODENT	126
	FLOVENT HFA 110 MCG INHALER	12
	FLUOXETINE HCL 20 MG CAPSUL	3
	FLUPHENAZINE 10 MG TABLET	277
	FLUPHENAZINE 2.5 MG/ML VIAL	90
	FLUPHENAZINE 5 MG TABLET	136
	FLUPHENAZINE DEC 25 MG/ML V	35
	FOLIC ACID 1 MG TABLET	8
	FUROSEMIDE 20 MG TABLET	31
	GABAPENTIN 300 MG CAPSULE	101
	GABAPENTIN 400 MG CAPSULE	11
	GABAPENTIN 600 MG TABLET	257
	GABAPENTIN 800 MG TABLET	31
	GEODON 20 MG VIAL	28
	GUAIFENESIN 100 MG/5 ML SYR	500
	HALDOL 5 MG/ML AMPUL	50
	HALOPERIDOL 10 MG TABLET	168
	HALOPERIDOL 20 MG TABLET	26
	HALOPERIDOL 5 MG TABLET	102
	HALOPERIDOL DEC 100 MG/ML V	30
	HUMULIN R 100 UNITS/ML VIAL	20
	HYDRALAZINE 10 MG TABLET	10
	HYDRALAZINE 25 MG TABLET	19
	HYDROCHLOROTHIAZIDE 12.5 MG	28
	HYDROCHLOROTHIAZIDE 25 MG T	14
	HYDROCODON-ACETAMINOPHEN 5-	13
	HYDROCODON-ACETAMINOPHN 10-	91
	HYDROXYZINE HCL 25 MG TABLE	94
	HYDROXYZINE PAM 100 MG CAP	1
	HYDROXYZINE PAM 25 MG CAP	12
	HYDROXYZINE PAM 50 MG CAP	30
	IBUPROFEN 200 MG TABLET	143
	IBUPROFEN 400 MG TABLET	201
	IBUPROFEN 600 MG TABLET	100
	IBUPROFEN 800 MG TABLET	21
	IPRAT-ALBUT 0.5-3(2.5) MG/3	15
	ISOPROPYL ALCOHOL 70%	1419
	KETOCONAZOLE 200 MG TABLET	1
	LAMOTRIGINE 100 MG TABLET	0
	LAMOTRIGINE 200 MG TABLET	2
	LAMOTRIGINE 25 MG UD TAB	2
	LEVEMIR 100 UNITS/ML VIAL	10

	LEVETIRACETAM 500 MG TABLET	145
	LISINOPRIL 10 MG TABLET	14
	LISINOPRIL 2.5 MG TABLET	15
	LISINOPRIL 5 MG TABLET	13
	LITHIUM CARB 300 MG CAP	31
	LITHIUM CARB 600 MG CAP	32
	LOPERAMIDE 2 MG CAPSULE	20
	LORAZEPAM 0.5 MG TABLET	20
	LORAZEPAM 1 MG TABLET	40
	LORAZEPAM 2 MG TABLET	51
	LORAZEPAM 2 MG/ML VIAL	50
	LOSARTAN POTASSIUM 50 MG TA	31
	LOVASTATIN 20 MG TABLET	21
	MAG-AL PLUS SUSPENSION	2100
	MELOXICAM 7.5 MG TABLET	20
	METFORMIN HCL 1000 MG TABL	5
	METFORMIN HCL 500 MG TABLET	58
	METOPROLOL TARTRATE 25 MG T	35
	MICROSPACER AEROSOL DEVICE	1
	MILK OF MAGNESIA SUSPENSION	900
	MIRTAZAPINE 15 MG TABLET	24
	MIRTAZAPINE 30 MG TABLET	20
	MULTIVITAMIN TABLET (THERA)	22
	NAPROXEN 500 MG TABLET	23
	NEOSPORIN OINTMENT UD	50
	NICOTINE 14 MG/24HR PATCH	22
	NICOTINE 21 MG/24HR PATCH	13
	NICOTINE 7 MG/24HR PATCH	10
	NITROFURANTOIN MCR 100 MG	1
	NITROSTAT 0.4 MG TABLET SL	25
	OLANZAPINE 10 MG VIAL	4
	OXCARBAZEPINE 300 MG TABLET	1
	OXCARBAZEPINE 600 MG TABLET	30
	OXYBUTYNIN 5 MG TABLET	18
	OXYCODON-APAP 7.5-325 MG	12
	PANTOPRAZOLE 20 MG TAB	8
	PHENOBARBITAL 32.4 MG TABLE	5
	PHENYTOIN SOD EXT 100 MG CA	147
	PRAVASTATIN SODIUM 20 MG TA	19
	PROMETHAZINE 25 MG TABLET	0
	PROPRANOLOL 20 MG TABLET	47
	PROPRANOLOL 40 MG TABLET	55
	QUETIAPINE FUMARATE 100 MG	15

	QUETIAPINE FUMARATE 25 MG T	46
	QUETIAPINE FUMARATE 400 MG	3
	QUETIAPINE FUMARATE 50 MG T	59
	QVAR 40 MCG INHALER	8.7
	QVAR 80 MCG INHALER	8.7
	RANITIDINE 150 MG TABLET	49
	RANITIDINE 300 MG TABLET	9
	RISPERIDONE 1 MG TABLET	31
	SERTRALINE HCL 100 MG TABLE	15
	SERTRALINE HCL 25 MG TABLET	15
	SERTRALINE HCL 50 MG TABLET	46
	SIMVASTATIN 20 MG TABLET	32
	SORE THROAT LOZENGE	54
	SPIRONOLACTONE 25 MG TABLET	57
	SPIRONOLACTONE 50 MG TABLET	30
	SYNTHROID 112 MCG TABLET	14
	SYNTHROID 25 MCG TABLET	13
	SYNTHROID 75 MCG TABLET	10
	TAMSULOSIN HCL 0.4 MG CAPSU	9
	THERA-DERM LOTION	944
	THIAMINE 200 MG/2 ML VIAL	50
	TOPIRAMATE 100 MG TABLET	28
	TRAZODONE 100 MG TABLET	7
	TRAZODONE 50 MG TABLET	3
	TRIFLUOPERAZINE 5 MG TABLET	1
	VAGISIL CREAM	28
	VALPROIC ACID 250 MG CAPSUL	1
	VALPROIC ACID 500 MG/10 ML	500
	VENTOLIN HFA 90 MCG INHALER	56
	VIMPAT 50 MG TABLET	13
	VITAMIN B-1 100 MG TABLET	30
	WATER FOR INJECTION VIAL	200
	ZIPRASIDONE HCL 20 MG CAPSU	5
	ZIPRASIDONE HCL 40 MG CAPSU	9
21 Total		14881.4
31	ABILIFY 10 MG TABLET	1
	ABILIFY 5 MG TABLET	1
	ACETAMINOPH (MAPAP) 325 MG	300
	ADVAIR 250-50 DISKUS	14
	AMANTADINE 100 MG CAPSULE	75
	AMLODIPINE BESYLATE 5 MG TA	1
	AMOXICILLIN 500 MG CAPSULE	3
	ANALGESIC BALM	84

	ARTIFICIAL TEARS DROPS	15
	ASPIRIN EC 81 MG TABLET	9
	ATORVASTATIN 20 MG TABLET	4
	ATORVASTATIN 40 MG TABLET	2
	BACITRACIN 500 UNIT/GM OINT	42
	BENZOYL PER. 5% WASH	148
	BENZTROPINE MES 1 MG TABLET	197
	BENZTROPINE MES 2 MG TABLET	89
	BETASEPT 4% SURGICAL SCRUB	236
	BRIMONIDINE 0.2% EYE DROP	5
	BUPROPION HCL XL 300 MG TAB	15
	BUSPIRONE HCL 10 MG TABLET	28
	BUSPIRONE HCL 5 MG TABLET	2
	CARBAMAZEPINE 200 MG TABLET	302
	CARBIDOPA-LEVODOPA 25-100 T	5
	CHLORHEXIDINE 0.12% RINSE	473
	CHLORPHENIRAMINE 4 MG TAB	20
	CHLORPROMAZINE 100 MG TABLE	135
	CHLORPROMAZINE 200 MG TABLE	1
	CHLORPROMAZINE 25 MG TABLET	4
	CHLORPROMAZINE 50 MG TABLET	3
	CITALOPRAM HBR 10 MG TABLET	15
	CITALOPRAM HBR 20 MG TABLET	42
	CLINDAMYCIN HCL 150 MG CAPS	2
	CLONIDINE HCL 0.1 MG TABLET	6
	CLONIDINE HCL 0.2 MG TABLET	1
	CLOZAPINE 100 MG TABLET	4
	CLOZAPINE 200 MG TABLET	5
	CLOZAPINE 50 MG TABLET	2
	COMBIVENT RESPIMAT INHAL SP	8
	COUMADIN 1 MG TABLET	13
	COUMADIN 3 MG TABLET	0
	COUMADIN 5 MG TABLET	15
	DEEP SEA 0.65% NOSE SPRAY	44
	DEPAKOTE DR 500 MG TABLET	114
	DIPHENHYDRAMINE 12.5 MG/5 M	1000
	DIPHENHYDRAMINE 25 MG CAPSU	7
	DIPHENHYDRAMINE 50 MG CAPSU	275
	DIPHENHYDRAMINE 50 MG/ML VI	50
	DIVALPROEX SOD DR 250 MG TA	5
	DIVALPROEX SOD DR 500 MG TA	442
	DONEPEZIL HCL 10 MG TABLET	28
	DONEPEZIL HCL 5 MG TABLET	8

	DOXAZOSIN MESYLATE 2 MG TAB	6
	EFFERDENT DENTURE CLEANSER	10
	ESTRADIOL 1 MG TABLET	1
	FIXODENT	21
	FLUOXETINE HCL 10 MG CAPSUL	42
	FLUOXETINE HCL 20 MG CAPSUL	14
	FLUOXETINE HCL 40 MG CAPSUL	14
	FLUPHENAZINE 10 MG TABLET	74
	FLUPHENAZINE 2.5 MG/ML VIAL	180
	FLUPHENAZINE 5 MG TABLET	94
	FLUPHENAZINE DEC 25 MG/ML V	20
	FUROSEMIDE 20 MG TABLET	2
	FUROSEMIDE 40 MG TABLET	3
	GABAPENTIN 300 MG CAPSULE	31
	GABAPENTIN 400 MG CAPSULE	148
	GABAPENTIN 600 MG TABLET	169
	GABAPENTIN 800 MG TABLET	84
	GEODON 20 MG VIAL	10
	GUAIFENESIN 100 MG/5 ML SYR	200
	HALDOL 5 MG/ML AMPUL	20
	HALOPERIDOL 1 MG TABLET	2
	HALOPERIDOL 10 MG TABLET	124
	HALOPERIDOL 5 MG TABLET	146
	HALOPERIDOL DEC 100 MG/ML V	15
	HUMULIN 70-30 VIAL	20
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCODON-ACETAMINOPHEN 5-	10
	HYDROXYZINE PAM 50 MG CAP	4
	IBUPROFEN 400 MG TABLET	200
	KETOCONAZOLE 2% SHAMPOO	120
	LAMOTRIGINE 100 MG TABLET	29
	LAMOTRIGINE 25 MG UD TAB	56
	LEVETIRACETAM 500 MG TABLET	22
	LISINOPRIL 10 MG TABLET	18
	LISINOPRIL 2.5 MG TABLET	8
	LISINOPRIL 20 MG TABLET	15
	LISINOPRIL 40 MG TABLET	26
	LITHIUM CARB 600 MG CAP	30
	LORAZEPAM 1 MG TABLET	30
	LORAZEPAM 2 MG TABLET	20
	LORAZEPAM 2 MG/ML VIAL	50
	LOVASTATIN 20 MG TABLET	35
	MAG-AL PLUS SUSPENSION	2100

	METFORMIN HCL 1000 MG TABL	30
	METFORMIN HCL 500 MG TABLET	7
	METHADONE HCL 10 MG TABLET	4
	METOPROLOL TARTRATE 25 MG T	56
	MILK OF MAGNESIA SUSPENSION	900
	MIRTAZAPINE 15 MG TABLET	57
	MIRTAZAPINE 30 MG TABLET	58
	MULTIVITAMIN TABLET (THERA)	2
	NAPROXEN 500 MG TABLET	45
	NEOSPORIN OINTMENT UD	105
	NICOTINE 14 MG/24HR PATCH	6
	NICOTINE 21 MG/24HR PATCH	19
	NICOTINE 7 MG/24HR PATCH	10
	OLANZAPINE 10 MG VIAL	10
	OLANZAPINE 20 MG TABLET	11
	ORTHO TRI-CYCLEN LO TABLET	28
	OXCARBAZEPINE 300 MG TABLET	1
	PAROXETINE HCL 20 MG TABLET	2
	PETROLATUM FOILPAC JELLY	150
	POLYETHYLENE GLYCOL 3350 PO	10
	PROPRANOLOL 40 MG TABLET	14
	QUETIAPINE FUMARATE 100 MG	1
	QUETIAPINE FUMARATE 200 MG	37
	QUETIAPINE FUMARATE 25 MG T	1
	QUETIAPINE FUMARATE 300 MG	30
	QUETIAPINE FUMARATE 400 MG	49
	QUETIAPINE FUMARATE 50 MG T	28
	QVAR 40 MCG INHALER	17.4
	RANITIDINE 150 MG TABLET	52
	RISPERDAL CONSTA 37.5 MG SY	1
	RISPERDAL CONSTA 50 MG SYR	1
	RISPERIDONE 1 MG TABLET	1
	RISPERIDONE 2 MG TABLET	135
	RISPERIDONE 4 MG TABLET	15
	SERTRALINE HCL 100 MG TABLE	9
	SERTRALINE HCL 50 MG TABLET	15
	SPIRIVA 18 MCG CP-HANDIHALE	30
	SULFAMETHOXAZOLE-TMP DS TAB	8
	SUMATRIPTAN SUCC 25 MG TABL	4
	SYMBICORT 160-4.5 MCG INHAL	10.2
	SYNTHROID 100 MCG TABLET	1
	SYNTHROID 25 MCG TABLET	15
	SYNTHROID 50 MCG TABLET	28

	TAMSULOSIN HCL 0.4 MG CAPSU	31
	THIOTHIXENE 5 MG CAPSULE	43
	TOPIRAMATE 100 MG TABLET	28
	TOPIRAMATE 200 MG TABLET	2
	TRAZODONE 150 MG TABLET	14
	TRAZODONE 50 MG TABLET	32
	TRIHEXYPHENIDYL 2 MG TABLET	42
	VALPROIC ACID 250 MG CAPSUL	12
	VALPROIC ACID 500 MG/10 ML	700
	VENLAFAXINE HCL 100 MG TABL	1
	VENLAFAXINE HCL 75 MG TABLE	32
	VENLAFAXINE HCL ER 150 MG C	14
	VENTOLIN HFA 90 MCG INHALER	32
	VERAPAMIL ER 180 MG TABLET	4
	VITAMIN B-1 100 MG TABLET	1
	WATER FOR INJECTION VIAL	210
31 Total		11744.6
41	ABILIFY 15 MG TABLET	14
	ABILIFY 5 MG TABLET	14
	ABILIFY 9.7 MG/1.3 ML VIAL	18.2
	ACETAMINOPH (MAPAP) 325 MG	400
	ADVAIR 250-50 DISKUS	14
	AMANTADINE 100 MG CAPSULE	29
	AMANTADINE 50 MG/5 ML SYRUP	90
	AMLODIPINE BESYLATE 5 MG TA	15
	AMOXICILLIN 250 MG CAPSULE	2
	ASPIRIN EC 325 MG TABLET	70
	ASPIRIN EC 81 MG TABLET	64
	ATROVENT HFA INHALER	12.9
	BACITRACIN 500 UNIT/GM OINT	14
	BENAZEPRIL HCL 10 MG TABLET	14
	BENZOYL PER. 5% WASH	148
	BENZTROPINE MES 1 MG TABLET	104
	BENZTROPINE MES 2 MG TABLET	165
	BETASEPT 4% SURGICAL SCRUB	354
	BIOTENE MOUTHWASH	474
	BOOSTRIX VACCINE VIAL	0.5
	BUPROPION HCL XL 150 MG TAB	2
	BUSPIRONE HCL 10 MG TABLET	28
	BUSPIRONE HCL 15 MG TABLET	1
	BUSPIRONE HCL 5 MG TABLET	1
	CALAMINE LOTION	177
	CARBAMAZEPINE 100 MG TAB CH	3

	CARBAMAZEPINE 200 MG TABLET	392
	CARVEDILOL 6.25 MG TABLET	4
	CHLORDIAZEPOXIDE 10 MG CAPS	60
	CHLORDIAZEPOXIDE 25 MG CAPS	30
	CHLORHEXIDINE 0.12% RINSE	946
	CHLORPHENIRAMINE 4 MG TAB	60
	CHLORPROMAZINE 100 MG TABLE	3
	CHLORPROMAZINE 200 MG TABLE	97
	CITALOPRAM HBR 20 MG TABLET	14
	CITALOPRAM HBR 40 MG TABLET	14
	CLINDAMYCIN HCL 150 MG CAPS	2
	CLINDAMYCIN HCL 300 MG CAPS	12
	CLONAZEPAM 0.5 MG TABLET	30
	CLONAZEPAM 1 MG TABLET	60
	CLONIDINE HCL 0.1 MG TABLET	107
	CLOZAPINE 100 MG TABLET	17
	CLOZAPINE 200 MG TABLET	107
	CLOZAPINE 25 MG TABLET	26
	CLOZAPINE 50 MG TABLET	28
	COUMADIN 1 MG TABLET	0
	COUMADIN 2.5 MG TABLET	0
	COUMADIN 4 MG TABLET	4
	CYPROHEPTADINE 4 MG TABLET	15
	DEPAKOTE DR 500 MG TABLET	127
	DIPHENHYDRAMINE 12.5 MG/5 M	600
	DIPHENHYDRAMINE 25 MG CAPSU	47
	DIPHENHYDRAMINE 50 MG CAPSU	431
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	9
	DIVALPROEX SOD DR 500 MG TA	666
	DIVALPROEX SOD ER 500 MG TA	193
	DOCUSATE SOD UD 100 MG CAPS	14
	DONEPEZIL HCL 10 MG TABLET	1
	DOXAZOSIN MESYLATE 2 MG TAB	28
	DOXYCYCLINE HYCLATE 100 MG	24
	EFFERDENT DENTURE CLEANSER	7
	FENTANYL 75 MCG/HR PATCH	2
	FLUOXETINE HCL 20 MG CAPSUL	2
	FLUPHENAZINE 10 MG TABLET	122
	FLUPHENAZINE 5 MG TABLET	108
	FLUPHENAZINE DEC 25 MG/ML V	25
	GABAPENTIN 100 MG CAPSULE	1
	GABAPENTIN 300 MG CAPSULE	5

	GABAPENTIN 400 MG CAPSULE	8
	GABAPENTIN 600 MG TABLET	271
	GABAPENTIN 800 MG TABLET	84
	GEODON 20 MG VIAL	17
	GERI-HYDROLAC 12% LOTION	222
	GLIMEPIRIDE 4 MG TABLET	13
	HALDOL 5 MG/ML AMPUL	30
	HALOPERIDOL 10 MG TABLET	203
	HALOPERIDOL 20 MG TABLET	30
	HALOPERIDOL 5 MG TABLET	92
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCHLOROTHIAZIDE 25 MG T	40
	HYDROXYZINE PAM 25 MG CAP	2
	HYDROXYZINE PAM 50 MG CAP	32
	IBUPROFEN 400 MG TABLET	362
	IBUPROFEN 800 MG TABLET	40
	LAMOTRIGINE 25 MG UD TAB	28
	LANTUS 100 UNITS/ML VIAL	20
	LEVETIRACETAM 500 MG TABLET	1
	LISINOPRIL 10 MG TABLET	17
	LISINOPRIL 2.5 MG TABLET	33
	LISINOPRIL 20 MG TABLET	61
	LISINOPRIL 5 MG TABLET	1
	LITHIUM CARB 300 MG CAP	73
	LITHIUM CARB 600 MG CAP	69
	LORATADINE 10 MG TABLET	14
	LORAZEPAM 1 MG TABLET	30
	LORAZEPAM 2 MG TABLET	56
	LORAZEPAM 2 MG/ML VIAL	25
	LOVASTATIN 20 MG TABLET	38
	LOXAPINE 25 MG CAPSULE	0
	MAG-AL PLUS SUSPENSION	3900
	METFORMIN HCL 500 MG TABLET	113
	METOPROLOL TARTRATE 25 MG T	31
	MINOCYCLINE 50 MG CAPSULE	24
	MIRTAZAPINE 15 MG TABLET	23
	MIRTAZAPINE 30 MG TABLET	30
	MIRTAZAPINE 45 MG TABLET	14
	MULTIVITAMIN TABLET (THERA)	8
	NAPROXEN 500 MG TABLET	27
	NEOMYC-POLYM-GRAMICID EYE D	10
	NEOSPORIN OINTMENT UD	50
	NICOTINE 14 MG/24HR PATCH	11

	NICOTINE 21 MG/24HR PATCH	26
	NITROFURANTOIN MCR 100 MG	24
	OLANZAPINE 10 MG TABLET	89
	OMEPRAZOLE DR 20 MG CAPSULE	6
	ORTHO TRI-CYCLEN LO TABLET	28
	OXYCODONE-APAP 10-325 MG TA	0
	OXYCODONE-APAP 5-325 MG TAB	0
	PANTOPRAZOLE SOD DR 40 MG T	17
	PERPHENAZINE 16 MG TABLET	28
	PERPHENAZINE 4 MG TABLET	3
	PERPHENAZINE 8 MG TABLET	42
	PETROLATUM FOILPAC JELLY	250
	POLYETHYLENE GLYCOL 3350 PO	30
	PRAZOSIN 1 MG CAPSULE	30
	PROMETHAZINE 25 MG TABLET	20
	PROPRANOLOL 20 MG TABLET	5
	QUETIAPINE FUMARATE 100 MG	1
	QUETIAPINE FUMARATE 400 MG	8
	RANITIDINE 150 MG TABLET	214
	RISPERIDONE 2 MG TABLET	35
	SERTRALINE HCL 100 MG TABLE	29
	SERTRALINE HCL 50 MG TABLET	28
	SIMVASTATIN 20 MG TABLET	1
	SORE THROAT LOZENGE	72
	SULFAMETHOXAZOLE-TMP DS TAB	14
	SYMBICORT 160-4.5 MCG INHAL	20.4
	SYNTHROID 100 MCG TABLET	28
	SYNTHROID 125 MCG TABLET	29
	TAMSULOSIN HCL 0.4 MG CAPSU	14
	TOPIRAMATE 200 MG TABLET	1
	TRAMADOL HCL 50 MG TABLET	42
	TRAZODONE 50 MG TABLET	15
	TRIAMCINOLONE 0.1% CREAM	15
	TRIAMCINOLONE 0.5% CREAM	15
	TRIFLUOPERAZINE 5 MG TABLET	1
	TRIHEXYPHENIDYL 2 MG TABLET	1
	VALPROIC ACID 500 MG/10 ML	2000
	VENTOLIN HFA 90 MCG INHALER	88
	VITAMIN B-1 100 MG TABLET	5
	VITAMIN D 1,000 UNIT TABLET	2
	WATER FOR INJECTION VIAL	170
41 Total		16303
51	ACETAMINOPH (MAPAP) 325 MG	500

	AMANTADINE 100 MG CAPSULE	148
	AMLODIPINE BESYLATE 5 MG TA	231
	AMOXICILLIN 250 MG CAPSULE	2
	AMOXICILLIN 500 MG CAPSULE	1
	ANALGESIC BALM	28
	ANUCORT-HC 25 MG SUPPOSITOR	5
	ASPIRIN EC 81 MG TABLET	102
	AZITHROMYCIN 250 MG TABLET	4
	BENZTROPINE MES 1 MG TABLET	196
	BENZTROPINE MES 2 MG TABLET	307
	BETASEPT 4% SURGICAL SCRUB	118
	BIOTENE MOUTHWASH	474
	CARBAMAZEPINE 100 MG/5 ML S	300
	CARBAMAZEPINE 200 MG TABLET	358
	CARVEDILOL 3.125 MG TABLET	60
	CARVEDILOL 6.25 MG TABLET	1
	CEFTRIAXONE 250 MG VIAL	1
	CHLORHEXIDINE 0.12% RINSE	473
	CHLORPROMAZINE 100 MG TABLE	6
	CHLORPROMAZINE 200 MG TABLE	588
	CHLORTHALIDONE 25 MG TABLET	60
	CIPROFLOXACIN HCL 500 MG TA	62
	CITALOPRAM HBR 10 MG TABLET	30
	CLONAZEPAM 0.5 MG TABLET	30
	CLONAZEPAM 1 MG TABLET	180
	CLONAZEPAM 2 MG TABLET	150
	CLONIDINE HCL 0.1 MG TABLET	168
	CLOPIDOGREL 75 MG TABLET	30
	CLOTRIMAZOLE 1% CREAM	28.35
	CLOZAPINE 100 MG TABLET	417
	CLOZAPINE 200 MG TABLET	399
	CLOZAPINE 25 MG TABLET	150
	CLOZAPINE 50 MG TABLET	155
	CYPROHEPTADINE 4 MG TABLET	3
	DAILY VITE WITH IRON TABLET	35
	DESMOPRESSIN ACETATE 0.1 MG	86
	DESMOPRESSIN ACETATE 0.2 MG	29
	DIAZEPAM 5 MG TABLET	6
	DIPHENHYDRAMINE 25 MG CAPSU	23
	DIPHENHYDRAMINE 50 MG CAPSU	203
	DIPHENHYDRAMINE 50 MG/ML VI	50
	DIVALPROEX SOD DR 250 MG TA	3
	DIVALPROEX SOD DR 500 MG TA	982

	DIVALPROEX SOD ER 500 MG TA	3
	DOCUSATE SOD UD 100 MG CAPS	190
	DOCUSATE SODIUM 100 MG CAPS	89
	DONEPEZIL HCL 10 MG TABLET	32
	DONEPEZIL HCL 5 MG TABLET	29
	EPIPEN 0.3 MG AUTO-INJECTOR	1
	FERROUS SULF EC 324 MG TABL	18
	FIBER-LAX CAPTABS	14
	FLUOXETINE HCL 20 MG CAPSUL	13
	FLUPHENAZINE 10 MG TABLET	26
	FLUPHENAZINE 5 MG TABLET	2
	FUROSEMIDE 40 MG TABLET	60
	GABAPENTIN 600 MG TABLET	158
	GEODON 20 MG VIAL	4
	GLIMEPIRIDE 1 MG TABLET	53
	HALOPERIDOL 10 MG TABLET	186
	HALOPERIDOL 5 MG TABLET	126
	HALOPERIDOL DEC 100 MG/ML V	20
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCHLOROTHIAZIDE 25 MG T	32
	HYDROCORT.2.5% CREAM	30
	HYDROCORTISONE 1% CREAM	85.2
	IBUPROFEN 400 MG TABLET	300
	ISOPROPYL ALCOHOL 70%	473
	KLOR-CON 10 MEQ TABLET	1
	LANTUS 100 UNITS/ML VIAL	30
	LEVEMIR 100 UNITS/ML VIAL	30
	LEVETIRACETAM 500 MG TABLET	2
	LIDOCAINE HCL 1% VIAL	20
	LISINOPRIL 10 MG TABLET	74
	LISINOPRIL 2.5 MG TABLET	154
	LISINOPRIL 20 MG TABLET	88
	LISINOPRIL 5 MG TABLET	49
	LITHIUM CARB 300 MG CAP	412
	LORAZEPAM 1 MG TABLET	90
	LORAZEPAM 2 MG TABLET	31
	LORAZEPAM 2 MG/ML VIAL	25
	LOVASTATIN 20 MG TABLET	95
	LOVASTATIN 40 MG TABLET	107
	LOXAPINE 50 MG CAPSULE	284
	MAG-AL PLUS SUSPENSION	1500
	METAMUCIL PACKET S-F	31
	METFORMIN HCL 1000 MG TABL	112

	METFORMIN HCL 500 MG TABLET	310
	METOPROLOL SUCC ER 25 MG TA	126
	METOPROLOL TARTRATE 25 MG T	12
	METOPROLOL TARTRATE 50 MG T	60
	METRONIDAZOLE 250 MG TABLET	8
	MILK OF MAGNESIA SUSPENSION	1500
	MIRTAZAPINE 30 MG TABLET	30
	NAMENDA 10 MG TABLET	61
	NAPROXEN 500 MG TABLET	116
	NEOSPORIN OINTMENT UD	25
	NICOTINE 21 MG/24HR PATCH	1
	OLANZAPINE 5 MG TABLET	2
	OLANZAPINE 7.5 MG TABLET	76
	OMEPRAZOLE DR 20 MG CAPSULE	187
	OXCARBAZEPINE 600 MG TABLET	9
	PETROLATUM FOILPAC JELLY	475
	PHENYTOIN SOD EXT 100 MG CA	168
	POLYETHYLENE GLYCOL 3350 PO	94
	PREDNISONE 10 MG TABLET	15
	PREDNISONE 20 MG TABLET	23
	PROPRANOLOL 10 MG TABLET	86
	QUETIAPINE FUMARATE 200 MG	1
	QUETIAPINE FUMARATE 300 MG	1
	QUETIAPINE FUMARATE 400 MG	95
	QVAR 80 MCG INHALER	17.4
	RANITIDINE 150 MG TABLET	188
	RISPERIDONE 1 MG TABLET	19
	RISPERIDONE 1 MG/ML SOLUTIO	30
	RISPERIDONE 2 MG TABLET	9
	RISPERIDONE 4 MG TABLET	52
	ROPINIROLE HCL 0.25 MG TABL	60
	ROPINIROLE HCL 1 MG TABLET	59
	SELENIUM SULFIDE 1% SHAMPOO	414
	SERTRALINE HCL 100 MG TABLE	65
	SIMVASTATIN 20 MG TABLET	28
	SODIUM BENZOATE 500MG CAPSU	310
	SODIUM CHLORIDE 1 GM TABLET	43
	SORE THROAT LOZENGE	126
	SPIRIVA 18 MCG CP-HANDIHALE	60
	SULFAMETHOXAZOLE-TMP DS TAB	8
	SYNTHROID 100 MCG TABLET	35
	SYNTHROID 137 MCG TABLET	73
	SYNTHROID 25 MCG TABLET	27

	SYNTHROID 75 MCG TABLET	2
	TAMOXIFEN 10 MG TABLET	60
	TAMOXIFEN 20 MG TABLET	300
	TAMSULOSIN HCL 0.4 MG CAPSU	28
	THERA-DERM LOTION	472
	TRAMADOL HCL 50 MG TABLET	96
	TRAZODONE 100 MG TABLET	30
	TRIHEXYPHENIDYL 2 MG TABLET	3
	TRIHEXYPHENIDYL 5 MG TABLET	252
	VALPROIC ACID 500 MG/10 ML	2000
	VENLAFAXINE HCL 75 MG TABLE	28
	WATER FOR INJECTION VIAL	60
	ZIPRASIDONE HCL 60 MG CAPSU	3
	ZONISAMIDE 100 MG CAPSULE	288
51 Total		20997.95
61	ACETAMINOPH (MAPAP) 325 MG	400
	ALBUTEROL 0.083% INHAL SOLN	312
	AMLODIPINE BESYLATE 10 MG T	30
	AMLODIPINE BESYLATE 5 MG TA	30
	ASPIRIN EC 325 MG TABLET	25
	ASPIRIN EC 81 MG TABLET	176
	ATORVASTATIN 20 MG TABLET	0
	BENZTROPINE MES 1 MG TABLET	84
	BETASEPT 4% SURGICAL SCRUB	472
	BISACODYL EC 5 MG TABLET	47
	BUPROPION HCL 100 MG TABLET	73
	CALMOSEPTINE OINTMENT	113
	CARBAMAZEPINE 200 MG TABLET	208
	CARVEDILOL 6.25 MG TABLET	56
	CETAPHIL GENTLE SKIN CLEANS	1419
	CHLORPROMAZINE 100 MG TABLE	64
	CHLORPROMAZINE 200 MG TABLE	59
	CITALOPRAM HBR 20 MG TABLET	37
	CLOMIPRAMINE 50 MG CAPSULE	149
	CLOMIPRAMINE 75 MG CAPSULE	61
	CLONAZEPAM 1 MG TABLET	270
	CLOTRIMAZOLE 1% CREAM	56.7
	CLOZAPINE 100 MG TABLET	114
	CLOZAPINE 200 MG TABLET	170
	CLOZAPINE 25 MG TABLET	178
	CLOZAPINE 50 MG TABLET	47
	COMBIVENT RESPIMAT INHAL SP	4
	DAILY VITE WITH IRON TABLET	31

	DELZICOL DR 400 MG CAPSULE	118
	DEPAKOTE DR 500 MG TABLET	1
	DESMOPRESSIN ACETATE 0.1 MG	2
	DESMOPRESSIN ACETATE 0.2 MG	40
	DILTIAZEM 24HR CD 120 MG CA	112
	DIOVAN 80 MG TABLET	30
	DIPHENHYDRAMINE 12.5 MG/5 M	100
	DIPHENHYDRAMINE 50 MG CAPSU	154
	DIVALPROEX SOD DR 250 MG TA	158
	DIVALPROEX SOD DR 500 MG TA	389
	DOCUSATE SOD UD 100 MG CAPS	68
	DOCUSATE SODIUM 100 MG CAPS	68
	DONEPEZIL HCL 10 MG TABLET	58
	DONEPEZIL HCL 5 MG TABLET	48
	ESTRADIOL 1 MG TABLET	51
	FERROUS SULF EC 324 MG TABL	64
	FERROUS SULF EC 325 MG TABL	29
	FLEET ENEMA	133
	FLUCONAZOLE 150 MG TABLET	1
	FLUOXETINE HCL 20 MG CAPSUL	57
	FLUOXETINE HCL 40 MG CAPSUL	30
	FLUPHENAZINE 10 MG TABLET	144
	FLUPHENAZINE 5 MG TABLET	42
	FOLIC ACID 1 MG TABLET	24
	FUROSEMIDE 20 MG TABLET	59
	FUROSEMIDE 40 MG TABLET	16
	GABAPENTIN 300 MG CAPSULE	337
	GABAPENTIN 400 MG CAPSULE	58
	GABAPENTIN 600 MG TABLET	8
	GABAPENTIN 800 MG TABLET	552
	GEODON 20 MG VIAL	8
	GUAIFENESIN 100 MG/5 ML SYR	400
	HALOPERIDOL 20 MG TABLET	59
	HYDRALAZINE 25 MG TABLET	47
	HYDROCHLOROTHIAZIDE 12.5 MG	9
	HYDROCHLOROTHIAZIDE 25 MG T	23
	HYDROCODON-ACETAMINOPHEN 5-	270
	IBUPROFEN 600 MG TABLET	100
	IBUPROFEN 800 MG TABLET	100
	IPRAT-ALBUT 0.5-3(2.5) MG/3	1000128
	ISOPROPYL ALCOHOL 70%	946
	KLOR-CON M20 TABLET	17
	LACTULOSE 20 GM/30 ML SOLUT	570

	LANTUS 100 UNITS/ML VIAL	10
	LEVETIRACETAM 500 MG TABLET	107
	LEVOFLOXACIN 750 MG TABLET	2
	LISINOPRIL 20 MG TABLET	34
	LISINOPRIL 5 MG TABLET	59
	LITHIUM 8 MEQ/5 ML SOLUTION	440
	LITHIUM CARB 300 MG CAP	181
	LITHIUM CARB 600 MG CAP	21
	LOPERAMIDE 2 MG CAPSULE	20
	LORATADINE 10 MG TABLET	5
	LORAZEPAM 0.5 MG TABLET	150
	LORAZEPAM 1 MG TABLET	110
	LORAZEPAM 2 MG TABLET	30
	LORAZEPAM 2 MG/ML VIAL	25
	LOVASTATIN 20 MG TABLET	93
	LOVASTATIN 40 MG TABLET	84
	METFORMIN HCL 1000 MG TABL	59
	METFORMIN HCL 500 MG TABLET	239
	METOPROLOL TARTRATE 25 MG T	101
	MILK OF MAGNESIA SUSPENSION	600
	MIRTAZAPINE 15 MG TABLET	34
	MIRTAZAPINE 30 MG TABLET	28
	MIRTAZAPINE 45 MG TABLET	30
	MULTIVITAMIN TABLET (THERA)	30
	NALTREXONE 50 MG TABLET	177
	NAMENDA 10 MG TABLET	123
	NAMENDA 5 MG TABLET	107
	NEOSPORIN OINTMENT UD	40
	NIFEDIPINE ER 30 MG TABLET	184
	OLANZAPINE 7.5 MG TABLET	58
	OLANZAPINE ODT 10 MG TABLET	1
	OMEPRAZOLE DR 20 MG CAPSULE	30
	OXYBUTYNIN 5 MG TABLET	94
	OXYCODONE HCL 10 MG TABLET	30
	OXYCODONE-APAP 5-325 MG TAB	90
	OYS SHELL CAL+D 500/200	31
	PERPHENAZINE 16 MG TABLET	77
	PHENOBARBITAL 64.8 MG TABLE	120
	POLYETHYLENE GLYCOL 3350 PO	60
	PROMETHAZINE 25 MG TABLET	20
	PROPRANOLOL 10 MG TABLET	5
	PROPRANOLOL 20 MG TABLET	30
	PROVIGIL 100 MG TABLET	50

	QUETIAPINE FUMARATE 100 MG	68
	QUETIAPINE FUMARATE 200 MG	62
	QUETIAPINE FUMARATE 25 MG T	16
	QUETIAPINE FUMARATE 300 MG	1
	QUETIAPINE FUMARATE 400 MG	55
	QUETIAPINE FUMARATE 50 MG T	90
	QVAR 80 MCG INHALER	8.7
	RANITIDINE 150 MG TABLET	36
	RANITIDINE 300 MG TABLET	42
	RENVELA 800 MG TABLET	35
	SENNA 8.6 MG TABLET	245
	SERTRALINE HCL 100 MG TABLE	10
	SIMVASTATIN 10 MG TABLET	25
	SODIUM BENZOATE 500MG CAPSU	190
	SORE THROAT LOZENGE	36
	SULFAMETHOXAZOLE-TMP DS TAB	16
	SYMBICORT 160-4.5 MCG INHAL	10.2
	SYNTHROID 125 MCG TABLET	28
	SYNTHROID 50 MCG TABLET	155
	SYNTHROID 75 MCG TABLET	30
	TEMAZEPAM 15 MG CAPSULE	50
	THERA-DERM LOTION	236
	TRAZODONE 100 MG TABLET	6
	TRAZODONE 150 MG TABLET	17
	TRAZODONE 50 MG TABLET	59
	VALPROIC ACID 500 MG/10 ML	1200
	VASELINE PETROLEUM JELLY	368
	VENLAFAXINE HCL 75 MG TABLE	29
	VENTOLIN HFA 90 MCG INHALER	24
	VITAMIN D 1,000 UNIT TABLET	31
	VOLTAREN 1% GEL	200
	WATER FOR INJECTION VIAL	120
	ZIPRASIDONE HCL 20 MG CAPSU	1
	ZIPRASIDONE HCL 40 MG CAPSU	1
	ZIPRASIDONE HCL 60 MG CAPSU	60
	ZONISAMIDE 100 MG CAPSULE	124
61 Total		1017817.6

MTMHI Tablets dispensed in a typical month. MTMHI has 9 units.

Sum of Quantity Dispensed		
Patient unit	Drug Name	Total
A	ACETAMINOPHEN 325 MG TABLET	600
	ACETAMINOPHEN-COD #3 TABLET	36
	ALLERGY RELIEF 10 MG TABLET	177
	AMANTADINE 100 MG CAPSULE	60
	AMLODIPINE BESYLATE 10 MG T	62
	AMLODIPINE BESYLATE 2.5 MG	30
	ASPIRIN EC 325 MG TABLET	30
	ASPIRIN EC 81 MG TABLET	60
	BAZA ANTIFUNGAL 2% CREAM	0
	BENZTROPINE MES 0.5 MG TAB	150
	BENZTROPINE MES 1 MG TABLET	544
	BENZTROPINE MES 2 MG TABLET	247
	BISACODYL EC 5 MG TABLET	200
	BUSPIRONE HCL 10 MG TABLET	119
	CARVEDILOL 12.5 MG TABLET	60
	CHLORHEXIDINE 0.12% RINSE	0
	CHLORPROMAZINE 100 MG TABLE	60
	CHLORPROMAZINE 200 MG TABLE	60
	CHLORPROMAZINE 25 MG/ML AMP	10
	CHLORPROMAZINE 50 MG TABLET	10
	CITALOPRAM HBR 20 MG TABLET	30
	CITALOPRAM HBR 40 MG TABLET	29
	CITROMA SOLUTION	1184
	CLONAZEPAM 0.5 MG TABLET	28
	CLONAZEPAM 1 MG TABLET	348
	CLONAZEPAM 2 MG TABLET	42
	CLONIDINE HCL 0.1 MG TABLET	89
	CLONIDINE HCL 0.2 MG TABLET	80
	CLOTRIMAZOLE-BETAMETHASONE	90
	CLOZAPINE 100 MG TABLET	45
	CLOZAPINE 200 MG TABLET	189
	CLOZAPINE 50 MG TABLET	13
	DIPHENHYDRAMINE 25 MG CAPSU	4
	DIPHENHYDRAMINE 50 MG CAPSU	42
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	255
	DIVALPROEX SOD DR 500 MG TA	617

	DIVALPROEX SODIUM 125 MG CA	363
	DOK 100 MG CAPSULE	500
	DUOFILM LIQUID	9.8
	FLUOXETINE HCL 20 MG CAPSUL	8
	FLUPHENAZINE 10 MG TABLET	151
	FLUPHENAZINE 2.5 MG/ML VIAL	40
	FLUPHENAZINE 5 MG TABLET	153
	FLUPHENAZINE DEC 25 MG/ML V	5
	FLUTICASONE PROP 50 MCG SPR	48
	FOLIC ACID 1 MG TABLET	30
	FUROSEMIDE 40 MG TABLET	28
	GABAPENTIN 100 MG CAPSULE	29
	GABAPENTIN 300 MG CAPSULE	316
	GABAPENTIN 400 MG CAPSULE	89
	GEMFIBROZIL 600 MG TABLET	22
	GERI-HYDROLAC 12% LOTION	240
	GOLYTELY SOLUTION	4000
	HALOPERIDOL 10 MG TABLET	298
	HALOPERIDOL 5 MG TABLET	223
	HALOPERIDOL DEC 100 MG/ML A	30
	HALOPERIDOL DECAN 50 MG/ML	1
	HALOPERIDOL LAC 2 MG/ML CON	600
	HUMALOG 100 UNITS/ML VIAL	30
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCORTISONE 1% CREAM	28.4
	HYDROXYZINE 50 MG/ML VIAL	0
	HYDROXYZINE PAM 25 MG CAP	10
	HYDROXYZINE PAM 50 MG CAP	159
	IBUPROFEN 600 MG TABLET	10
	KLOR-CON **M20** TABLET	8
	LACTULOSE 10 GM/15 ML SOLUT	1892
	LAMOTRIGINE 100 MG TABLET	117
	LAMOTRIGINE 25 MG TABLET	114
	LANTUS 100 UNITS/ML VIAL	30
	LEVOTHYROXINE 100 MCG TABLE	30
	LEVOTHYROXINE 150 MCG TABLE	58
	LEVOTHYROXINE 25 MCG TABLET	13
	LEVOTHYROXINE 75 MCG TABLET	110
	LISINOPRIL 10 MG TABLET	60
	LITHIUM **ER** 300 MG TAB	178
	LITHIUM CARB 150 MG CAP	30
	LITHIUM CARB 300 MG CAPSULE	180
	LITHIUM ER 450 MG TABLET	177

	LORAZEPAM 0.5 MG TABLET	208
	LORAZEPAM 1 MG TABLET	220
	LORAZEPAM 2 MG TABLET	74
	LORAZEPAM 2 MG/ML VIAL	9
	LOVASTATIN 20 MG TABLET	74
	MELOXICAM 15 MG TABLET	25
	METFORMIN HCL 500 MG TABLET	422
	METFORMIN HCL 850 MG TABLET	96
	METOPROLOL TARTRATE 25 MG T	76
	MIRTAZAPINE 15 MG TABLET	36
	MONTELUKAST SOD 10 MG TABLE	26
	MUPIROCIN 2% OINTMENT	66
	OLANZAPINE 15 MG TABLET	51
	OMEPRAZOLE DR 20 MG CAPSULE	446
	OXCARBAZEPINE 300 MG TABLET	4
	PAROXETINE HCL 20 MG TABLET	45
	POLYETHYLENE GLYCOL 3350 PO	3094
	PROPRANOLOL 10 MG TABLET	21
	PROPRANOLOL 20 MG TABLET	236
	QUETIAPINE FUMARATE 100 MG	6
	QUETIAPINE FUMARATE 200 MG	83
	QUETIAPINE FUMARATE 300 MG	24
	QUETIAPINE FUMARATE 400 MG	146
	QUETIAPINE FUMARATE 50 MG T	37
	QVAR 40 MCG INHALER	8.7
	RANITIDINE 150 MG TABLET	375
	RISPERIDONE 1 MG TABLET	53
	RISPERIDONE 2 MG TABLET	104
	RISPERIDONE 3 MG TABLET	119
	ROBAFEN 100 MG/5 ML SYRUP	473
	RULOX SUSPENSION	3550
	SELENIUM SULFIDE 2.5% LOTIO	0
	SERTRALINE HCL 100 MG TABLE	22
	SERTRALINE HCL 50 MG TABLET	55
	SIMVASTATIN 20 MG TABLET	96
	SIMVASTATIN 40 MG TABLET	63
	TAB-A-VITE TABLET	300
	TOPIRAMATE 200 MG TABLET	41
	TOTAL B WITH VIT C CAPLET	260
	TRAMADOL HCL 50 MG TABLET	4
	TRAZODONE 100 MG TABLET	33
	TRAZODONE 50 MG TABLET	46
	TRIHEXYPHENIDYL 2 MG TABLET	209

	VALPROIC ACID 250 MG/5 ML S	2365
	VITAMIN D3 1,000 UNIT TABLE	500
	ZIPRASIDONE HCL 80 MG CAPSU	63
	ZOLPIDEM TARTRATE 10 MG TAB	51
A Total		30368.9
B	ACETAMINOPHEN 325 MG TABLET	100
	ALLERGY RELIEF 10 MG TABLET	82
	AMANTADINE 100 MG CAPSULE	70
	AMLODIPINE BESYLATE 10 MG T	28
	AMLODIPINE BESYLATE 5 MG TA	19
	ARTIFICIAL TEARS DROPS	15
	BENZOYL PEROXIDE 10% GEL	42.5
	BENZTROPINE MES 0.5 MG TAB	119
	BENZTROPINE MES 1 MG TABLET	737
	BENZTROPINE MES 2 MG TABLET	57
	BETHANECHOL 25 MG TABLET	152
	BISACODYL EC 5 MG TABLET	1
	BUSPIRONE HCL 10 MG TABLET	89
	CALCIUM 500 + VIT D 200 TAB	120
	CARBAMAZEPINE 200 MG TABLET	3
	CHLORHEXIDINE 0.12% RINSE	946
	CITALOPRAM HBR 20 MG TABLET	38
	CLONAZEPAM 0.5 MG TABLET	126
	CLONAZEPAM 1 MG TABLET	252
	CLONAZEPAM 2 MG TABLET	148
	CLONIDINE HCL 0.1 MG TABLET	10
	CLOTRIMAZOLE 1% CREAM	30
	CLOZAPINE 100 MG TABLET	40
	CLOZAPINE 200 MG TABLET	242
	CLOZAPINE 50 MG TABLET	1
	DIPHENHYDRAMINE 25 MG CAPSU	124
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	13
	DIVALPROEX SOD DR 500 MG TA	407
	DIVALPROEX SODIUM 125 MG CA	104
	DOK 100 MG CAPSULE	402
	DOXYCYCLINE HYCLATE 100 MG	6
	FLUOXETINE HCL 20 MG CAPSUL	25
	FLUPHENAZINE 10 MG TABLET	58
	FLUPHENAZINE 5 MG TABLET	129
	FLUPHENAZINE DEC 25 MG/ML V	5
	GABAPENTIN 300 MG CAPSULE	152
	GEMFIBROZIL 600 MG TABLET	103

	HALOPERIDOL 10 MG TABLET	406
	HALOPERIDOL 5 MG TABLET	273
	HALOPERIDOL DEC 100 MG/ML A	15
	HALOPERIDOL DECAN 50 MG/ML	1
	HALOPERIDOL LAC 2 MG/ML CON	120
	HALOPERIDOL LAC 5 MG/ML VIA	25
	HUMALOG 100 UNITS/ML VIAL	0
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROXYZINE PAM 25 MG CAP	10
	HYDROXYZINE PAM 50 MG CAP	137
	IBUPROFEN 400 MG TABLET	50
	KETOCONAZOLE 2% CREAM	60
	KONSYL-D POWDER	397
	LACTULOSE 10 GM/15 ML SOLUT	3784
	LANTUS 100 UNITS/ML VIAL	10
	LATUDA 40 MG TABLET	119
	LATUDA 80 MG TABLET	122
	LEVOTHYROXINE 100 MCG TABLE	5
	LEVOTHYROXINE 112 MCG TABLE	11
	LEVOTHYROXINE 25 MCG TABLET	11
	LEVOTHYROXINE 50 MCG TABLET	56
	LISINOPRIL 10 MG TABLET	6
	LISINOPRIL 2.5 MG TABLET	29
	LITHIUM CARB 300 MG CAPSULE	71
	LITHIUM ER 450 MG TABLET	530
	LORAZEPAM 0.5 MG TABLET	9
	LORAZEPAM 1 MG TABLET	218
	LORAZEPAM 2 MG TABLET	54
	LORAZEPAM 2 MG/ML VIAL	33
	LOVASTATIN 20 MG TABLET	65
	METFORMIN HCL 500 MG TABLET	151
	METFORMIN HCL 850 MG TABLET	97
	METOPROLOL TARTRATE 25 MG T	39
	MILK OF MAGNESIA SUSPENSION	946
	MINERIN CREME	908
	MUCINEX ER 600 MG TABLET	164
	NAPROXEN 500 MG TABLET	65
	NEW PATIENT	0
	NICOTINE 14 MG/24HR PATCH	3
	OLANZAPINE 10 MG TABLET	71
	OLANZAPINE 15 MG TABLET	22
	OMEPRAZOLE DR 20 MG CAPSULE	280
	ORABASE 20% PASTE	11.9

	PANTOPRAZOLE SOD DR 40 MG T	16
	POLYETHYLENE GLYCOL 3350 PO	1190
	PRAVASTATIN SODIUM 20 MG TA	20
	PROMETHAZINE 25 MG TABLET	26
	PROPRANOLOL 10 MG TABLET	151
	PROPRANOLOL 20 MG TABLET	177
	PROPRANOLOL 40 MG TABLET	90
	QUETIAPINE FUMARATE 200 MG	121
	QUETIAPINE FUMARATE 300 MG	118
	QUETIAPINE FUMARATE 400 MG	90
	RANITIDINE 150 MG TABLET	172
	RISPERIDONE 4 MG TABLET	120
	RULOX SUSPENSION	1775
	SIMVASTATIN 20 MG TABLET	70
	SIMVASTATIN 40 MG TABLET	63
	SUCRALFATE 1 GM TABLET	122
	SYMBICORT 160-4.5 MCG INHAL	6
	TAB-A-VITE TABLET	101
	TOPIRAMATE 200 MG TABLET	118
	TRAZODONE 100 MG TABLET	30
	TRAZODONE 50 MG TABLET	172
	TRIFLUOPERAZINE 10 MG TABLE	19
	TRIFLUOPERAZINE 5 MG TABLET	1
	TRIHEXYPHENIDYL 2 MG TABLET	61
	TRIVORA-28 TABLET	28
	TUCKS HEMORRHOIDAL OINTMENT	28.3
	VALPROIC ACID 250 MG/5 ML S	2838
	VENLAFAXINE HCL 75 MG TABLE	59
	VITAMIN D3 1,000 UNIT TABLE	80
	ZIPRASIDONE HCL 80 MG CAPSU	73
	ZOLPIDEM TARTRATE 10 MG TAB	107
	ZOLPIDEM TARTRATE 5 MG TABL	27
B Total		22484.7
C	ABILIFY 15 MG TABLET	10
	ACETAMINOPHEN 325 MG TABLET	400
	ALLERGY RELIEF 10 MG TABLET	66
	AMLODIPINE BESYLATE 10 MG T	28
	AMLODIPINE BESYLATE 5 MG TA	62
	AMPICILLIN TR 250 MG CAPSUL	44
	ARTIFICIAL TEARS DROPS	15
	ASPIRIN EC 325 MG TABLET	9
	ASPIRIN EC 81 MG TABLET	43
	ATENOLOL 25 MG TABLET	43

	BENZTROPINE MES 0.5 MG TAB	98
	BENZTROPINE MES 1 MG TABLET	256
	BENZTROPINE MES 2 MG TABLET	67
	BISCOLAX 10 MG SUPPOSITORY	12
	BUPROPION HCL SR 100 MG TAB	14
	BUPROPION SR 150 MG TABLET	73
	CHLORDIAZEPOXIDE 25 MG CAPS	187
	CHLORPROMAZINE 50 MG TABLET	40
	CITALOPRAM HBR 10 MG TABLET	14
	CITALOPRAM HBR 20 MG TABLET	270
	CITALOPRAM HBR 40 MG TABLET	14
	CLINDAMYCIN HCL 150 MG CAPS	36
	CLONAZEPAM 1 MG TABLET	33
	CLONAZEPAM 2 MG TABLET	17
	CLONIDINE HCL 0.1 MG TABLET	56
	CLONIDINE HCL 0.2 MG TABLET	55
	CLOTRIMAZOLE 1% CREAM	30
	CYCLOBENZAPRINE 10 MG TABLE	13
	DICYCLOMINE 10 MG CAPSULE	124
	DILTIAZEM ER 180 MG CAPSULE	32
	DIPHENHYDRAMINE 25 MG CAPSU	100
	DIPHENHYDRAMINE 50 MG/ML VI	0
	DIVALPROEX SOD DR 250 MG TA	28
	DIVALPROEX SOD DR 500 MG TA	769
	DOK 100 MG CAPSULE	0
	DOXYCYCLINE HYCLATE 100 MG	32
	DULERA 200 MCG/5 MCG INHALE	0
	EAR DROPS 6.5%	15
	FISH OIL 1,000 MG SOFTGEL	8
	FLUOXETINE HCL 20 MG CAPSUL	68
	FLUPHENAZINE 10 MG TABLET	10
	FLUPHENAZINE 2.5 MG/ML VIAL	20
	FLUPHENAZINE 5 MG TABLET	31
	FLUPHENAZINE 5 MG/ML CONC	0
	FLUTICASONE PROP 50 MCG SPR	32
	FOLIC ACID 1 MG TABLET	62
	FUROSEMIDE 20 MG TABLET	34
	FUROSEMIDE 40 MG TABLET	68
	GABAPENTIN 100 MG CAPSULE	94
	GABAPENTIN 300 MG CAPSULE	793
	GABAPENTIN 400 MG CAPSULE	16
	GERI-HYDROLAC 12% LOTION	720
	GLIMEPIRIDE 2 MG TABLET	14

	HALOPERIDOL 10 MG TABLET	75
	HALOPERIDOL 2 MG TABLET	70
	HALOPERIDOL 5 MG TABLET	306
	HALOPERIDOL DEC 100 MG/ML A	4
	HALOPERIDOL DECAN 50 MG/ML	1
	HALOPERIDOL LAC 2 MG/ML CON	720
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HUMALOG 100 UNITS/ML VIAL	30
	HUMULIN R 100 UNITS/ML VIAL	0
	HYDROCHLOROTHIAZIDE 12.5 MG	28
	HYDROCHLOROTHIAZIDE 25 MG T	14
	HYDROCORTISONE 1% CREAM	113.6
	HYDROXYZINE PAM 100 MG CAP	14
	HYDROXYZINE PAM 25 MG CAP	110
	HYDROXYZINE PAM 50 MG CAP	190
	IBUPROFEN 400 MG TABLET	64
	IBUPROFEN 600 MG TABLET	10
	LACTULOSE 10 GM/15 ML SOLUT	946
	LANTUS 100 UNITS/ML VIAL	20
	LEVETIRACETAM 500 MG TABLET	12
	LEVOFLOXACIN 750 MG TABLET	2
	LEVOTHYROXINE 112 MCG TABLE	22
	LISINOPRIL 10 MG TABLET	36
	LISINOPRIL 2.5 MG TABLET	6
	LISINOPRIL 20 MG TABLET	116
	LISINOPRIL 5 MG TABLET	14
	LITHIUM 8 MEQ/5 ML SOLUTION	500
	LITHIUM CARB 300 MG CAPSULE	86
	LITHIUM ER 450 MG TABLET	95
	LORAZEPAM 2 MG TABLET	86
	LORAZEPAM 2 MG/ML VIAL	6
	LOVASTATIN 20 MG TABLET	47
	LUMIGAN 0.01% EYE DROPS	2.5
	MECLIZINE 25 MG TABLET	10
	MELOXICAM 7.5 MG TABLET	14
	METFORMIN HCL 500 MG TABLET	141
	METFORMIN HCL 850 MG TABLET	68
	METHIMAZOLE 10 MG TABLET	6
	METOPROLOL TARTRATE 25 MG T	28
	METOPROLOL TARTRATE 50 MG T	60
	MIRTAZAPINE 15 MG TABLET	21
	MIRTAZAPINE 30 MG TABLET	14
	MUCINEX ER 600 MG TABLET	35

	MUPIROCIN 2% OINTMENT	22
	NAPROXEN 500 MG TABLET	88
	NEOMYC-BACIT-POLYMIX EYE OI	0
	NEOMYC-POLYM-GRAMICID EYE D	10
	NEW PATIENT	0
	NICOTINE 21 MG/24HR PATCH	84
	NITROGLYCERIN 0.4 MG/HR PAT	22
	OLANZAPINE 10 MG TABLET	6
	OLANZAPINE 15 MG TABLET	4
	OMEPRAZOLE DR 20 MG CAPSULE	25
	ORABASE 20% PASTE	47.6
	OXCARBAZEPINE 300 MG TABLET	28
	PANTOPRAZOLE SOD DR 40 MG T	17
	PAROXETINE HCL 20 MG TABLET	21
	POLYETHYLENE GLYCOL 3350 PO	0
	POTASSIUM CL 10% (20 MEQ/15	558
	PRAZOSIN 1 MG CAPSULE	90
	PROMETHAZINE 50 MG/ML AMPUL	0
	PROPRANOLOL 10 MG TABLET	56
	QUETIAPINE FUMARATE 100 MG	52
	QUETIAPINE FUMARATE 50 MG T	14
	QVAR 40 MCG INHALER	8.7
	RANITIDINE 150 MG TABLET	37
	RISPERIDONE 0.5 MG TABLET	28
	RISPERIDONE 1 MG TABLET	140
	RISPERIDONE 2 MG TABLET	159
	RULOX SUSPENSION	355
	SERTRALINE HCL 100 MG TABLE	56
	SIMVASTATIN 20 MG TABLET	1
	SORE THROAT LOZENGE	54
	SPIRIVA 18 MCG 30CP-HANDIHA	1
	SPIRONOLACTONE 25 MG TABLET	10
	SULFAMETHOXAZOLE-TMP DS TAB	4
	SURE COMFORT 1 ML SYRINGE	90
	TAB-A-VITE TABLET	0
	TAMSULOSIN HCL 0.4 MG CAPSU	12
	THIAMINE 200 MG/2 ML VIAL	50
	TOPIRAMATE 100 MG TABLET	6
	TRAZODONE 100 MG TABLET	93
	TRAZODONE 50 MG TABLET	520
	TRIAMCINOLONE 0.1% CREAM	80
	TUBERSOL 5T UNITS/0.1 ML VI	2
	VALPROIC ACID 250 MG/5 ML S	946

	VENLAFAXINE HCL 75 MG TABLE	56
	VENTOLIN HFA 90 MCG INHALER	80
	VITAMIN B-1 100 MG TABLET	200
	ZOLPIDEM TARTRATE 5 MG TABL	15
C Total		13366.4
D	ACETAMINOPHEN 325 MG TABLET	900
	ACETAMINOPHEN-COD #3 TABLET	5
	ALBUTEROL 0.083% INHAL SOLN	98
	ALLERGY RELIEF 10 MG TABLET	158
	AMANTADINE 100 MG CAPSULE	58
	AMLODIPINE BESYLATE 10 MG T	39
	AMLODIPINE BESYLATE 2.5 MG	68
	AMLODIPINE BESYLATE 5 MG TA	151
	ASPIRIN EC 325 MG TABLET	87
	ASPIRIN EC 81 MG TABLET	110
	BAZA ANTIFUNGAL 2% CREAM	284
	BENZTROPINE MES 0.5 MG TAB	288
	BENZTROPINE MES 1 MG TABLET	303
	BETHANECHOL 25 MG TABLET	121
	BISACODYL EC 5 MG TABLET	202
	BISCOLAX 10 MG SUPPOSITORY	12
	BUSPIRONE HCL 10 MG TABLET	254
	BUSPIRONE HCL 5 MG TABLET	90
	CALCITRIOL 0.5 MCG CAPSULE	18
	CALCIUM 500 + VIT D 200 TAB	263
	CALCIUM ACETATE 667 MG CAPS	72
	CARVEDILOL 3.125 MG TABLET	1
	CARVEDILOL 6.25 MG TABLET	59
	CHLORPROMAZINE 100 MG TABLE	9
	CHLORPROMAZINE 25 MG/ML AMP	0
	CIPROFLOXACIN HCL 500 MG TA	5
	CITALOPRAM HBR 40 MG TABLET	28
	CITROMA SOLUTION	1184
	CLONAZEPAM 0.5 MG TABLET	9
	CLONAZEPAM 1 MG TABLET	63
	CLONIDINE HCL 0.1 MG TABLET	113
	CLONIDINE HCL 0.2 MG TABLET	60
	CLOTRIMAZOLE 1% CREAM	60
	CLOZAPINE 200 MG TABLET	30
	COMPLETE TABLET CHEW	19
	DIOVAN 80 MG TABLET	30
	DIPHENHYDRAMINE 25 MG CAPSU	117

	DIPHENHYDRAMINE 50 MG CAPSU	133
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	267
	DIVALPROEX SOD DR 500 MG TA	536
	DIVALPROEX SODIUM 125 MG CA	246
	DIVALPROEX*SOD*ER*500*MG*TA	117
	DOK 100 MG CAPSULE	723
	DONEPEZIL HCL 10 MG TABLET	30
	EXTRA ACTION COUGH SYRUP	473
	FLUOXETINE HCL 20 MG CAPSUL	76
	FLUPHENAZINE 10 MG TABLET	51
	FLUPHENAZINE 2.5 MG TABLET	7
	FLUPHENAZINE 2.5 MG/ML VIAL	0
	FLUPHENAZINE 5 MG TABLET	39
	FLUPHENAZINE 5 MG/ML CONC	0
	FLUPHENAZINE DEC 25 MG/ML V	5
	FOLIC ACID 1 MG TABLET	43
	FURLOUGH MEDICATIONS	0
	FUROSEMIDE 20 MG TABLET	30
	FUROSEMIDE 40 MG TABLET	168
	GABAPENTIN 300 MG CAPSULE	256
	GEMFIBROZIL 600 MG TABLET	37
	GLIMEPIRIDE 1 MG TABLET	37
	GLIMEPIRIDE 2 MG TABLET	7
	GLUCOS-CHONDR 500-400 CAP	99
	HALOPERIDOL 10 MG TABLET	166
	HALOPERIDOL 2 MG TABLET	13
	HALOPERIDOL 5 MG TABLET	207
	HALOPERIDOL DEC 100 MG/ML A	5
	HALOPERIDOL LAC 5 MG/ML VIA	50
	HUMALOG 100 UNITS/ML VIAL	10
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCHLOROTHIAZIDE 12.5 MG	30
	HYDROCHLOROTHIAZIDE 25 MG T	105
	HYDROCORTISONE 1% CREAM	28.4
	IBUPROFEN 400 MG TABLET	90
	IBUPROFEN 600 MG TABLET	15
	KLOR-CON **M20** TABLET	82
	KONSYL-D POWDER	794
	LACTULOSE 10 GM/15 ML SOLUT	2365
	LANTUS 100 UNITS/ML VIAL	30
	LEVETIRACETAM 250 MG TABLET	60
	LEVETIRACETAM 500 MG TABLET	131

	LEVOTHYROXINE 100 MCG TABLE	91
	LEVOTHYROXINE 125 MCG TABLE	39
	LEVOTHYROXINE 150 MCG TABLE	19
	LEVOTHYROXINE 50 MCG TABLET	133
	LISINOPRIL 10 MG TABLET	118
	LISINOPRIL 20 MG TABLET	114
	LITHIUM **ER** 300 MG TAB	61
	LITHIUM CARB 300 MG CAPSULE	60
	LITHIUM ER 450 MG TABLET	75
	LORAZEPAM 0.5 MG TABLET	210
	LORAZEPAM 1 MG TABLET	167
	LORAZEPAM 2 MG TABLET	13
	LORAZEPAM 2 MG/ML VIAL	33
	LOVASTATIN 20 MG TABLET	75
	MELOXICAM 15 MG TABLET	18
	MELOXICAM 7.5 MG TABLET	12
	METFORMIN HCL 500 MG TABLET	808
	METFORMIN HCL 850 MG TABLET	232
	METOPROLOL TARTRATE 25 MG T	152
	MILK OF MAGNESIA SUSPENSION	946
	MONTELUKAST SOD 10 MG TABLE	22
	MUCINEX ER 600 MG TABLET	219
	MUPIROCIN 2% OINTMENT	22
	NAPROXEN 500 MG TABLET	15
	NEOMYCIN-POLYMYXIN-HC EAR S	20
	NEW PATIENT	0
	NEXIUM DR 40 MG CAPSULE	30
	NIACIN ER 500 MG TABLET	137
	NORVIR 100 MG TABLET	49
	OMEPRAZOLE DR 20 MG CAPSULE	326
	PENICILLIN VK 500 MG TABLET	14
	PHENYTOIN SOD EXT 100 MG CA	15
	PIOGLITAZONE HCL 45 MG TABL	91
	POLYETHYLENE GLYCOL 3350 PO	238
	POTASSIUM CL 10% (20 MEQ/15	946
	PREZISTA 800 MG TABLET	60
	PROPRANOLOL 20 MG TABLET	37
	QUETIAPINE FUMARATE 100 MG	103
	QUETIAPINE FUMARATE 200 MG	60
	QUETIAPINE FUMARATE 25 MG T	47
	QUETIAPINE FUMARATE 300 MG	81
	QUETIAPINE FUMARATE 400 MG	258
	QUETIAPINE FUMARATE 50 MG T	71

	RANITIDINE 150 MG TABLET	197
	RENAL CAPS SOFTGEL	28
	RISPERIDONE 0.5 MG TABLET	28
	RISPERIDONE 2 MG TABLET	65
	RISPERIDONE 3 MG TABLET	28
	RULOX SUSPENSION	355
	SELENIUM SULFIDE 2.5% LOTIO	120
	SEROQUEL XR 400 MG TABLET	59
	SERTRALINE HCL 100 MG TABLE	119
	SERTRALINE HCL 50 MG TABLET	36
	SIMVASTATIN 20 MG TABLET	168
	SORE THROAT LOZENGE	54
	SPIRONOLACTONE 25 MG TABLET	120
	SULFACETAMIDE 10% EYE DROPS	15
	SULFAMETHOXAZOLE-TMP DS TAB	9
	TAB-A-VITE TABLET	100
	TAMOXIFEN 10 MG TABLET	56
	TAMSULOSIN HCL 0.4 MG CAPSU	25
	TRAZODONE 100 MG TABLET	63
	TRAZODONE 50 MG TABLET	235
	TRIHEXYPHENIDYL 2 MG TABLET	47
	TRUVADA 200 MG-300 MG TABLE	47
	TUCKS HEMORRHOIDAL OINTMENT	56.6
	VALPROIC ACID 250 MG/5 ML S	1892
	VENLAFAXINE HCL 75 MG TABLE	62
	VENLAFAXINE HCL ER 150 MG C	2
	VIMPAT 100 MG TABLET	59
	VIT D2 1.25 MG (50,000 UNIT	1
	VITAMIN B-6 50 MG TABLET	49
	VITAMIN C 500 MG TABLET	100
	VITAMIN D3 1,000 UNIT TABLE	176
	ZIPRASIDONE HCL 80 MG CAPSU	108
	ZOLPIDEM TARTRATE 10 MG TAB	82
	ZOLPIDEM TARTRATE 5 MG TABL	17
	ZONISAMIDE 100 MG CAPSULE	120
D Total		23900
DRUG	ACETAZOLAMIDE 250 MG TABLET	55
	ANUCORT-HC 25 MG SUPPOSITOR	32
	ATHLETE'S FOOT 1% LIQUID SP	300
	BENZTROPINE MES 1 MG TABLET	2
	CLONIDINE HCL 0.1 MG TABLET	15
	CLOZAPINE 25 MG TABLET	34
	FLECAINIDE ACETATE 50 MG TA	58

	JANTOVEN 4 MG TABLET	54
	LYRICA 75 MG CAPSULE	47
	METHOTREXATE 2.5 MG TABLET	3
	OLANZAPINE 2.5 MG TABLET	70
	PHENAZOPYRIDINE 100 MG TAB	137
	PHENOBARBITAL 65 MG/ML VIAL	25
	PRIMIDONE 250 MG TABLET	40
	PYRAZINAMIDE 500 MG TABLET	68
	SULFAMETHOXAZOLE-TMP DS TAB	1
DRUG Total		941
E	ABILIFY 10 MG TABLET	56
	ABILIFY 20 MG TABLET	55
	ABILIFY 5 MG TABLET	30
	ACETAMINOPHEN 325 MG TABLET	400
	ACETAMINOPHEN-COD #3 TABLET	90
	ALBUTEROL 0.083% INHAL SOLN	616
	ALLERGY RELIEF 10 MG TABLET	91
	ALLOPURINOL 100 MG TABLET	83
	AMANTADINE 100 MG CAPSULE	58
	AMLODIPINE BESYLATE 10 MG T	85
	ANTI-DIARRHEAL 2 MG CAPLET	18
	ARTIFICIAL TEARS DROPS	30
	ASPIRIN EC 81 MG TABLET	291
	BACLOFEN 10 MG TABLET	176
	BENZTROPINE MES 0.5 MG TAB	271
	BENZTROPINE MES 1 MG TABLET	178
	BETHANECHOL 25 MG TABLET	80
	BISACODYL EC 5 MG TABLET	106
	BUPROPION SR 150 MG TABLET	8
	BUSPIRONE HCL 15 MG TABLET	59
	BUSPIRONE HCL 5 MG TABLET	91
	CALCIUM 500 + VIT D 200 TAB	480
	CARVEDILOL 6.25 MG TABLET	8
	CHLORPROMAZINE 200 MG TABLE	82
	CHLORPROMAZINE 50 MG TABLET	20
	CITALOPRAM HBR 10 MG TABLET	58
	CITALOPRAM HBR 20 MG TABLET	29
	CLONAZEPAM 0.5 MG TABLET	82
	CLONAZEPAM 1 MG TABLET	39
	CLONIDINE HCL 0.1 MG TABLET	59
	CLOPIDOGREL 75 MG TABLET	29
	CLOZAPINE 100 MG TABLET	30
	CLOZAPINE 200 MG TABLET	126

	CLOZAPINE 50 MG TABLET	60
	DEPAKOTE*ER* 250 MG TABLET	59
	DESMOPRESSIN ACETATE 0.2 MG	5
	DIPHENHYDRAMINE 25 MG CAPSU	60
	DIPHENHYDRAMINE 50 MG CAPSU	61
	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	172
	DIVALPROEX SOD DR 500 MG TA	309
	DIVALPROEX*SOD*ER*500*MG*TA	58
	DOK 100 MG CAPSULE	414
	DONEPEZIL HCL 10 MG TABLET	118
	ERYTHROMYCIN EYE OINTMENT	3.5
	EXTRA ACTION COUGH SYRUP	1419
	FINASTERIDE 5 MG TABLET	51
	FLUPHENAZINE 2.5 MG TABLET	45
	FLUTICASONE PROP 50 MCG SPR	16
	FUROSEMIDE 20 MG TABLET	23
	GABAPENTIN 100 MG CAPSULE	105
	GABAPENTIN 300 MG CAPSULE	25
	GABAPENTIN 400 MG CAPSULE	159
	GEMFIBROZIL 600 MG TABLET	114
	GEODON 20 MG VIAL	1
	GERI-HYDROLAC 12% LOTION	240
	GLIMEPIRIDE 1 MG TABLET	29
	HALOPERIDOL 10 MG TABLET	111
	HALOPERIDOL 2 MG TABLET	60
	HALOPERIDOL 5 MG TABLET	111
	HALOPERIDOL DEC 100 MG/ML A	10
	HALOPERIDOL LAC 2 MG/ML CON	1680
	HALOPERIDOL LAC 5 MG/ML VIA	55
	HYDRALAZINE 25 MG TABLET	168
	HYDROCHLOROTHIAZIDE 25 MG T	57
	HYDROXYZINE PAM 50 MG CAP	33
	IBUPROFEN 400 MG TABLET	79
	IPRATROPIUM BR 0.02% SOLN	427.975
	LACRI-LUBE S.O.P. OINTMENT	3.5
	LACTULOSE 10 GM/15 ML SOLUT	1419
	LAMOTRIGINE 200 MG TABLET	49
	LEVETIRACETAM 500 MG TABLET	172
	LEVOTHYROXINE 100 MCG TABLE	102
	LEVOTHYROXINE 50 MCG TABLET	77
	LEVOTHYROXINE 75 MCG TABLET	28
	LISINOPRIL 10 MG TABLET	19

	LISINOPRIL 20 MG TABLET	59
	LISINOPRIL 5 MG TABLET	29
	LITHIUM 8 MEQ/5 ML SOLUTION	500
	LITHIUM CARB 300 MG CAPSULE	203
	LORAZEPAM 0.5 MG TABLET	53
	LORAZEPAM 1 MG TABLET	253
	LORAZEPAM 2 MG TABLET	140
	LORAZEPAM 2 MG/ML VIAL	34
	LOVASTATIN 20 MG TABLET	22
	MELOXICAM 15 MG TABLET	27
	METFORMIN HCL 500 MG TABLET	563
	METFORMIN HCL 850 MG TABLET	30
	METOPROLOL TARTRATE 25 MG T	43
	MONTELUKAST SOD 10 MG TABLE	26
	MUCINEX ER 600 MG TABLET	356
	NAPROXEN 500 MG TABLET	3
	NASAL DECONGESTANT 0.05% SP	30
	NEW PATIENT	0
	NYSTATIN 100,000 UNITS/ML S	180
	OLANZAPINE 10 MG TABLET	23
	OLANZAPINE 20 MG TABLET	32
	OMEPRAZOLE DR 20 MG CAPSULE	94
	ORABASE 20% PASTE	23.8
	OXCARBAZEPINE 600 MG TABLET	115
	OXYBUTYNIN 5 MG TABLET	50
	PANTOPRAZOLE SOD DR 40 MG T	7
	PHENYTOIN 125 MG/5 ML SUSP	474
	PHENYTOIN SOD EXT 100 MG CA	103
	PIOGLITAZONE HCL 15 MG TABL	28
	POLYETHYLENE GLYCOL 3350 PO	714
	PRAMIPEXOLE 1.5 MG TABLET	88
	PROMETHAZINE 25 MG TABLET	10
	PROPRANOLOL 10 MG TABLET	150
	PROPRANOLOL 20 MG TABLET	266
	QUETIAPINE FUMARATE 100 MG	307
	QUETIAPINE FUMARATE 200 MG	155
	QUETIAPINE FUMARATE 300 MG	59
	QUETIAPINE FUMARATE 400 MG	30
	QUETIAPINE FUMARATE 50 MG T	196
	QVAR 40 MCG INHALER	8.7
	RANITIDINE 150 MG TABLET	180
	RISPERIDONE 0.5 MG TABLET	90
	RISPERIDONE 1 MG TABLET	62

	RISPERIDONE 3 MG TABLET	59
	ROBAFEN 100 MG/5 ML SYRUP	473
	RULOX SUSPENSION	1065
	SERTRALINE HCL 50 MG TABLET	29
	SIMETHICONE 80 MG TAB CHEW	83
	SIMVASTATIN 10 MG TABLET	42
	SODIUM CHLORIDE 1 GM TABLET	324
	SORE THROAT LOZENGE	18
	SUCRALFATE 1 GM TABLET	81
	TAB-A-VITE TABLET	100
	TAMSULOSIN HCL 0.4 MG CAPSU	146
	TERAZOSIN 5 MG CAPSULE	31
	TRAZODONE 100 MG TABLET	29
	TRAZODONE 50 MG TABLET	82
	TUBERSOL 5T UNITS/0.1 ML VI	1
	VALPROIC ACID 250 MG/5 ML S	5676
	VENLAFAXINE HCL 75 MG TABLE	49
	VENTOLIN HFA 90 MCG INHALER	16
	VITAMIN D3 1,000 UNIT TABLE	157
	WATER FOR INJECTION VIAL	10
	ZOLPIDEM TARTRATE 10 MG TAB	53
	ZOLPIDEM TARTRATE 5 MG TABL	36
E Total		26523.475
EMP	ADACEL SYRINGE	10
	ALLERGY RELIEF 10 MG TABLET	20
	HYDROCORTISONE 1% CREAM	56.8
	IBUPROFEN 200 MG TABLET	100
	ROBAFEN 100 MG/5 ML SYRUP	473
	RULOX SUSPENSION	355
	SUDOGEST 30 MG TABLET	24
	TUBERSOL 5T UNITS/0.1 ML VI	10
	TWINRIX VACCINE SYRINGE	10
EMP Total		1058.8
F	ACETAMINOPHEN 325 MG TABLET	400
	ACETAMINOPHEN-COD #3 TABLET	106
	ALLERGY RELIEF 10 MG TABLET	10
	ALLOPURINOL 100 MG TABLET	42
	AMLODIPINE BESYLATE 10 MG T	42
	AMLODIPINE BESYLATE 2.5 MG	2
	AMLODIPINE BESYLATE 5 MG TA	21
	AMOX TR-K CLV 875-125 MG TA	24
	AMOXICILLIN 500 MG CAPSULE	12
	ANTI-FUNGAL 1% POWDER	45

	ANTIPYRINE-BENZOCAINE EAR D	10
	ASPIRIN EC 325 MG TABLET	16
	ASPIRIN EC 81 MG TABLET	29
	ATENOLOL 25 MG TABLET	28
	AZITHROMYCIN 250 MG TABLET	5
	BACLOFEN 10 MG TABLET	6
	BENZTROPINE MES 0.5 MG TAB	56
	BENZTROPINE MES 1 MG TABLET	576
	BENZTROPINE MES 2 MG TABLET	40
	BUPROPION HCL 75 MG TABLET	113
	BUPROPION HCL SR 100 MG TAB	28
	BUPROPION SR 150 MG TABLET	28
	CARBAMAZEPINE 100 MG TAB CH	28
	CARBAMAZEPINE 200 MG TABLET	33
	CARVEDILOL 3.125 MG TABLET	24
	CARVEDILOL 6.25 MG TABLET	28
	CHLORDIAZEPOXIDE 25 MG CAPS	357
	CITALOPRAM HBR 10 MG TABLET	18
	CITALOPRAM HBR 20 MG TABLET	404
	CITALOPRAM HBR 40 MG TABLET	14
	CITROMA SOLUTION	592
	CLONAZEPAM 0.5 MG TABLET	56
	CLONAZEPAM 1 MG TABLET	61
	CLONAZEPAM 2 MG TABLET	21
	CLONIDINE HCL 0.1 MG TABLET	84
	CLOPIDOGREL 75 MG TABLET	43
	CLOTRIMAZOLE 1% CREAM	60
	CYCLOBENZAPRINE 10 MG TABLE	168
	DILTIAZEM ER 180 MG CAPSULE	24
	DIPHENHYDRAMINE 25 MG CAPSU	113
	DIPHENHYDRAMINE 50 MG CAPSU	20
	DIPHENHYDRAMINE 50 MG/ML VI	185
	DIVALPROEX SOD DR 250 MG TA	91
	DIVALPROEX SOD DR 500 MG TA	724
	DOK 100 MG CAPSULE	100
	EAR DROPS 6.5%	0
	FLUCONAZOLE 100 MG TABLET	3
	FLUOXETINE HCL 20 MG CAPSUL	62
	FLUPHENAZINE 2.5 MG/ML VIAL	80
	FLUPHENAZINE 5 MG TABLET	64
	FLUPHENAZINE 5 MG/ML CONC	120
	FLUPHENAZINE DEC 25 MG/ML V	5
	FLUTICASONE PROP 50 MCG SPR	64

	FOLIC ACID 1 MG TABLET	7
	FURLOUGH MEDICATIONS	0
	FUROSEMIDE 40 MG TABLET	32
	GABAPENTIN 100 MG CAPSULE	51
	GABAPENTIN 300 MG CAPSULE	603
	GABAPENTIN 400 MG CAPSULE	409
	GEODON 20 MG VIAL	2
	GERI-HYDROLAC 12% LOTION	480
	HALOPERIDOL 10 MG TABLET	14
	HALOPERIDOL 5 MG TABLET	500
	HALOPERIDOL DEC 100 MG/ML A	1
	HALOPERIDOL DECAN 50 MG/ML	1
	HALOPERIDOL LAC 2 MG/ML CON	360
	HALOPERIDOL LAC 5 MG/ML VIA	132
	HUMALOG 100 UNITS/ML VIAL	10
	HUMULIN 70-30 VIAL	10
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDROCHLOROTHIAZIDE 12.5 MG	28
	HYDROCHLOROTHIAZIDE 25 MG T	44
	HYDROCORTISONE 1% CREAM	28.4
	HYDROXYZINE PAM 25 MG CAP	135
	HYDROXYZINE PAM 50 MG CAP	130
	IBUPROFEN 400 MG TABLET	210
	IBUPROFEN 600 MG TABLET	24
	IMIPRAMINE HCL 25 MG TABLET	18
	ISOSORBIDE DN 10 MG TABLET	21
	JANTOVEN 5 MG TABLET	14
	KONSYL-D POWDER	397
	LABETALOL HCL 200 MG TABLET	42
	LAMOTRIGINE 100 MG TABLET	38
	LAMOTRIGINE 25 MG TABLET	98
	LANOXIN 125 MCG TABLET	14
	LANTUS 100 UNITS/ML VIAL	0
	LEVETIRACETAM 500 MG TABLET	153
	LEVOFLOXACIN 750 MG TABLET	2
	LEVOTHYROXINE 125 MCG TABLE	28
	LEVOTHYROXINE 25 MCG TABLET	21
	LEVOTHYROXINE 75 MCG TABLET	11
	LISINOPRIL 10 MG TABLET	105
	LISINOPRIL 20 MG TABLET	87
	LITHIUM CARB 300 MG CAPSULE	12
	LITHIUM ER 450 MG TABLET	199
	LORAZEPAM 0.5 MG TABLET	35

	LORAZEPAM 2 MG TABLET	54
	LORAZEPAM 2 MG/ML VIAL	73
	LOVASTATIN 20 MG TABLET	42
	MECLIZINE 25 MG TABLET	48
	MELOXICAM 15 MG TABLET	14
	MELOXICAM 7.5 MG TABLET	14
	METFORMIN HCL 500 MG TABLET	167
	METOPROLOL TARTRATE 25 MG T	61
	METOPROLOL TARTRATE 50 MG T	6
	MICONAZOLE 7 CREAM	1
	MILK OF MAGNESIA SUSPENSION	946
	MIRTAZAPINE 15 MG TABLET	42
	MIRTAZAPINE 30 MG TABLET	31
	MUCINEX ER 600 MG TABLET	9
	NAPROXEN 500 MG TABLET	3
	NEW PATIENT	1
	NICOTINE 21 MG/24HR PATCH	252
	NYSTOP 100,000 UNITS/GM POW	15
	OLANZAPINE 10 MG TABLET	23
	OLANZAPINE 10 MG VIAL	0
	OLANZAPINE 5 MG TABLET	2
	OMEPRAZOLE DR 20 MG CAPSULE	30
	OXCARBAZEPINE 300 MG TABLET	33
	OXCARBAZEPINE 600 MG TABLET	0
	OXYBUTYNIN 5 MG TABLET	28
	PACERONE 200 MG TABLET	7
	PANTOPRAZOLE SOD DR 40 MG T	33
	PERMETHRIN 1% LOTION	59
	PERMETHRIN 5% CREAM	60
	PERPHENAZINE 2 MG TABLET	28
	PERPHENAZINE 4 MG TABLET	28
	PHENYTOIN SOD EXT 100 MG CA	6
	POLYETHYLENE GLYCOL 3350 PO	238
	POTASSIUM CL ER 10 MEQ TABL	4
	PRAVASTATIN SODIUM 20 MG TA	66
	PRAZOSIN 1 MG CAPSULE	38
	PROMETHAZINE 50 MG/ML AMPUL	25
	PROPRANOLOL 20 MG TABLET	10
	QUETIAPINE FUMARATE 100 MG	22
	QUETIAPINE FUMARATE 200 MG	67
	QUETIAPINE FUMARATE 400 MG	43
	QUETIAPINE FUMARATE 50 MG T	47
	QVAR 40 MCG INHALER	17.4

	RANEXA ER 500 MG TABLET	28
	RANITIDINE 150 MG TABLET	47
	RISPERIDONE 1 MG TABLET	200
	RISPERIDONE 2 MG TABLET	146
	RISPERIDONE 3 MG TABLET	13
	RULOX SUSPENSION	710
	SERTRALINE HCL 100 MG TABLE	56
	SERTRALINE HCL 50 MG TABLET	16
	SIMVASTATIN 10 MG TABLET	3
	SIMVASTATIN 20 MG TABLET	28
	SIMVASTATIN 40 MG TABLET	14
	SPIRIVA 18 MCG 30CP-HANDIHA	31
	SULFAMETHOXAZOLE-TMP DS TAB	3
	TAB-A-VITE TABLET	100
	TAMSULOSIN HCL 0.4 MG CAPSU	28
	THIAMINE 200 MG/2 ML VIAL	50
	TOTAL B WITH VIT C CAPLET	0
	TRAMADOL HCL 50 MG TABLET	0
	TRAZODONE 100 MG TABLET	117
	TRAZODONE 50 MG TABLET	599
	TUBERSOL 5T UNITS/0.1 ML VI	10
	VALPROIC ACID 250 MG/5 ML S	1419
	VENLAFAXINE HCL 37.5 MG TAB	32
	VENLAFAXINE HCL 75 MG TABLE	144
	VENTOLIN HFA 90 MCG INHALER	112
	WATER FOR INJECTION VIAL	20
	ZOLPIDEM TARTRATE 10 MG TAB	32
	ZOLPIDEM TARTRATE 5 MG TABL	9
F Total		16461.8
FSE	ACETAMINOPHEN 325 MG TABLET	100
	AMANTADINE 100 MG CAPSULE	117
	BENZTROPINE MES 1 MG TABLET	149
	BENZTROPINE MES 2 MG TABLET	3
	BUPROPION HCL 100 MG TABLET	33
	BUPROPION HCL 75 MG TABLET	18
	BUSPIRONE HCL 10 MG TABLET	46
	CALCIUM 500 + VIT D 200 TAB	120
	CLONAZEPAM 1 MG TABLET	31
	CLONAZEPAM 2 MG TABLET	5
	CLOTRIMAZOLE 1% CREAM	30
	CLOZAPINE 200 MG TABLET	61
	DEEP SEA 0.65% NOSE SPRAY	88
	DIPHENHYDRAMINE 25 MG CAPSU	23

	DIPHENHYDRAMINE 50 MG/ML VI	25
	DIVALPROEX SOD DR 250 MG TA	62
	DIVALPROEX SOD DR 500 MG TA	82
	DOK 100 MG CAPSULE	100
	EAR DROPS 6.5%	30
	FLUPHENAZINE 10 MG TABLET	120
	FLUPHENAZINE 2.5 MG/ML VIAL	70
	FLUPHENAZINE DEC 25 MG/ML V	20
	GABAPENTIN 100 MG CAPSULE	4
	GABAPENTIN 300 MG CAPSULE	10
	GABAPENTIN 400 MG CAPSULE	33
	HALOPERIDOL 5 MG TABLET	6
	HALOPERIDOL DEC 100 MG/ML A	0
	HALOPERIDOL LAC 5 MG/ML VIA	0
	HYDROCORTISONE 1% CREAM	0
	IBUPROFEN 400 MG TABLET	0
	LITHIUM CARB 300 MG CAPSULE	61
	LORAZEPAM 1 MG TABLET	162
	LORAZEPAM 2 MG TABLET	238
	LORAZEPAM 2 MG/ML VIAL	81
	METFORMIN HCL 500 MG TABLET	8
	METFORMIN HCL 850 MG TABLET	3
	NAPROXEN 500 MG TABLET	19
	NEOMYCIN-POLYMYXIN-HC EAR S	20
	NEW PATIENT	0
	OLANZAPINE 5 MG TABLET	3
	OMEPRAZOLE DR 20 MG CAPSULE	61
	PIOGLITAZONE HCL 45 MG TABL	2
	PROMETHAZINE 50 MG/ML AMPUL	25
	RANITIDINE 150 MG TABLET	53
	RISPERIDONE 1 MG TABLET	9
	RISPERIDONE 2 MG TABLET	24
	RISPERIDONE 4 MG TABLET	61
	ROBAFEN 100 MG/5 ML SYRUP	473
	TUBERSOL 5T UNITS/0.1 ML VI	1
	VALPROIC ACID 250 MG/5 ML S	473
FSE Total		3163
FST	ACETAMINOPHEN 325 MG TABLET	400
	AMITRIPTYLINE HCL 50 MG TAB	5
	ANTI-DIARRHEAL 2 MG CAPLET	18
	ASPIRIN EC 325 MG TABLET	16
	ATENOLOL 25 MG TABLET	14
	BAZA ANTIFUNGAL 2% CREAM	142

	BENZTROPINE MES 1 MG TABLET	375
	BENZTROPINE MES 2 MG TABLET	119
	BISACODYL EC 5 MG TABLET	300
	CHLORPROMAZINE 200 MG TABLE	119
	CIPROFLOXACIN HCL 500 MG TA	1
	CITALOPRAM HBR 20 MG TABLET	27
	CITROMA SOLUTION	1776
	CLONAZEPAM 0.5 MG TABLET	259
	CLONAZEPAM 1 MG TABLET	86
	CLONAZEPAM 2 MG TABLET	280
	CLOZAPINE 100 MG TABLET	60
	CLOZAPINE 200 MG TABLET	30
	DEEP SEA 0.65% NOSE SPRAY	88
	DIPHENHYDRAMINE 25 MG CAPSU	366
	DIPHENHYDRAMINE 50 MG CAPSU	15
	DIPHENHYDRAMINE 50 MG/ML VI	75
	DIVALPROEX SOD DR 250 MG TA	38
	DIVALPROEX SOD DR 500 MG TA	382
	DOCUSATE SOD 20 MG/5 ML SYR	0
	DOK 100 MG CAPSULE	300
	DOXEPIN 50 MG CAPSULE	58
	EAR DROPS 6.5%	0
	EPZICOM TABLET	30
	FERROUS SULFATE 325 MG TABL	2
	FLUOXETINE HCL 20 MG CAPSUL	30
	FLUPHENAZINE 10 MG TABLET	329
	FLUPHENAZINE 2.5 MG/ML VIAL	80
	FLUPHENAZINE 5 MG TABLET	80
	FLUPHENAZINE 5 MG/ML CONC	0
	FLUPHENAZINE DEC 25 MG/ML V	15
	GEMFIBROZIL 600 MG TABLET	6
	GERI-HYDROLAC 12% LOTION	0
	HALOPERIDOL 10 MG TABLET	383
	HALOPERIDOL 5 MG TABLET	59
	HALOPERIDOL DEC 100 MG/ML A	30
	HALOPERIDOL LAC 2 MG/ML CON	120
	HALOPERIDOL LAC 5 MG/ML VIA	108
	HYDROCORTISONE 1% CREAM	56.8
	HYDROXYZINE PAM 100 MG CAP	97
	HYDROXYZINE PAM 50 MG CAP	280
	IBUPROFEN 400 MG TABLET	20
	LEVOTHYROXINE 100 MCG TABLE	3
	LISINOPRIL 10 MG TABLET	10

	LITHIUM CARB 300 MG CAPSULE	142
	LORAZEPAM 0.5 MG TABLET	36
	LORAZEPAM 1 MG TABLET	244
	LORAZEPAM 2 MG TABLET	460
	LORAZEPAM 2 MG/ML VIAL	43
	METFORMIN HCL 500 MG TABLET	159
	MILK OF MAGNESIA SUSPENSION	946
	NAPROXEN 500 MG TABLET	4
	NEW PATIENT	0
	NICOTINE 21 MG/24HR PATCH	28
	NORVIR 100 MG TABLET	30
	OMEPRAZOLE DR 20 MG CAPSULE	212
	PERPHENAZINE 8 MG TABLET	68
	PHENYTOIN SOD EXT 100 MG CA	4
	PROMETHAZINE 25 MG TABLET	10
	PROPRANOLOL 10 MG TABLET	108
	QUETIAPINE FUMARATE 300 MG	60
	QUETIAPINE FUMARATE 400 MG	164
	REYATAZ 300 MG CAPSULE	30
	RULOX SUSPENSION	1065
	SEROQUEL XR 400 MG TABLET	59
	SORE THROAT LOZENGE	36
	TAB-A-VITE TABLET	100
	TRAZODONE 100 MG TABLET	29
	TRAZODONE 50 MG TABLET	8
	VALPROIC ACID 250 MG/5 ML S	2365
	VIT D2 1.25 MG (50,000 UNIT	3
	VITAMIN D3 1,000 UNIT TABLE	30
FST Total		13530.8
I	ABREVA 10% CREAM	2
	ACETAMINOPHEN 325 MG TABLET	700
	ACYCLOVIR 200 MG CAPSULE	63
	ALLERGY RELIEF 10 MG TABLET	4
	ALLOPURINOL 100 MG TABLET	42
	AMLODIPINE BESYLATE 10 MG T	28
	AMLODIPINE BESYLATE 2.5 MG	3
	AMLODIPINE BESYLATE 5 MG TA	57
	AMOX TR-K CLV 875-125 MG TA	12
	ARTIFICIAL TEARS DROPS	45
	ASPIRIN EC 81 MG TABLET	17
	BENAZEPRIL HCL 10 MG TABLET	6
	BENZOYL PEROXIDE 10% GEL	42.5
	BENZTROPINE MES 0.5 MG TAB	113

	BENZTROPINE MES 1 MG TABLET	623
	BENZTROPINE MES 2 MG TABLET	28
	BUPROPION HCL SR 100 MG TAB	6
	BUSPIRONE HCL 10 MG TABLET	28
	BUSPIRONE HCL 5 MG TABLET	79
	CARBAMAZEPINE 200 MG TABLET	11
	CARVEDILOL 12.5 MG TABLET	4
	CARVEDILOL 6.25 MG TABLET	28
	CEPHALEXIN 500 MG CAPSULE	14
	CHLORDIAZEPOXIDE 25 MG CAPS	248
	CHLORHEXIDINE 0.12% RINSE	473
	CHLORPROMAZINE 25 MG/ML AMP	20
	CITALOPRAM HBR 10 MG TABLET	14
	CITALOPRAM HBR 20 MG TABLET	283
	CITALOPRAM HBR 40 MG TABLET	14
	CLINDAMYCIN HCL 150 MG CAPS	62
	CLONAZEPAM 0.5 MG TABLET	26
	CLONAZEPAM 1 MG TABLET	76
	CLONAZEPAM 2 MG TABLET	61
	CLONIDINE HCL 0.1 MG TABLET	41
	CLONIDINE HCL 0.2 MG TABLET	6
	CLOPIDOGREL 75 MG TABLET	24
	CLOTRIMAZOLE 1% CREAM	150
	CYCLOBENZAPRINE 10 MG TABLE	50
	CYCLOBENZAPRINE 5 MG TABLET	14
	CYCLOPENTOLATE 1% EYE DROPS	0
	DIPHENHYDRAMINE 25 MG CAPSU	65
	DIPHENHYDRAMINE 50 MG CAPSU	14
	DIPHENHYDRAMINE 50 MG/ML VI	175
	DIVALPROEX SOD DR 250 MG TA	28
	DIVALPROEX SOD DR 500 MG TA	908
	DOK 100 MG CAPSULE	100
	DOXEPIN 25 MG CAPSULE	1
	EAR DROPS 6.5%	0
	ENOXAPARIN 100 MG/ML SYRING	0
	ESTRADIOL 1 MG TABLET	36
	FINASTERIDE 5 MG TABLET	14
	FLUCONAZOLE 100 MG TABLET	1
	FLUOXETINE HCL 20 MG CAPSUL	11
	FLUPHENAZINE 10 MG TABLET	15
	FLUPHENAZINE 2.5 MG/ML VIAL	90
	FLUPHENAZINE 5 MG TABLET	110

	FLUPHENAZINE DEC 25 MG/ML V	5
	FLUTICASONE PROP 50 MCG SPR	80
	FOLIC ACID 1 MG TABLET	36
	FUROSEMIDE 20 MG TABLET	28
	FUROSEMIDE 40 MG TABLET	84
	GABAPENTIN 100 MG CAPSULE	52
	GABAPENTIN 300 MG CAPSULE	947
	GABAPENTIN 400 MG CAPSULE	304
	GLIMEPIRIDE 1 MG TABLET	55
	GLIMEPIRIDE 2 MG TABLET	1
	HALOPERIDOL 1 MG TABLET	2
	HALOPERIDOL 10 MG TABLET	65
	HALOPERIDOL 2 MG TABLET	118
	HALOPERIDOL 5 MG TABLET	507
	HALOPERIDOL DEC 100 MG/ML A	14
	HALOPERIDOL LAC 2 MG/ML CON	360
	HALOPERIDOL LAC 5 MG/ML VIA	105
	HUMALOG 100 UNITS/ML VIAL	20
	HUMULIN R 100 UNITS/ML VIAL	10
	HYDRALAZINE 25 MG TABLET	40
	HYDROCHLOROTHIAZIDE 25 MG T	31
	HYDROCORTISONE 1% CREAM	170.4
	HYDROXYZINE PAM 25 MG CAP	140
	HYDROXYZINE PAM 50 MG CAP	550
	IBUPROFEN 400 MG TABLET	90
	IBUPROFEN 600 MG TABLET	42
	ISOSORBIDE MN ER 30 MG TABL	7
	JANTOVEN 2.5 MG TABLET	14
	JANTOVEN 5 MG TABLET	14
	KETOCONAZOLE 2% CREAM	120
	KLOR-CON **M20** TABLET	42
	KONSYL-D POWDER	0
	LACTULOSE 10 GM/15 ML SOLUT	2575
	LANTUS 100 UNITS/ML VIAL	50
	LATANOPROST 0.005% EYE DROP	2.5
	LEVETIRACETAM 250 MG TABLET	31
	LEVETIRACETAM 500 MG TABLET	168
	LEVOTHYROXINE 100 MCG TABLE	16
	LEVOTHYROXINE 150 MCG TABLE	14
	LEVOTHYROXINE 75 MCG TABLET	14
	LISINOPRIL 10 MG TABLET	52
	LISINOPRIL 2.5 MG TABLET	14
	LISINOPRIL 20 MG TABLET	143

	LISINOPRIL 5 MG TABLET	37
	LITHIUM CARB 300 MG CAPSULE	2
	LITHIUM ER 450 MG TABLET	302
	LORAZEPAM 2 MG/ML VIAL	41
	LOVASTATIN 20 MG TABLET	70
	LOVENOX 80 MG PREFILLED SYR	4
	MECLIZINE 25 MG TABLET	42
	MEDROXYPROGESTERONE 150 MG/	1
	MELOXICAM 15 MG TABLET	14
	MELOXICAM 7.5 MG TABLET	1
	METFORMIN HCL 500 MG TABLET	101
	METFORMIN HCL 850 MG TABLET	28
	METOPROLOL TARTRATE 25 MG T	114
	METOPROLOL TARTRATE 50 MG T	142
	MILK OF MAGNESIA SUSPENSION	473
	MINERIN CREME	454
	MIRTAZAPINE 15 MG TABLET	50
	MONTELUKAST SOD 10 MG TABLE	22
	MUCINEX ER 600 MG TABLET	0
	NAPROXEN 500 MG TABLET	55
	NEW PATIENT	0
	NICOTINE 14 MG/24HR PATCH	10
	NICOTINE 21 MG/24HR PATCH	378
	NIFEDIPINE ER 30 MG TABLET	14
	NIFEDIPINE ER 60 MG TABLET	22
	OLANZAPINE 10 MG TABLET	3
	OLANZAPINE 10 MG VIAL	3
	OLANZAPINE 15 MG TABLET	16
	OLANZAPINE 5 MG TABLET	28
	OMEPRAZOLE DR 20 MG CAPSULE	39
	OXCARBAZEPINE 300 MG TABLET	28
	OXCARBAZEPINE 600 MG TABLET	3
	OXYBUTYNIN 5 MG TABLET	28
	PANTOPRAZOLE SOD DR 40 MG T	43
	PAROXETINE HCL 20 MG TABLET	16
	PHENYTOIN SOD EXT 100 MG CA	192
	PIOGLITAZONE HCL 15 MG TABL	7
	POLYETHYLENE GLYCOL 3350 PO	238
	POTASSIUM CL 10% (20 MEQ/15	578
	POTASSIUM CL ER 10 MEQ TABL	18
	PRAVASTATIN SODIUM 20 MG TA	2
	PRAZOSIN 1 MG CAPSULE	62

	PREDNISOLONE AC 1% EYE DROP	5
	PROMETHAZINE 25 MG TABLET	60
	PROMETHAZINE 50 MG/ML AMPUL	15
	PROPRANOLOL 10 MG TABLET	16
	QUETIAPINE FUMARATE 100 MG	14
	QUETIAPINE FUMARATE 200 MG	14
	QUETIAPINE FUMARATE 50 MG T	14
	RANITIDINE 150 MG TABLET	106
	RISPERIDONE 1 MG TABLET	48
	RISPERIDONE 2 MG TABLET	34
	RISPERIDONE 3 MG TABLET	56
	RULOX SUSPENSION	1420
	SERTRALINE HCL 100 MG TABLE	56
	SERTRALINE HCL 50 MG TABLET	98
	SIMETHICONE 80 MG TAB CHEW	7
	SIMVASTATIN 20 MG TABLET	46
	SIMVASTATIN 40 MG TABLET	56
	SPIRONOLACTONE 25 MG TABLET	112
	SULFACETAMIDE 10% EYE DROPS	15
	SULFAMETHOXAZOLE-TMP DS TAB	28
	SURE COMFORT 1 ML SYRINGE	120
	SYMBICORT 160-4.5 MCG INHAL	36
	TAB-A-VITE TABLET	100
	TAMSULOSIN HCL 0.4 MG CAPSU	14
	THIAMINE 200 MG/2 ML VIAL	50
	TOPIRAMATE 25 MG TABLET	84
	TOTAL B WITH VIT C CAPLET	130
	TRAMADOL HCL 50 MG TABLET	2
	TRAZODONE 100 MG TABLET	129
	TRAZODONE 50 MG TABLET	534
	TUBERSOL 5T UNITS/0.1 ML VI	6
	TUCKS HEMORRHOIDAL OINTMENT	28.3
	VALPROIC ACID 250 MG/5 ML S	0
	VENLAFAXINE HCL 37.5 MG TAB	35
	VENLAFAXINE HCL 75 MG TABLE	84
	VENLAFAXINE HCL ER 75 MG CA	14
	VENTOLIN HFA 90 MCG INHALER	136
	VITAMIN B-1 100 MG TABLET	200
	WARFARIN SODIUM 2.5 MG TABL	12
	WARFARIN SODIUM 5 MG TABLET	2
	WATER FOR INJECTION VIAL	30
	ZIPRASIDONE HCL 20 MG CAPSU	1
I Total		19866.7

Pharmacy Interface Requirements

Cabinets must be able to receive the following data elements from the pharmacy software system:

Patient Information

- First name
- Last name
- Date of birth
- Medical record number
- Gender
- Assigned unit
- Allergies
- Admission/discharge status

Medication Order

- Rx number
- Drug name
- Drug strength
- Drug NDC
- Directions for use (SIG)
- Quantity per dose
- Time of administration
- Order date
- Discontinue Date
- Start date
- Stop date
- Active/Discontinue status
- Prescriber Name

AMDC system must be able to send the following data elements to the pharmacy software system:

Medication Order Information

- Rx number
- Patient name
- Patient date of birth
- Patient medical record number
- Drug name
- Drug strength
- Quantity removed
- Time of removal